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Abstract 
Insect carboxylesterases (CBEs) have great importance in insect biology and play a crucial 
role in the ever-increasing occurrence of insecticide resistance. This resistance to 
insecticides (e.g. organophosphates) leads to downstream effects on agriculture and to 
human health (through reduced crop production and the spread of insect-borne diseases). 
Structural and functional studies of insect CBEs are vital for combating insecticide 
resistance, finding new potential targets and in providing insight into the evolution of new 
protein function. The work described in this thesis contributes to the overall understanding 
of the structure, function and evolution of insect CBEs.  
Chapter 1 is the introduction into the structure, function and evolution of insect CBEs. In 
particular, the classification of CBEs is discussed, as well, the current understanding of the 
role CBEs play in insect species. Chapter 2 describes the evolution of new oligomeric 
structure in the CBE αE7 from Lucilia cuprina and shows that higher order thermostable 
oligomers can be selected for during evolution. This work affirms the importance of 
oligomers in evolution to maintain or increase protein stability and demonstrates 
structure/activity trade-offs that are observed throughout enzyme evolution.  
Chapter 3 describes structural studies into the CBE esterase-6 (EST6) from Drosophila 
melanogaster - a CBE that has shown to be important for the reproductive success of 
Drosophila species. The enzyme has a unique active site entry for insect CBEs, which 
results in a narrow and shortened active site. Docking simulations in combination with 
kinetic analyses show that the enzyme is a probable odorant-degrading enzyme. It also 
indicates that EST6 does not directly interact with the sex pheromone 11-cis vaccenyl 
acetate (cVA), which contradicts the previously held belief that it is the main substrate of 
the enzyme. 
The evolution of CBEs involved in insecticide resistance in several species is discussed in 
Chapter 4. α-esterase orthologs from different dipteran species were analysed to discern 
important factors for the evolution of qualitative insecticide resistance and the signifiance 
of evolutionary contingency. A large variation in binding and turnover for the 
organophosphate compound was observed with the introduction of the Gly137Asp 
mutation into the orthologs. Given the similarity in the predicted structures of the orthologs, 
it suggests that second and third shell mutations are important in mediating the catalytic 
effects conferred by the Gly137Asp mutation in the orthologs.  
v 
Chapter 5 discusses the development and testing of new inhibitors to treat the symptoms of 
Alzheimer’s disease, through molecular docking simulations. Galanthamine derivatives 
showed no significant binding to AChE, however, the tested marinoquinoline derivatives 
displayed a large variation in affinity for AChE. Chapter 6 summarises the conclusions that 
these studies have allowed us to make regarding the structures, functions and evolution of 
insect CBEs. The chapter finishes with a discussion of future work that could be undertaken 
to extend these findings and further develop our understanding of this important enzyme 
family. 
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1.1. Introduction 
 
1.1.1. Overview 
This section will introduce carboxylesterases (CBEs), a large family of enzymes that have 
been of major interest in humans (e.g. carboxylesterase 1 (1)) and insects (LcαE7 (2)), 
where the enzymes have been shown to play important roles in xenobiotic metabolism. 
CBEs will be introduced in terms of their classification, followed by a discussion of the 
structures of CBEs with a particular focus on insect CBEs. 
1.1.2. Esterases 
Esterases are a class of hydrolase enzymes that are ubiquitous in nature and catalyse the 
cleavage of ester bonds by the addition of water (Figure 1.1) (3–6). Esterases are important 
for the metabolism of several classes of compounds and have evolved independently in 
multiple superfamilies (7–10). Esterases perform crucial functions ranging from hormone 
metabolism, pheromone processing and neurotransmission in a wide variety of organisms 
(5, 11–14). They have received attention in recent years for their role in insecticide 
resistance, metabolism of pharmaceuticals and for use as biocatalysts (11, 15–17). 
Esterases that hydrolyse carboxyl esters (carboxylesterases or CBEs) will be discussed in 
this thesis as most esterases belong to the carboxyl/cholinesterase family (14). 
 
 
Figure 1.1. Basic reaction of a CBE: the breakage of the ester bond leads to an alcohol and a 
carboxylic acid as products. Figure adapted from Wheelock et al (18). 
1.1.3. Classification of Carboxylesterases 
There has been a significant effort to functionally define and classify eukaryotic CBEs. One 
of the main ways to classify enzymes is through activity, however, due to overlapping 
substrate ranges, this has proven difficult with CBEs (14, 19). Historically, interactions 
with inhibitors have been used to subdivide esterases, with the initial classification by 
Aldridge defining esterases into three classes (20–22). This system was widely used due to 
the ease of classification and lack of other classification systems (18). The three classes 
were A, B and C which subdivided esterases that hydrolyse organophosphates (Est-A), 
those that are irreversibly inhibited by organophosphates (Est-B) and esterases that do not 
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interact with organophosphates (Est-C) (18, 20, 23, 24). A problem with this classification 
was that it was considered to be too broad as a large majority of insect esterases would be 
categorised as Est-B (18, 19). 
With more refined studies, an alternative scheme was proposed to address the difficulties 
in classifying esterases (20). Esterases were grouped into four classes: arylesterases, 
acetylesterases, carboxylesterases and cholinesterases (14, 20). The classes were defined 
by the sensitivity to three different types of inhibitors and several ester substrates following 
native PAGE (Table 1.1) (25–27). 
Table 1.1. Classification of esterases based on inhibition and substrate specificity (27). 
Esterases Classification 
Arylesterases Inhibited only by sulfhydryl inhibitors and prefers esters with 
aromatic alcohol groups. 
Carboxylesterases Inhibited only by organophosphates and a preference for aliphatic 
esters. 
Cholinesterases Inhibited by organophosphates and eserine sulphates. Prefers 
charged substrates (choline esters). 
Acetylesterases No sensitivity to the 3 inhibitors and a preference for aliphatic esters 
with acetyl acid or aromatic alcohol groups. 
 
A further classification has been used to group eukaryotic CBEs, which has been adopted 
in Drosophila and Culex species. This classifies esterases based on the preferential 
hydrolysis of two artificial carboxylic ester substrates: α-naphthyl acetate (Est-α) or β-
naphthyl acetate (Est-β) and on electrophoretic mobility (28–31). A superscript number is 
used after the α or β to designate alleles for each variant as the increasing numbers of 
esterases are described in the species (28, 31, 32). The α/β nomenclature is still used for 
studying enzyme clusters in insects despite the limitations in a classification that only uses 
two substrates, such as having no broad biological distinctions and not being an informative 
predictor of enzyme function (19, 32, 33). In particular species (e.g. aphids) a different 
nomenclature is used to classify esterases based only on their different mobility on 
electrophoretic gels (34, 35). Electrophoretic mobility has limitations for classification as 
20-30% of the variability in mobility is hidden, resulting in variants not being identified 
(36). 
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The International Union of Biochemistry and Molecular Biology (IUBMB) has also 
attempted to classify esterases on reaction type, however, the overlapping substrate range 
has made classification by substrate specificity difficult. The IUBMB gives a four series of 
numbers to classify enzymes (23, 37). EC 3 designates the subgroup of hydrolases, 3.1 are 
for hydrolases that act on an ester bond which also include lipases and exonucleases. EC 
3.1.1 are for carboxyl ester hydrolases which includes acetylcholinesterase (Table 1.2) (23, 
37). EC 3.1.1.1 is designated for esterases with a preference for aliphatic esters that are 
inhibited by paraoxon (14). This designation is also known as the CBEs or Est-B. In some 
cases, the overlapping substrate specificity means esterases in EC 3.1.1.1 fit into EC 3.1.1.2 
as well (esterases that preferably act on aromatic compounds and hydrolyse triester 
organophosphates) but the inhibition by paraoxon distinguishes the two groups (14). 
Table 1.2. EC 3.1.1 classification for hydrolases that work on ester bonds. Only the first eight 
in the 3.1.1.X designation are shown (23, 37). 
More recently, phylogenetics has been used to split insect CBE families into 14 major 
clades (annotated as A-N) and into three major groups for classification (32, 38). This 
classification was based on 35 Drosophila melanogaster sequences, 51 Anopheles gambiae 
sequences and 35 other insect sequences. Similarity of the gene, physiological 
characteristics, catalytic competence and cellular localisation is used to differentiate the 
CBEs into three main functional groups: dietary detoxification (mostly intracellular active 
EC 
Number 
Classification Substrates Products 
3.1.1.1 Carboxylesterase Carboxylic Ester Alcohol, Carboxylate 
3.1.1.2 Arylesterase Phenyl acetate Phenol, Acetate 
3.1.1.3 Triacylglycerol 
lipase 
Triacylglycerol Diacylglycerol, Carboxylate 
3.1.1.4 Phospholipase A2 Phosphatidylcholine Acylglycerophosphocholine, 
Carboxylate 
3.1.1.5 Lysophospholipase Lysophosphatidylcholine Glycerophosphocholine , 
Carboxylate 
3.1.1.6 Acetylesterase Acetic Ester Acetate, Alcohol 
3.1.1.7 Acetylcholinesterase Acetylcholine Acetate, Choline 
3.1.1.8 Cholinesterase Acylcholine Choline, Carboxylate 
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enzymes, enzymes with broad substrate specificity and those that are involved in insecticide 
resistance, A-C), hormone and pheromone degradation (secreted and catalytic enzymes, D-
G) and neurodevelopmental functions (mostly non-catalytic, secreted, membrane-
associated enzymes, H-N) (32, 38). An update to the classification was released in 2010 
with the genome of Nasonia vitripennis sequenced (39). The updated clades were based on 
the genomes of N. vitripennis, D. melanogaster, A. gambiae, Apis mellifera and Tribolium 
castaneum with other previously characterized CBE sequences included (Table 1.3) (39). 
The assignment of the clades is similar to the previous assignment, however, clade B and 
C are combined to reflect a closer relationship between higher and lower dipteran CBEs 
and a new clade comprising of coleopteran CBEs of unknown function. Many authors have 
used the phylogenetic classification criteria recently for classification as it has the ability 
to functionally distinguish esterases, however, a better understanding of the physiological 
function of the esterases by genomic and biochemical studies is required. 
Table 1.3. Clade classification of invertebrate esterases by Oakeshott et al. (2010) (39) based 
on the initial clades of Oakeshott et al. (2005) (38) (A) Dietary/detoxification function class (red) 
(B) Hormone/semiochemical processing class (blue) (C) Neuro-developmental, cell adhesion 
functions class (brown). 
Clade Classified Examples 
A Hymenopteran xenobiotic metabolising esterases - 
B α-esterases type enzymes, generally microsomal LcαE7 
C Unknown function  - 
D Integument esterases - 
E Secreted β-esterases Esterase-6, E4 
F Dipteran type juvenile hormone esterases  Juvenile hormone esterase 
G Lepidoteran type juvenile hormone esterases Juvenile hormone esterase  
H Glutactin enzymes Glutactin 
I Unknown function - 
J Acetylcholinesterases Acetylcholinesterase 
K Gliotactins Gliotactin 
L Neuroligins Neuroligin 
M Neurotactins Neurotactin 
 
Overall, there is no universal standard used in the classification of esterases, and multiple 
systems have been adopted in attempt to find a single method to classify esterases. 
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Subdividing esterases by substrate specificity, interactions with inhibitors and 
electrophoretic mobility all have issues for classification. However, the phylogenetic 
criteria is the favoured method currently, especially with the increase in sequencing 
information. Future biochemical, functional and structural studies are important to help 
establish the understanding of members of the 14 clades in the future. It has been suggested 
that future classification could involve the use of selective inhibitors or substrates, which 
would help to elucidate isozyme abundance (18). 
1.1.4. Carboxylesterases 
The CBEs are a multigene family that extensively radiated in higher eukaryotes (mammals 
and insects) (5, 12, 13). Despite their abundance in eukaryotes, CBE genes are 
comparatively rare in bacterial genomes, which suggests that the gene family evolved from 
ancient bacteria but has not expanded in prokaryotes (40, 41).  The CBEs in higher 
eukaryotes show a large diversity in function that is highlighted in their broad substrate 
spectrum and complex expression profiles (Figure 1.2). In some cases, there is strong 
substrate selectivity and specialised function (acetylcholinesterase) or less specific function 
and poor substrate selectivity (LcαE7) and in rare cases, proteins from this fold can be non-
catalytic (neuroligin) (32). 
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Figure 1.2. List of substrates (natural or artificial) hydrolysed by CBEs. The bonds that are 
subject to hydrolysis are indicated by the arrow. Figure adapted from Montella et al (14). 
1.1.5. α/β hydrolase fold 
Members of the CBE family do not share a high degree of sequence identity with an average 
sequence identity of 29% (42). Despite the low average sequence identity, the conservation 
of the tertiary structure is high. CBEs belong to the α/β hydrolase fold protein superfamily 
with a conserved arrangement of residues in the catalytic site (43–45). The conserved 
structure and arrangement of the active site suggest that CBEs originated from a common 
ancestor (46). This canonical fold is found in many functionally diverse enzymes that 
hydrolyse a wide range of substrates and is one of the most common protein folds. This 
superfamily includes proteases, esterases, lipases, dehalogenases, peroxidases, 
phosphotriesterases and epoxide hydrolases (4, 45, 46). The structure is well conserved 
with at least 20% amino acid identity between the most distantly related family members 
and 73 conserved residues identified (47). The ESTHER database collects published 
protein sequences and gene information of proteins with the α/β hydrolase fold and the list 
of CBEs is growing with 6157 of the 46165 sequences being CBEs as of May 2016 (45).  
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The core of the α/β hydrolase fold contains eight β-sheets in a parallel orientation (except 
β2), which are connected by six surrounding α-helices (Figure 1.3) (4). Loops and helices 
are spread among the β-strands in the primary sequence. The core fold is important for 
maintaining the position of the catalytic triad found in the active site (4). The protein fold 
allows for a large variation in domain size depending on the loop sizes and other secondary 
structure (25 - 65 kDa) (48).  
Figure 1.3. Secondary structure diagram of the ‘canonical’ α/β hydrolase fold (4). α-helices are 
represented by green cylinders and β-strands by gray arrows. The location of the catalytic triad 
is indicated by black dots (47). 
The active site is formed by highly conserved loops and contains a nucleophilic residue 
(serine, cysteine or aspartate), a histidine residue and an acidic residue (glutamate or 
aspartate) (3, 4). The common triad is Ser, Glu, His (eukaryotic CBEs) but can also be Ser, 
Asp, His (minority of eukaryotic CBEs) and Cys, Asp, His (bacterial arylesterases) (Figure 
1.4) (42). The nucleophilic residue is optimally positioned on a highly conserved turn 
known as the nucleophilic elbow (Gly-X-Ser-X-Gly) (4). Other conserved regions include 
the oxyanion hole, which stabilises the carbonyl group of the substrate, the P1 subsite 
(leaving group pocket) and the P2 subsite (acyl pocket) (43). All catalytic residues are 
required for esterase activity but there are examples of CBEs that are non-catalytic (49). 
The inactive members have large insertions with the catalytic residues relative positions 
still maintained (49). This highlights the large variation found within the α/β hydrolase fold 
and shows the great capacity of the fold for adaptation (50–52). 
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Figure 1.4. The canonical α/β hydrolase active site makeup. The oxyanion hole is shown and 
the catalytic triad of Glu, His and Ser (18). 
Three structures of insect carboxyl/cholinesterases had been reported at the time of writing 
this thesis: acetylcholinesterase (AChE) from the species D. melanogaster (53), juvenile 
hormone esterase from Manduca sexta (54) and αE7 from Lucilia cuprina (55). The 
structure of AChE has been used in the past for modelling insect esterases to give structure-
function insight (56). The active site of the solved insect CBEs varies significantly in the 
two P1 and P2 subsites (55, 57–59). Other noticeable differences are the entry to the 
catalytic site, alternative binding sites involved in allostery, and the number of disulfide 
bonds (54, 55, 57–59). Little is known about the aspects of the structure affecting catalytic 
processes in CBEs, as small sequence changes can affect catalytic machinery. To improve 
the understanding of the functional diversity found within CBEs, further structural data are 
required. 
1.1.6. Regulation of CBEs 
As well as the lack of structural information about insect CBEs, there is little known about 
the gene regulation of insect CBEs particularly in response to insecticides. Insecticide 
resistance can be achieved by the amplification of CBE genes in the genome of resistant 
insects during all life stages (60). The amplification level is usually variable with minimal 
control and exposure to an insecticide leads to a higher copy number (60). More recently it 
has been suggested cis-regulation is important to control gene amplification (60, 61). 
Resistance can also be achieved by CBE genes being ‘switched on’ in resistant species by 
methylation (34, 62). This form of transcriptional regulation is able to reduce fitness costs 
in the absence of insecticide selection by stopping the overproduction of enzyme by 
demethylation (34, 62). The methylation control is evidence for an epigenetic feature 
playing a role in insecticide resistance as the resistance mechanism is inherited to future 
generations and contributes to phenotype variability (34, 62, 63). Recent evidence is 
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suggesting histone modifications can affect gene expression of CBEs and that epigenetics 
plays a major regulatory role in the development of insecticide resistance and adaptation 
(63). More work is required, however, to identify the relationship with insect CBEs, genetic 
evolution, and epistasis.  
1.1.7. Reaction Mechanism 
The proposed mechanism of CBEs proceeds by a two-step reaction catalysed by the 
catalytic triad via an acyl-enzyme intermediate to generate an acid and an alcohol as 
products (64). The hydrolysis is base-mediated, requiring water, and is highly conserved 
among CBEs (64). The currently accepted mechanism is based on work by Satoh, 
Hosokawa, Sogorb, Vilanova, and Redinbo (Figure 1.5) (1, 65–68). The first step of the 
proposed reaction mechanism involves covalent binding between the catalytic nucleophilic 
residue and the carbonyl carbon of the substrate, resulting in liberation of the alcohol (1, 
65–68). Nucleophilic attack on the carbonyl carbon forms the relatively stable acyl-enzyme 
intermediate. The nucleophilicity of the serine is increased and the reaction stabilised by 
the catalytic histidine (1, 65–68). The histidine itself is stabilised and oriented by the 
carboxyl group of the acidic residue (1, 65–68). In the second step, the acyl-enzyme 
tetrahedral intermediate that is covalently attached is attacked by a nucleophilic water 
molecule to regenerate the free enzyme and to liberate the acid portion of the substrate (37, 
69). The water molecule in this step is activated by the histidine and the acid residue of the 
triad.  
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Figure 1.5. The mechanism of ester hydrolysis by CBEs. The essential catalytic amino acids 
are shown (Ser, His and Glu) and the mechanism depicts the hydrolysis of a generic ester. 
Figure adapted from Montella et al (14).  
The glycine residues in the oxyanion hole are important in stabilising and lowering the 
energy of the tetrahedral transition state during both nucleophilic substitution reactions (1, 
65–68). The tetrahedral transition state involves a charge being moved to the carbonyl 
oxygen and the nitrogens of the oxyanion hole help to stabilise the transition state by 
hydrogen bonding interactions (1, 65–68). This reaction mechanism is similar to those of 
serine proteases and is a form of convergent evolution as the structures are unrelated (32). 
Recently, it has been proposed that the mechanism involves four steps instead of two, based 
on computational studies (70).  
The hydrolysis is energetically favourable and in some cases can be diffusion limited (57, 
71–73). The low energy barrier also allows for this reaction to be easily reversible and in 
non-aqueous environments, esterification reactions are possible (74, 75). In this reaction, 
the alcohol molecule is in competition with the water molecules in the active site during 
the attack of the acyl-enzyme intermediate. This results in an ester being obtained instead 
of a carboxylic acid (70). 
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1.1.8. Insect Carboxylesterases 
Insect esterases have been well studied in insect biochemical research for over 50 years and 
fall under the carboxyl/cholinesterase gene family (32). There is little sequence information 
regarding acetyl or arylesterases from invertebrates, with most research focusing on CBEs 
(76). CBEs are rich in the genomes of insects and have been investigated for their diverse 
functions in insecticide resistance (xenobiotic defence), lipid metabolism, reproduction and 
insect development (3, 43, 57, 77). Certain insect pheromones or hormones have been 
identified as being metabolized by CBEs, which has led to significant research on these 
enzymes (32). Insecticide detoxification of organophosphates, carbamates and pyrethroids 
has also been a major research area involving CBEs (32).  
In D. melanogaster and other insect species, there appears to be between 30-76 different 
choline/carboxylesterase genes and a majority are catalytically active (38, 39, 43, 78–80). 
Most of the CBEs identified have no known physiological role (43, 44). The two main 
clusters of focus have been separated as the α and β clusters. The large cluster in D. 
melanogaster is known as the α-cluster with over 10 genes and has roles in xenobiotic 
metabolism (81). The second cluster is known as the β-cluster, which is much smaller and 
appears to be rapidly evolving (42). This cluster has been well studied for models of 
microevolution and contains two genes in D. melanogaster (42).  
An important characteristic observed in insect species is the large number of duplications 
and tolerance to mutations in CBEs, which has resulted in the functional diversification of 
this family and a significant expansion of CBEs (43, 44, 50, 77, 79). With the functional 
diversity found, the sequence diversity is similarly distant with as little as 20% amino acid 
identity between members of the CBEs (43). It has suggested CBEs are rapidly evolving, 
as the enzymes are commonly associated with xenobiotic detoxification mechanisms in 
insect species (38, 39). Gene redundancy (from overlapping substrate ranges) and mutation 
tolerance are possible reasons for the rapid evolution of CBEs (43, 44, 50, 77, 79). 
1.1.9. Vertebrate Carboxylesterases 
CBEs in vertebrate species have been studied for their roles in the biotransformation of 
compounds and fall under the carboxyl/cholinesterase gene family (66). The CBEs are 
responsible for the pharmacokinetic behaviour of several drugs and interact with 
compounds such as heroin, cocaine and the anticancer drug CPT-11 (5, 64, 82). Similar to 
insect CBEs, structures of vertebrate CBEs are also lacking in the PDB. The major 
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structural representation of vertebrate CBEs is liver carboxylesterase 1, which has been 
solved in humans and rabbits (83, 84). Both human cholinesterase protein structures 
(acetylcholinesterase and butyrylcholinesterase) have also been solved and are well studied 
for their association with Alzheimer’s disease and interactions with OP nerve agents (85–
88). This is further discussed in chapter five.  
1.2. Focus of the Thesis 
This thesis will encompass five chapters that will cover α-esterases and β-esterases from a 
variety of species. The first three chapters include three separate projects on insect CBEs 
from dipteran species to understand oligomerization, evolution, structure, and function in 
CBEs. Chapter five discusses the development of inhibitors for vertebrate 
acetylcholinesterase.  
There is a current lack of understanding regarding the structures of CBEs from different 
clades and structure-function relationships within the superfamily. Some questions that are 
unanswered include: do CBEs from different clades vary significantly in structure? Do 
possible small changes in structure affect the evolution of insect resistance? In this work, 
the structure of esterase-6 from Clade E will attempted to be solved to further understand 
the structures of CBEs and the variation within the 14 clades. This can also provide 
evidence for the function of esterase-6, which has been under investigation for several 
decades. To further learn about structure-function relationships in insect CBEs, the activity 
of dipteran CBEs will be characterised with an organophosphate compound in combination 
with homology model analysis to expand on the results. This will also help to understand 
if historical contingency playing a role in the evolution of insecticide resistance involving 
CBEs. 
As well as structural analysis, the effect of quaternary structure on stability in insect CBEs 
is not understood in detail. By studying the formation of new oligomeric species from a 
directed evolution experiment on an insect CBE, the question if quaternary structure 
directly provides stability to proteins can be answered. Lastly, to further develop drugs to 
target the carboxyl/cholinesterase superfamily, two different types of potential inhibitors 
will be tested and analysed structurally against the enzyme, acetylcholinesterase. It is 
unknown how the two natural and modified inhibitors will interact with the protein, 
therefore assays and structural analysis is important to know how effective the new 
potential inhibitors are. 
14 
 
 
 
 
 
 
 
 
Chapter 2. Evolution of oligomeric 
structure in response to heat stress 
 
 
 
 
 
 
  
15 
 
2.1. Declaration of Author Contribution 
The research article in this chapter was peer-reviewed and published as a regular original 
research article. I contributed to >50% of the work included in this paper: I wrote a major 
portion of the text and designed and carried out the majority of the experimental work. 
James M. Murphy was involved in the experimental work involving SAXS (Figure 2F), 
and Matthew A. Perugini contributed towards the AUC data (Figure 2E). Jian-Wei Liu was 
involved in the initial (previously published) directed evolution experiment along with 
Chris W. Coppin and John G. Oakeshott. The initial observation of the difference in 
oligomeric structure between the wild-type and variant proteins involved the authors Colin 
J. Jackson, Mathilde Lethier and Martin Weik. The contributions of the authors Jian-Wei 
Liu, Peter D. Mabbitt, Galen J. Correy, John G. Oakeshott and Colin J. Jackson were 
towards the writing of the paper. 
  
16 
2.2. Introduction 
2.2.1. Oligomers 
A large number of proteins consist of more than one polypeptide chain in their native state 
and the arrangement of these folded chains forms the quaternary structure (Figure 2.1). 
Oligomeric proteins (two or more associating polypeptide chains) are vital and highly 
abundant in nature, comprising a significant percentage of cellular proteins (89–93). 
Oligomerization represents a fundamental strategy for generating complex protein 
structure, functional complexity and regulation in enzymes (94). This has led to protein-
protein interactions and assemblies being the target of structural genomic initiatives to 
understand oligomers (94).  
Figure 2.1. The four levels of protein structure. Primary (amino acid sequence), secondary 
(local sub-substructure), tertiary (three-dimensional structure of a monomeric protein), 
quaternary (three-dimensional structure of a multi-subunit protein) (95). 
A majority of oligomers are composed of identical protein subunits known as homo-
oligomers, based on a snapshot of protein crystal structures from the Protein Databank 
(PDB) and from Escherichia coli annotation (92, 96–98). In contrast, heteromeric 
complexes are composed of multiple different protein subunits and structures for these 
complexes are not well represented in the PDB (99). Higher-order oligomers are less 
frequently found and odd-numbered stoichiometries make up a small number of all 
oligomeric proteins (92, 100). Several explanations have been proposed to account for the 
large amount of homo-oligomeric proteins including self-attraction, symmetry, stability, 
foldability and evolutionary optimization arguments (101–103). 
2.2.2. Why study oligomerization? 
Oligomeric proteins are ubiquitous within the cell and are essential in most biological 
processes (104–106). Given this, it is important to understand how oligomeric protein 
assembly occurs, and factors affecting quaternary structure organisation (104–106). The 
study of oligomeric proteins can provide information about the early protein environment, 
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protein evolution and the general characteristics of an oligomeric protein (107). It is 
important to understand the structural and evolutionary principles of protein-protein 
interactions as many unfavourable interactions can result in disease (108, 109). With a 
greater understanding, the ability to predict and engineer oligomerization is possible. This 
has the potential for the development of new drugs to target complex assembly or induce 
disassembly (110–113). 
2.2.3. Oligomer Evolution 
Although oligomeric proteins are central to biology, the general mechanisms of 
oligomerization have not been fully understood and only anecdotal knowledge exists on 
the factors affecting oligomer evolution and assembly (107, 114). Investigations into the 
formation of new oligomeric species are difficult as the generation of new oligomeric states 
can expose hydrophobic surfaces, which in some cases, results in aggregation and 
solubilisation issues (107). However, it has been shown that soluble oligomerization can 
occur to form stable functional proteins and to protect proteins from aggregation (102, 115, 
116). Currently, no work has focussed on the directed evolution of a protein to a new 
oligomeric state (117). There are several proposed mechanisms for the evolution of new 
oligomeric species and it is likely that oligomerization in different proteins have evolved 
by alternative routes (Figure 2.2) (107, 118). Some proposed mechanisms of oligomer 
evolution are (1) amino acid substitutions, (2) domain swapping, (3) insertions and 
deletions, (4) gene duplication and (5) gene fusion. 
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Figure 2.2 An example of the multiple pathways for the evolution of new oligomers. Changes 
in oligomers can be through point mutations or by the gain of new subunits. Symmetry point 
groups are given for each oligomer. Figure adapted from Marsh et al (99). 
 
 (1) Amino acid substitutions. Point mutations introduced on the protein surface or 
interface can cause the association of oligomers (119–121). The mutations can either be 
located directly in an interface or located away from the interface exerting an indirect effect 
(Figure 2.3) (119–121). The replacement of surface residues to more hydrophobic and/or 
larger residues can favour the formation of oligomers (121, 122). It is difficult to distinguish 
an interface from the surface based solely on amino acid composition, and as few as two 
surface substitutions can generate a new oligomeric interface (121, 122). This shows that 
protein surfaces are similar to interfaces based on amino acid composition alone (122–125). 
 
Figure 2.3. The introduction of surface mutations can give rise to new oligomer structure and 
gene duplication results in further changes in the oligomerization state. Figure adapted from 
Hashimoto et al (126). 
 
(2) Domain Swapping. Oligomers can occur naturally or artificially through the exchange 
of small or large regions (Figure 2.4) (127). In some cases, entire domains of monomeric 
subunits can be exchanged (127). This mechanism is known as three-dimensional domain 
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swapping where tertiary structure exchanges with another copy of itself (128). 24% of 
homo-oligomers have been identified as having domain swapped structures (129). 
Figure 2.4. An example of three-dimensional domain swapping with two monomeric proteins 
exchanging secondary structure. The opening of the loop in the monomer allows for the 
formation of the dimer. Figure adapted from Gotte et al (130). 
(3) Insertions and deletions. In a single step, the insertion of a short loop can introduce a
new interface (118, 131–133). This is an important mechanism to control oligomeric states 
in protein evolution (126). The removal of insertions has been shown to result in a complete 
or partial loss of oligomer stability (118, 131, 132). 
(4) Gene duplication. Protein complex evolution can occur through the gain of subunits
by gene duplication events (Figure 2.3) (115, 134–137). If a gene encoding an oligomeric 
protein is duplicated, at first the two identical genes will still form the same oligomer (99). 
However, as one copy of the gene retains its original function, the other gene copy will be 
under relaxed evolutionary constraints, allowing it to develop a new specific function. 
Eventually, this mechanism will lead to two dissimilar genes and the formation of 
oligomeric paralogs (115, 132, 137–139).  
(5) Gene fusion. Oligomerization can arise by gene fusion when two separate genes
become fused into one open reading frame (Figure 2.5) (140). For example, a gene 
encoding an oligomerization domain can fuse with a previously monomeric protein, 
forming a new oligomeric protein (107).  
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Figure 2.5. An example of gene fusion where a new covalent association between two 
separate subunits of the same complex is formed. Figure adapted from Marsh et al (99). 
2.2.4. Features of oligomerization 
As oligomeric proteins are important in numerous pathways including gene expression, ion 
channels, and cell-cell adhesion processes, the question of how oligomeric proteins evolved 
is a fundamental question which is still being explored (98, 107, 141). There are several 
advantages oligomerization offers compared to a monomeric protein that can be selected 
for during evolution. Currently, there is no single theory to explain how a specific oligomer 
has emerged and it has been suggested that oligomeric structure could occur by chance 
(114).  
2.2.5. General characteristics of oligomerization. 
(1) Complex scaffolds can result in the better support for function or functional gain (142–
144). For example, a new interface can be directly involved in protein function (142–144). 
This is commonly found in heteromeric proteins where distinct functions are brought 
together (92).  
(2) Allostery introduces an additional level of control and is commonly associated with 
oligomeric proteins. Oligomerization can provide sites for cofactors to interact with, 
resulting in substrate-induced cooperativity (Figure 2.6) (145, 146).  
 
Figure 2.6. Allosteric control between two states (T, R) associated with oligomerization is 
observed in haemoglobin induced by oxygen binding (145). 
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(3) Oligomerization can result in a protein being encoded using less genetic material. This
represents a form of coding economy, as larger proteins can be formed without increasing 
the genome size (147). 
(4) The increase in oligomerization state results in larger proteins that are typically more
resistant to degradation and denaturation (92, 116, 125, 148). This is due to a reduced 
surface-to-volume ratio in oligomeric proteins than that of free monomers. Oligomerization 
can increase stability in this manner and also offers protection against denaturation (92, 
116, 125, 148). 
2.2.6. Oligomer Equilibrium and Regulation 
While new oligomers can evolve, the formation of a new oligomer can be induced by 
ligands, posttranslational modifications or by changes in physiological conditions (pH, 
ionic strength, temperature and protein concentration) (98, 149). The strength and duration 
of an association between subunits can vary significantly (107). Oligomeric proteins can 
be found primarily in one higher oligomeric state or can weakly associate and fluctuate 
between several states (107). This can serve a regulatory mechanism by changing 
oligomeric states in response to a stimulus (98, 149–151). 
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2.3. Research Article 
 
2.3.1. Preface 
There are several suggested mechanisms of how new oligomers can form and the functional 
or stability advantages that arise from forming a new oligomeric species. However, direct 
evidence for this is missing in the literature. Previous evidence comes from the comparison 
of ancestry proteins to modern day proteins and few studies have directly validated stability 
with newly formed oligomeric species. It has also been suggested that oligomerisation can 
arise during evolution neutrally and offer no benefits. Investigations into evolutionary 
experiments involving oligomeric proteins can provide the necessary evidence to refute this 
claim. In the carboxylesterase αE7 from the Australian sheep blowfly (L. cuprina), a 
directed evolution experiment for increase thermal stability resulted in a variant with 
increased amounts of unknown oligomeric species compared to the wild type protein (55). 
The following article discusses the characterisation of the identified oligomeric species and 
the nature of the stabilisation of αE7 in the directed evolution experiment. 
 
2.3.2. Published Research Article: Evolution of Protein Quaternary Structure in 
Response to Selective Pressure for Increased Thermostability 
 
Supplementary Information is found in Appendix A 
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Edited by S. A. TeichmannAbstract
Oligomerization has been suggested to be an important mechanism for increasing or maintaining the
thermostability of proteins. Although it is evident that protein–protein contacts can result in substantial
stabilization in many extant proteins, evidence for evolutionary selection for oligomerization is largely indirect
and little is understood of the early steps in the evolution of oligomers. A laboratory-directed evolution
experiment that selected for increased thermostability in the αE7 carboxylesterase from the Australian sheep
blowfly, Lucilia cuprina, resulted in a thermostable variant, LcαE7-4a, that displayed increased levels of
dimeric and tetrameric quaternary structure. A trade-off between activity and thermostability was made during
the evolution of thermostability, with the higher-order oligomeric species displaying the greatest
thermostability and lowest catalytic activity. Analysis of monomeric and dimeric LcαE7-4a crystal structures
revealed that only one of the oligomerization-inducing mutations was located at a potential protein–protein
interface. This work demonstrates that by imposing a selective pressure demanding greater thermostability,
mutations can lead to increased oligomerization and stabilization, providing support for the hypothesis that
oligomerization is a viable evolutionary strategy for protein stabilization.
© 2016 Elsevier Ltd. All rights reserved.Introduction
Oligomerization is one of the most fundamental
biophysical interactions in protein chemistry. Bioin-
formatics and pull-down experiments have revealed
that a large number of proteins exist as homo-
oligomers consisting of two or more identical chains
[1–4]. Similarly, many proteins function in the cell as
hetero-oligomers composed of non-identical chains
[5–9]. Oligomerization has been shown to play
important roles in the genetic economy [10], func-
tional gain [11–13], structural stability [14,15],
allosteric regulation [16–19], and protection from
degradation [17]. Given the biological importance of
oligomerization, there is substantial interest iner Ltd. All rights reserved.understanding how the evolution of new oligomeric
species occurs [20,21], engineering new oligomeric
structure [22,23], and developing drugs targeted at
complex assembly and disassembly [24,25].
The cellular milieu is a precarious environment for
the evolution of oligomeric proteins as the physical
forces that drive beneficial protein association are
the same as those that drive deleterious aggregation
[26,27]. It is well established that changes in protein
sequence through non-synonymous point muta-
tions, insertions, and deletions can shift the balance
of oligomeric states [21,28–30]. Both rational muta-
genesis and directed evolution have been exploited
to advance our understanding of how oligomers form
[31–34] and to design new hetero-oligomers [35,36].J Mol Biol (2016) 428, 2359–2371
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Table 1. Mutations incorporated into LcαE7 during
laboratory-directed evolution for thermostability
Round of evolution and mutation
2a 2b 2c 2d 3a 3b 4a
Residue
Asp83 Ala
Ala285 Ser
Met364 Leu
Ile419 Phe Phe Phe
Ala472 Thr Thr Thr Thr Thr Thr
Phe478 Leu
Ile505 Thr Thr
Lys530 Glu Glu Glu
Asp554 Gly
Mutations were not recorded in the first round of mutagenesis. In
round 2, four variants (2a, 2b, 2c, and 2d) were selected for DNA
shuffling andmutagenesis resulting in round 3 variants. In round 3,
two variants (3a and 3b) were selected for DNA shuffling and
mutagenesis resulting in the round 4a variant.
2360 Evolution of Protein Quaternary StructureProtein flexibility, shape, and symmetry have all
been identified as being important for the formation
of new oligomeric structure [37,38], since symmet-
rical and complementary interfaces may form stron-
ger interactions than heterologous surfaces [39–41].
Despite a growing understanding of the nature of
oligomers and protein complexes, it is difficult to
predict how a new and beneficial protein–protein
interface will develop, let alone design one de novo
[23,42,43]. Moreover, despite intense study, de novo
evolution of oligomeric structure has not been
observed directly, to the best of our knowledge.
The fundamental importance of stability in protein
evolution and the stabilizing contribution of oligomer-
ization (via reduction of the surface-to-volume ratio of
the complex compared to a free monomer) are well
established [44,45,2]. Protein–protein interactions can
provide stabilizing polar or hydrophobic contacts
(although interfaces in homodimers predominantly
involve polar interactions), leading to tighter molecular
packing and offering protection from denaturation
[2,46]. Indirect evidence for the stabilizing effects of
protein–protein interactions comes from thermophilic
Archaea and bacteria, where oligomerization has been
suggested to be one of the contributing factors to the
high thermostability of proteins in these organisms
[47,48]. Other examples of oligomerization leading to
increased stability come from studies in which the
disruption of protein–protein interfaces leads to de-
creased thermostability or enzymatic activity [14,49] or
the engineered formation of oligomers leads to
increased stability [50,51]. However, despite several
lines of evidence that oligomerization increases protein
stability, most of the evidence for an evolutionary role
for oligomerization had been indirect until the recent
work of Perica et al., who used ancestral protein
reconstruction to identify specific mutations directly
involved in the process [20]. Notably, many of the
mutations were found to be remote from the protein–
protein interface.
LcαE7 is a carboxylesterase involved in organo-
phosphate insecticide resistance in the sheep blowfly,
Lucilia cuprina [52]. We have previously reported an
experiment in which we performed directed evolution
of LcαE7 in order to stabilize the protein for crystalli-
zation. However, there was little analysis of the
evolution of thermostability, beyond the observation
that after four rounds of evolution a variant (D83A,
M364L, I419F, A472T, I505T, K530E, and D554G)
was obtained that readily crystallized and displayed
enhanced thermostability [53]. In this work, we have
focused on the process by which the thermostable
variant evolved and the nature of the stabilization.
Here, we demonstrate that stabilization of the protein
occurred via two related routes: stabilization of the
monomeric protein through improved side-chain pack-
ing, and through the enrichment of more stable dimeric
and tetrameric species. Oligomerization as a route to
thermostability has been inferred through analysisof extant proteins and through ancestral reconstruc-
tion [20], but seldom has de novo evolution of
oligomerization been observed. These results allow
us to understand the first steps in this process, which
will benefit future engineering efforts.Results
Directed evolution of LcαE7 for increased thermal
stability
As reported previously, the wild-type (WT) LcαE7
protein was unstable both during and after purifica-
tion [53]. Thus, the original rationale behind the
design of this directed evolution experiment was to
extend the half-life of LcαE7 at temperatures that
it might experience during expression and purifica-
tion to facilitate crystallization. To achieve this, we
designed a medium throughput screen in which
LcαE7 was heterologously expressed in Escherichia
coli, replica plated onto filter paper, and assayed
colorimetrically for activity using 2-napthyl acetate
and fast-red dye. By randomly mutating the LcαE7
gene in an expression vector and incubating
the replica-plated E. coli transformed with the mutant
library on filter paper for up to 1 h at elevated
temperatures, we were able to iteratively select more
thermostable variants and progressively increase the
thermostability of the protein. After one round of
random mutagenesis, only marginal improvements in
activity over that of the WT enzyme were evident.
Accordingly, these variants were not sequenced, but
potentially improved variants were pooled for further
random mutagenesis (which includes some recombi-
nation [54]) ahead of three further rounds of evolution.
By round 2, significant increases in thermostability24
2361Evolution of Protein Quaternary Structurewere apparent, allowing specific mutants to be isolated
and sequenced (Table 1). In round 2, four variants (2a,
2b, 2c, and 2d) were selected for DNA shuffling and
mutagenesis resulting in round 3 variants. In round 3,
two variants (3a and 3b) were selected for DNA
shuffling and mutagenesis resulting in the round 4a
variant. The most stable variant from the experiment
was LcαE7-4a (Fig. 1a), which incorporates three
mutations first observed in round 2 (I419F, A472T,
K530E), one mutation from round 3 (I505T), and three
mutations from round 4 (D83A, M364L, D554G). The
mutationD83Awasaccidentlymissed in the previously
reported structure of this protein [49]. Subsequent DNA
sequencing and analysis of electron density maps
(5IKX, 5CH3) of LcαE7-4a have confirmed that this
mutation is present.
The LcαE7-4a variant was then characterized in
detail. We found that its half-life (time at which 50%
of original activity remains) at 40 °C was indeed
much greater than that of the WT enzyme (N60 min
versus 1.6 min), indicating that some of the muta-
tions in LcαE7-4a stabilize the protein (Fig. 1a).
Notably, whereas the activity of the WT proteinFig. 1. Directed evolution of LcαE7 for enhanced
thermostability. (a) When incubated at 40 °C over a
time-course, there was a one-phase exponential decay
curve of activity in the WT protein, and of the LcαE7-4a
protein (b) SEC detected the presence of LcαE7 in four
main peaks, fraction 12, fraction 22, fraction 24, and
fraction 28. A contaminating band was present, represent-
ed by a peak in fraction 14.rapidly diminished to background levels (7.5% of the
initial activity) with a half-life of 1.6 min, consistent
with a single population of enzymes with similar
thermostability, the activity of LcαE7-4a decayed
with a half-life of 24 min, but extrapolates to 56% of
its original activity when fit to a one-phase exponen-
tial decay curve. Thus, LcαE7-4a appears to be
heterogeneous, consisting of one species with a
half-life of 24 min, and other species that are
essentially stable at 40 °C.
To investigate the composition of LcαE7-4a in
greater detail, we performed size exclusion chroma-
tography (SEC), with kinetic and SDS-PAGE anal-
ysis of each fraction (Fig. 1b). These analyses
revealed that, other than minor contamination by a
protein of approximately 70 kDa in fractions 12–18,
LcαE7-4a comprised the majority of the protein in the
sample. However, the protein quaternary structurewas
not homogeneous. In fact, there were four distinct
species present in the sample: a high-molecular weight
(HMW) species, which eluted near the void volume of
the column, and three species relatively close in elution
volume which primarily eluted in fractions 22, 24, and
26, respectively.
Characterization of the oligomeric species
The SEC was repeated several times, using a
range of protein concentrations (5–20 mg/mL).
LcαE7-WT was consistently observed to elute
primarily as a monomer, with small amounts of an
HMW species (~120 mL) and small shoulders
(170 mL, 185 mL) on the primary monomer peak
(~215 mL) (Fig. 2a–c). In contrast and at all
concentrations, LcαE7-4a eluted with a significantly
greater proportion of larger species eluting at
~170 mL and 185 mL. The peak UV absorbance
of these fractions relative to that of the monomer in
LcαE7-4a was approximately double those found for
LcαE7-WT. Because the cytosol of the cell, where
LcαE7-WT and LcαE7-4a were expressed and
assayed during the laboratory evolutionary selec-
tion, is a viscous environment [55], we repeated
these experiments in the presence of 10% glycerol.
This revealed that in a more viscous solution, the
tetrameric and dimeric HMW species comprised
approximately half of the total LcαE7-4a protein,
whereas for LcαE7-WT, the majority of the protein
was monomeric (SI Fig. 1).
We next performed SEC–multi-angle laser light
scattering (SEC–MALLS) analysis to obtain more
accurate estimates of the absolute molecular weight
of the various LcαE7 forms [56]. This analysis
indicated that the three lower-molecular-weight
species, which are composed exclusively of LcαE7
protein (Fig. 1b), are approximately 60 kDa,
120 kDa, and 260 kDa (Fig. 2d). These molecular
masses correspond to the theoretical molecular
masses of LcαE7 monomer (66.3 kDa), dimer25
Fig. 2. Characterization of the oligomeric species observed in this work. (a and b) Comparison between size exclusion
chromatographic spectra of WT LcαE7 (a) and LcαE7-4a (b) reveals that directed evolution has resulted in substantial
increases in the amounts of dimeric and tetrameric species (c). Monomer (M), dimer (D), and tetramer (T) peaks are
labeled. Each line in the graphs (a and b) corresponds to an independent purification. (d) SEC–MALLS analysis reveals
the three species of LcαE7-4a correspond to monomer, dimer, and tetramer stoichiometry. (e) AUC sedimentation velocity
analysis of LcαE7-4a at an initial concentration of 3.0 mg/mL. The continuous sedimentation coefficient [c(s)] distribution is
plotted as a function of the standardized sedimentation coefficient. Analysis was performed using a resolution of 200 with a
sedimentation coefficient range of 0–20 S and a P-value of 0.95. The nonlinear least squares fit shown resulted in an rmsd
of 0.00585 and a runs test Z of 4.61. Inset: residuals from the c(s) distribution best fit plotted as a function of radial distance
from the axis of rotation. (f) Small angle X-ray scattering analysis of the HMW species reveals it to be a heterogeneous
aggregate.
2362 Evolution of Protein Quaternary Structure(132.6 kDa), and tetramer (265.2 kDa). We then
performed analytical ultracentrifugation (AUC) sed-
imentation velocity experiments on the complex
sample of LcαE7-4a (Fig. 2e). These results confirm
that LcαE7-4a exists as a mixture of monomeric
species and high-order oligomeric species, with the
majority of the protein sedimenting as monomerFig. 3. Characterization of the oligomeric species. Rate versus
hydrolysis byWT LcαE7 and LcαE7-4a. All curves were fit to the M
exception of LcαE7-4a monomer, which was fitted to the equatio
(1 + [S]/Ksi)).(66 kDa versus 66.3 kDa theoretical molecular
mass) but a significant amount forming dimers
(137 kDa versus 132.6 kDa theoretical molecular
mass) and tetramers (230 kDa versus 265.2 kDa
theoretical mass).
Whereas the stoichiometry of the ~260, ~136, and
~66 kDa species is readily apparent, the HMWconcentration plots for the catalysis of 4-nitrophenyl butyrate
ichaelis–Menten equation v = (kcat · [S])/(KM + [S]), with the
n modified for substrate inhibition v = (kcat · [S])/((KM + [S]) ·
26
Table 2. Kinetic parameters for the oligomers of LcαE7 with the model carboxylesterase substrate 4-nitrophenyl butyrate
KM (μM) kcat (s
−1) kcat/KM (M
−1 s−1) Ki (mM)
LcαE7 68.6 ± 12.3 40.6 ± 2.2 6.0 × 105 ± 1.3 × 105 —
LcαE7-4 monomer 38.1 ± 8.3 14.5 ± 1.1 3.8 × 105 ± 1.6 × 105 2.6 ± 0.8
dimer 30.4 ± 4.8 4.5 ± 0.2 1.5 × 105 ± 0.2 × 105 —
LcαE7-4 tetramer 35.6 ± 4.9 5.7 ± 0.3 1.6 × 105 ± 0.3 × 105 —
Kinetic data for LcαE7, LcαE7-4 dimer, and LcαE7-4 tetramer were fit to a model for standard Michaelis–Menten kinetics (v = (kcat · [S])/
(KM + [S])), whereas kinetic data for LcαE7-4monomer were fit to a Michaelis–Menten kinetic model incorporating substrate inhibition (v =
(kcat · [S])/((KM + [S]) · (1 + [S]/Ksi))).
Table 3. Calculated transition temperature (TT50) for the
LcαE7 proteins as measured by temperature-ramp CD
Protein TT50 (°C)
LcαE7 48.8 ± 0.2
LcαE7-4a monomer 55.5 ± 0.5, 66.2 ± 0.6
dimer 56.3 ± 0.6, 61.7 ± 0.9
LcαE7-4a tetramer 65.2 ± 2.0
Ellipticity was recorded at 208 nm and fitted by non-linear
regression to two-state model (LcαE7 monomer and LcαE7-4a
tetramer) and a three-state model (LcαE7-4a monomer and
LcαE7-4a tetramer. The best fitting model was chosen based on
the sum of residuals. Raw data is plotted in SI Fig. 2.
2363Evolution of Protein Quaternary Structurespecies (~400 kDa) was more difficult to analyze.
We performed small angle X-ray scattering on this
sample in order to determine, at low resolution, its
molecular structure (Fig. 2f). These results indicate
that this species is very heterogeneous, consistent
with HMW protein aggregates that likely formed
during recombinant expression and purification. The
observation that the HMW peak is present in the WT
sample at similar abundance to the LcαE7-4a
samples suggests that this species is not directly
relevant to the evolutionary stabilization of the
protein. Accordingly, it was not considered further
in this study.
We then investigated whether the dimeric and
tetrameric oligomeric species were representative of
the protein in an equilibrium state, or were artifacts of
the purification and concentration process. We
obtained single 5-mL fractions from the center of
the monomer and tetramer peaks from SEC and
then performed SEC again after approximately 5 h at
4 °C (monomer) or 24 h at 4 °C (tetramer) (SI Fig. 2).
We found that the tetramer had equilibrated into
approximately equal distributions of monomer,
dimer, and tetramer, while the monomer had also
equilibrated to form dimeric and tetrameric species.
Thus, the tendency of LcαE7-4a to self-associate is
a genuine equilibrium property.
The effect of oligomerization on enzyme activity
and thermostability
Kinetic analyses of each species from LcαE7-4a
(Fig. 3 and Table 2) showed that the monomeric,
dimeric, and tetrameric forms were all significantly
less active than the WT enzyme with the model
substrate 4-nitrophenyl butyrate. However, the di-
meric and tetrameric species were kinetically distinct
from the monomer. Interestingly, the monomeric
LcαE7-4a species exhibited significant substrate
inhibition (Ki), which was not apparent in either the
dimeric or tetrameric species or the monomeric WT
species. When the activity of the tetrameric and
monomeric species was assayed at 46 °C over a
time course (SI Fig. 3), the tetrameric species retained
greater activity, after 1 h (the monomeric species was
almost fully inactivated). Given that the evolutionary
selection was used to identify mutants that could retainactivity after a 1-h incubation at elevated temperature,
this suggests that the greater thermostability of the
higher-order species was selected for and made a
significant contribution to the global enhancement of
LcαE7 thermostability.
Circular dichroism (CD) spectroscopy was used to
investigate the thermostability of the three LcαE7-4a
species (Table 3; SI Fig. 4). None of these species
underwent reversible folding, meaning that accurate
estimates of the free energy of folding energy could not
be obtained. Nevertheless, the thermal melting curves
provide an appropriate measurement of the tempera-
ture at which the majority of secondary structure in
these proteins was lost (unfolding). All three LcαE7-4a
species were significantly more stable that the WT
protein. As was the case with the catalytic activity of
these species, the thermostability was different
between the monomer, dimer, and tetramer. Given
the propensity of the higher-order species to slowly
re-equilibrate (SI Fig. 2), we were unable to obtain
completely homogeneous samples, although those
sampled were analyzed within 2 h of SEC (after buffer
exchange). This was apparent in the monomer and
dimer samples, where the use of a three-state model
showed that separate unfolding transitions corre-
sponding to the monomer (55.5 °C) and dimer
(66.2 °C) were apparent (Table 3; SI Fig. 4). The
tetrameric sample showed a single transition at
~65 °C. Thus, the higher-order species are significant-
ly more thermostable, consistent with the results from
the activity decay measurement (SI Fig. 3).27
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using differential scanning fluorimetry (DSF) [57].
These results showed that, whereas a complex
mixture (pre-SEC) of LcαE7-WT appeared to com-
prise a single dominant species that permitted the
use of a two-state unfolding model, the complex
mixture of LcαE7-4a consisted of two species, with
one having a significantly higher melting tempera-
ture (SI Fig. 5). When monomeric and tetrameric
fractions from SEC (0.3 mg/mL) were immediately
analyzed by DSF (the dimeric fraction was found to
comprise a mixture of both species), we could obtain
pure samples with a single transition temperature.
This confirmed that the higher-order tetramer frac-
tion was more stable by ~5 °C. After concentration
to 3 mg/mL, some re-equilibration occurred and both
tetrameric and monomeric samples showed two
transitions, one corresponding to monomer and
the other corresponding to tetramer (SI Table 1; SI
Fig. 6). Overall, the melting temperatures were slightly
lowerwithDSF thanwithCD (although the results were
qualitatively identical), which can be explained by local
exposure of hydrophobic surface (enabling binding of
the fluorescent dye) before complete loss of secondary
structure.
Structural comparison between monomeric and
dimeric LcαE7-4a
We have previously reported the structures of
monomeric and dimeric LcαE7-4a [53]. Monomeric
LcαE7-4a was crystallized in the P21 space group
(5IKX), with two molecules in the asymmetric unit.
However, there was no close association reminis-
cent of a dimer/tetramer interface between the twomolecules, or between them and any of the other
molecules in the crystal lattice via symmetry (Fig. 5).
In confirmation of this, the PISA algorithm did not
detect any potential association interfaces or any
potential assemblies [58]. In contrast, the LcαE7-4a
protein crystallized in the C2221 space group (5CH3)
had a monomer in the asymmetric unit, yet formed
extensive, symmetrical, interactions with a neigh-
boring molecule that were visually consistent with a
typical oligomeric interface (Fig. 5a). Analysis using
PISA confirmed that this structure is likely to be a
dimer under physiological conditions: 2260 Å2 of
protein surface areas is buried within the dimer
interface. A total of 16 hydrogen bonds and 8 salt
bridges were observed between the two-monomer
chains (Fig. 5). The monomeric (P21) and dimeric
(C2221) structures were very similar in terms of
bother overall topology (C-α RMSD 0.339 Å) and the
main chain conformation at the dimer interface.
Thus, in the case of LcαE7-4a, dimerization does not
require any large-scale rearrangement.
Interestingly, none of the mutations observed in
LcαE7-4a are located at the dimer interface (Fig. 5a
and b). However, three of the mutations are located
on the protein surface near regions that are involved
in the dimer interface and display some conforma-
tional disorder, as indicated by their atomic
B-factors: D83A is located at the rear of the protein,
M364L is located at a tight turn between two
α-helices that overhang the dimer interface and
active site entrance, D554G is located on an α-helix
that is adjacent to one of the α-helices that comprise
a significant part of the dimer interface. K530E is
located at the rear of the protein in another
comparatively disordered region.Fig. 4. Proportion of oligomeric
species in the reverse mutations
LcαE7-4a (A83D LcαE7-4a, L364M
LcαE7-4a, E530K LcαE7-4a,
G554D LcαE7-4a) and two muta-
tions found in round 2 of the directed
evolution (A285S LcαE7-4a and
F478L LcαE7-4a) as estimated by
peak heights obtained by SEC.
Standard errors are shown for each
species.
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oligomerization and thermal stability of LcαE7-4a
To better understand the effects of the four surface
mutations (D83A, M364L, K530E, and D554G)
present in the thermostable LcαE7-4a protein, they
were individually reverted to the WT state. Purified
proteins were subject to SEC in order to investigate the
formation of oligomeric species (Fig. 4). The A83D and
L364M reversionmutationshadnodiscernible effect on
the oligomeric equilibrium. The G554D reversion
mutation resulted in a loss of dimer, which suggests
that itmaystabilize theadjacentα-helix that participates
in the dimer interface, but had no effect on the
proportion of tetrameric species. This observation is
consistent with recent work that has shown that
mutations can alter the oligomeric equilibrium of
proteins through long-range effects on mobile regions
(protein dynamics) [20]. The E530K mutation had no
effect on the amount of dimer that was formed, but
resulted in a significant reduction in the abundance of
tetramer. In theX-crystal structure of LcαE7-4a, E530 is
located in a putative tetramerization interface (Fig. 5c).Fig. 5. (a and b) The structure of dimeric LcαE7-4a (5CH3),
of the mutations. The surface mutations D83A, M364L, K530E,
mutations I505T, A472T, and I419F are shown on the left. Th
location of the active site. B is rotated 90° relative to A. (c) A nu
dimer interface. Monomer A is shown in cyan and monomer
interactions of the P21 crystal form of LcαE7-4a (5IKX). The tw
symmetry mates, light gray. Other symmetry-related moleculeA salt bridge was observed between E530 and K104
from the adjacent chain; this salt bridge would be
absent from theWT protein andmay act to stabilize the
LcαE7-4a tetramer. Relative to other amino acids, a
large proportion of lysine residues are present on
protein surface of LcαE7. Lysine residues are less
frequently found at interfaces of oligomeric proteins
[59], and removal of lysine residues has been shown to
increase the probability of protein crystallization [60],
which is a controlled form of aggregation. Thus, it is
likely that the K530E mutation is at least partially
responsible for formation of the tetrameric species and
the increased propensity of LcαE7-4a to crystallize in
the C2221 space group.
The effects of the surface mutations on the
thermostability of LcαE7-4a were measured by CD
(Table 4). The four surface mutations in LcαE7-4a
were individually returned to theWT state. The charge
reversal mutation, E530K, was the only mutation to
significantly affect the thermostability of the LcαE7-4a
monomer, while the other three surface mutations
A83D, L364M, andG554D had no significant effect on
the thermostability of LcαE7-4a. This suggests that theshowing the location of the dimer interface and the location
and D554G are shown on the right, while the three internal
e catalytic serine (S218) is shown in black to indicate the
mber of salt bridges and hydrogen bonds are formed at the
B in green. (d) The comparatively loose crystal packing
o molecules in the asymmetric unit are colored dark gray;
s are omitted for clarity.
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Table 4. Calculated transition temperature (TT50) for the
LcαE7-4a proteins variants with reversed surface
mutations for thermostabi l i ty as measured by
temperature-ramp CD
Protein TT50 (°C)
LcαE7-4a 55.5 ± 0.5
LcαE7-4a A83D 55.7 ± 0.4
LcαE7-4a L364M 56.5 ± 0.6
LcαE7-4a E530K 53.9 ± 0.2
LcαE7-4a G554D 56.3 ± 0.8
Ellipticity was recorded at 208 nm and fitted to non-linear
regression to a three-state model (Eq. (1)).
2366 Evolution of Protein Quaternary StructureK530E mutation along with at least one of the three
internal mutations (I419F, T472A, and I505T) plays
a role in the stabilization of monomeric LcαE7-4a
protein, relative to LcαE7. We also investigated the
A285S and F478L mutations that occurred in round 2
mutants 2a and 2c, but did not fixate during the
evolution. In terms of both oligomerization (Fig. 4) and
thermostability (SI Fig. 7), these mutations were
selectively neutral, explaining their disappearance by
round 4.
Stabilizing and oligomerization-inducing
mutations are found in fly species closely related
to L. cuprina
To determine if the amino acid substitutions we
observed in this experiment also occur in orthologs
of LcαE7, we performed a multiple sequence
alignment of α-esterase 7 genes from four closely
related species of flies: Calliphora stygia (New
Zealand brown blowfly), Cochliomyia hominivorax
(New World screw-worm fly), Musca domestica
(house fly), and Haematobia irritans (horn fly) (SI
Fig. 8). Interestingly, many of the mutations that
fixated during this laboratory evolution experiment to
produce LcαE7-4a are commonly occurring amino
acid differences among these sequences. Three of
them, I419F, T472A, and I505T, occur among the
five species' sequences exactly as we find them in
LcαE7-4a and variation is also found at three of the
other sites, albeit not to exactly the same amino
acid D83(E), M364(A/E/H), and D554(E) in those
cases. Only K530 is strongly conserved across the
five species. Thus, several of the mutations that we
observed in our directed evolution experiment are
also present in orthologous enzymes.Discussion
In this work, we have evolved an enzyme with a
greater propensity to adopt higher-order molecular
structure. In practical terms, the evolution of high-
er-molecular-weight species could be advantageous
to the possible application of LcαE7 as a biosca-venger to treat individuals poisoned by organophos-
phates, since it is known that proteins less than
~60 kDa are cleared through glomerular filtration
[52,61]. The use of protein engineering or directed
evolution to produce proteins with enhanced
thermostability is perhaps one of the most common
applications of these techniques: several high-profile
studies have shed substantial light on the mecha-
nisms by which thermostability can evolve
[44,45,62–64]. The increase in the thermostability
of monomeric LcαE7-4a over monomeric LcαE7
conforms to our expectations of how monomers can
be stabilized and is likely due to improved packing of
hydrophobic residues in the core of LcαE7, as has
we have discussed previously [53]. However, the
oligomeric states of these stabilized proteins are
seldom characterized; enzymes are most often
assayed either in crude lysate or after affinity
purification. It is therefore possible that our obser-
vation that the increased thermostability of LcαE7-4a
can be partially attributed to enrichment of high-
er-order oligomeric species could be a more
common process than currently thought.
Our results exemplify a trade-off between activity
and stability that has been demonstrated in a
number of studies of other enzymes [44,45,65].
Specifically, we observe the monomeric species to
be more active than the dimeric and tetrameric
species. Furthermore, we find that the monomer
displays substrate inhibition, whereas the other
species do not. This suggests that the monomeric
species is able to adopt conformations in which
multiple substrate molecules can bind at one time,
inhibiting the reaction, whereas these, presumably
more open, conformations are not available to the
dimeric and tetrameric species. This is consistent
with the location of the dimer interface: directly at the
entrance to (but not occluding) the active site. Thus,
we see that oligomerization can have significant
stabilizing effects on certain protein regions [37] that
can indirectly affect activity [66].
Recent work has shown that oligomers are more
tolerant to mutation and thus more evolvable,
primarily owing to their stability [64]. Indeed, numer-
ous studies have implicated oligomerization in
protein thermostability, through observation of olig-
omers in thermophiles [47,48], or engineered
disruption/formation of protein–protein interfaces
[14,49]. Despite this, there have been few, if any,
direct observations (to the best of our knowledge), of
proteins spontaneously evolving thermostability
through the gain in additional oligomeric structure
in laboratory settings in response to a thermal
challenge. Because of our inability to replicate the
stepwise evolution of oligomers in the laboratory and
characterize evolutionary intermediates, our under-
standing of the sequence changes and structural
mechanisms that underlie protein self-association has
been limited. Only recently has the use of ancestral30
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cess of oligomerization to be recapitulated, yielding
valuable new insights into the mechanism of oligo-
merization and highlighting the role of remote muta-
tions and protein dynamics [20]. The results presented
here show that the evolution of thermostability in
LcαE7 has occurred in parallel with enrichment of
higher-order oligomeric states that display greater
thermostability than themonomeric species, that point
mutations can lead to a gradual shift in the oligomeric
equilibrium of states in a protein population, and that
these mutations can alter the propensity for mono-
mers to oligomerize either via the formation of new
bonds, or indirectly via the stabilization of mobile
regions of the protein.Materials and Methods
Directed evolution
The directed evolution experiment was performed as
described previously [53]. Selection of improved variants
was carried out through library screening (approximately
100,000 colonies). Cells were spread onto Lysogeny Broth
agar plates supplemented with 100 μg/mL ampicillin at a
cell density which resulted in ~200 colonies per plate.
Colonies were blotted onto Whatman grade 3 filter paper
(GE Healthcare) and incubated for 1 h at 50 °C (increased
to 55 °C, 60 °C, and 70 °C for rounds 2, 3, and 4). The
residual esterase activity was assayed by spraying
heat-treated colonies with substrate solution [0.8% wt/vol
Fast Red, 10 mM β-naphthyl acetate, and 100 mM Tris
(pH 7.0)]. The most active mutants after thermal challenge
were identified as those colonies that produced the most
intense red color. A secondary screen of the best variants
was carried out, in which the best variants from the plate
screen were picked and grown in 96-deep well plate
formats. The overnight cultures were heat stressed for 1 h
at the same temperatures used in the primary screen, and
25 μL overnight cultures were assayed using a Molecular
Devices plate reader at 490 nm in the presence of 0.5 mM
β-naphthyl acetate, 0.5 mM Fast Red dye, and 100 mM
Tris (pH 7.0). The best 5–10 variants of each generation
were carried forward to the next generation, and the final
product LcαE7-4a and several variants from rounds 2 and
3 were sequenced at the Micromon Sequencing Facility,
Melbourne, Australia.
Site-directed mutagenesis
Surface mutations of LcαE7-4a were individually
reverted back to the WT state (A83D, L364M, E530K, or
G554D) by the DNA-fragment assembly method described
by Gibson and coworkers [67]. A285S and F478L were
introduced into LcαE7-4a by the same assembly method.
Pairs of primers were designed to introduce the required
codon change in the LcαE7 gene located in a pETMCSIII
vector. The resulting vectors were sequenced at the
Biomolecular Resource Facility, Australian National Uni-
versity, Australia.Protein expression and purification
LcαE7-WT and LcαE7-4a were expressed in E. coli BL21
(DE3) cells and grown in LysogenyBroth supplementedwith
100 μg/mL of ampicillin in the leaky expression vector
pETMCSIII [68]. Cultures were grown at 25 °C for 18 h,
without induction. The cells were resuspended in buffer A
[10 mM imidazole, 50 mM Hepes (pH 7.5), 300 mM NaCl]
and lysed by sonication using the Sonic Ruptor 400 (Omni
International). Clarified lysate was applied to a 5 mLNi-NTA
column (Qiagen) for nickel-affinity chromatography and the
protein was eluted with buffer A supplemented with 300 mM
imidazole. Protein purified by affinity chromatography was
tested for esterase activity with 4-nitrophenyl butyrate and
analyzed by SDS-PAGE to identify pure fractions.
SEC–MALLS
Pure LcαE7 fractions were pooled and further purified by
SEC using a Hiload 26/600 Superdex-200 column (GE
Healthcare), equilibrated with buffer B [200 mM NaCl,
20 mM Hepes (pH 7.5)]. The effect of viscosity on
LcαE7-WT and LcαE7-4a was investigated by SEC as
described above, with the addition of 10% glycerol to the
running buffer. The total protein loaded (estimated by total
area under the curve) was 24.5, 12.1, 11.5, and 10.8 mg
(highest to lowest) for the LcαE7-WT samples and 16.6,
15.3, 13.2, and 13 mg (highest to lowest) for LcαE7-4a. For
SEC–MALLS, purified LcαE7-4a (3.0 mg/mL) was applied
at a flow rate of 1 mL/min to a WTC-030S5-column (Wyatt
Technology) connected to a DAWN8+MALLS detector and
tREX refractive index detector (Wyatt Technology). The
column was equilibrated with buffer B. Data analysis was
performed using ASTRA software (Wyatt Technology).Small-angle X-ray scattering
Data were collected in 200 mM NaCl, 20 mM Hepes
(pH 7.5), and 5% glycerol using an inline S200, 5/150GL
(3.2 mL; GE Healthcare) column at a 0.2-mL/min flow rate
at the Australian Synchrotron SAXS beam line. Data were
collected serially in 2-s quanta. The radius of gyration was
unable to be estimated for any of the eluted protein owing
to scatter patterns synonymous with the presence of HMW
aggregates. Data were collected using a Pilatus 1 M
detector at a distance of 3.3 m allowing collection of data in
the Q range: 0.00486–0.25 nm−1.AUC
Sedimentation velocity experiments were conducted in a
Beckman model XL-A analytical ultracentrifuge at a temper-
ature of 20 °C. LcαE7 and LcαE7-4a were solubilized in
20 mM Hepes, and 500 mM NaCl (pH 7.5) and were
analyzed at an initial concentration of 3.0 mg/mL. The sample
and reference solution were loaded into conventional double-
sector quartz cells andmounted inaBeckman4-holeAn-60Ti
rotor. The sample of 380 μL and reference solution of 400 μL
were centrifuged at a rotor speed of 40,000 rpm, and the data
were collected at a single wavelength (295 nm) in continuous
mode, using a step-size of 0.003 cm without averaging. The31
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variant proteins), buffer density (1.0202 g/mL), and buffer
viscosity (1.0635 cp) were computed using the program
SEDNTERP [69]. Sedimentation velocity data atmultiple time
points were fitted to a continuous sedimentation coefficient
[c(s)] distribution and a continuous mass [c(M)] distribution
model [70–72] using the program SEDFIT, which is available
at www.analyticalultracentrifugation.com.
CD
Purified LcαE7 at 0.3 mg/mL was exchanged into 20 mM
NaH2PO4 and 20 mM NaCl buffer (pH 7.5). CD data were
collected with a Chirascan CD spectrometer (Applied
Photophysics) in a 1-mm quartz cuvette. The protein was
heated from 25 °C to 90 °C at a rate of 1 °C/min, while
ellipticity was monitored at 208 nm. The thermally induced
unfolding of LcαE7 was not reversible. CD data were fitted
using the by non-linear regression to a two-state model
(Eq. (1)) using GraphPad Prism 6.00 (GraphPad Software).
yobs ¼
y F−yU
1þ exp TT50−T
c
  ð1Þ
where yobs is the observed elipticity, yF nand yU are the
elipticity values observed for the native and unfolded
states, respectively. TT50 is the temperature at which the
population of unfolded protein is 50% and c is the slope.
Curves were fit by non-linear regression using GraphPad
Prism 6.00 (GraphPad Software, USA). A three-state
model was used for curve fitting with the monomer and
dimer data using the software CDpal [73].Thermal shift fluorescence assay
The thermal shift of LcαE7 and LcαE7-4a was measured
using the ViiA7 real-time PCR system (Life Technologies) in
MicroAmp EnduraPlate Optical 384 well plates (Life
Technologies) with a final volume of 20 μL per well. The
plates were covered with optical seal and shaken before
denaturation. Each samplewasmeasured in duplicate using
the SYPRO Orange dye to measure protein unfolding.
Protein was diluted to concentrations between 0.3 mg/mL
and 3 mg/mL in buffer B. The 5000× SYPRO Orange dye
stockwas diluted in buffer B to a final concentration of 20× in
the plate. Thermal denaturation was measured by increas-
ing the temperature from 20 °C to 90 °C at a rate of
0.017 °C/s, and the plate was measured with wavelengths
of excitation at 470 nm and emission at 580 nm. The TT50
was calculated by nonlinear regression with the Boltzmann
sigmoidal equation in Graphpad Prism 6.00 (GraphPad
Software, USA). A three-state model was used for curve
fitting with the LcαE7-4a data using the software CDpal [73].Enzyme kinetic assays
Purified LcαE7-WT and LcαE7-4a were assayed against
the ester substrate 4-nitrophenyl butyrate in buffer B
[200 mMNaCl, 20 mMHepes (pH 7.5)] at 25 °C. Formation
of the product 4-nitrophenolate was monitored at 405 nmusing an Epoch microplate spectrophotometer (BioTeK
Instruments). Velocities were obtained from the initial linear
portion of the reaction progress curves, and product
concentration was determined with the extinction coefficient
calculated from a standard curve of 4-nitrophenol. Assays
were done in triplicate, and the protein concentration was
used in the range of 0.01 to 0.05 μM as final concentration.
The Michaelis constant and the inhibition constant were
determined by non-linear regression of the initial velocities to
the Michaelis–Menten equation or substrate inhibition
equation using GraphPad Prism 6.00 (GraphPad Software).
For thermal stability assays, purified LcαE7-WT and
LcαE7-4a were incubated at 40 °C, aliquots were removed
at set time points, and specific activity was assayed as
described above with 200 μM 4-nitrophenyl butyrate in
triplicate. To measure the decay of LcαE7-4a monomer and
tetramer activity over a time course, the proteins were
incubated at 46 °C in a buffer consisting of 20 mM Hepes,
200 mM NaCl, and 10% glycerol. Aliquots removed at
various time points and subsequently assayed with 200 μM
4-nitrophenyl butyrate in triplicate as described above. The
data were fit by non-linear regression to a one-phase
exponential decay curve using GraphPad Prism 6.00
(GraphPad Software, USA).
Supplementary data to this article can be found
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3.2. Introduction 
 
3.2.1. β-Esterases 
Clade E is one of the most studied clades of CBEs in Drosophila species (152). Enzymes 
in this clade have been collectively known as β-esterases based on the preferential 
hydrolysis of β-napthyl acetate in Drosophila (32). This cluster however, is able to 
breakdown α-napthyl acetate which makes substrate preference not necessarily indicative 
of the evolutionary history. Regardless, the name for the β-cluster is widely used and has 
been retained in the literature (32). The β-esterase cluster generally contains two to four 
members and it has been suggested to have evolved after a relatively ancient gene 
duplication event  (Table 3.1) (42, 43, 56, 152–155). After the gene duplication event, the 
proteins have adopted distinct functions and expression patterns (42, 152, 153, 156–158). 
The β-cluster has been studied to investigate the molecular basis of functional evolution 
and for understanding allozymes (56, 152, 153). 
Table 3.1. List of the β-esterase gene cluster in various Drosophila species, red represents 
the orthologs of EST6 from D. melanogaster and blue represents the EST7 equivalent (32). 
Drosophila Species Members of the β-Cluster 
melanogaster, simulans, mauritiana, sechellia, 
yakuba, teissieri, erecta, orena 
EST6, EST7 
ananassae EST6a, EST6b, EST6c, EST7 
pseudoobscura, persimilis, miranda EST5a, EST5b, EST5c 
affinis EST5b 
wilistoni EST6 
mojavensis EST1, EST2a, EST2b, EST2c 
virilis EST1, EST2d, EST2e, EST2f 
grimshawi EST2 
 
3.2.2. EST6 and EST7 
In several Drosophila species, the cluster is comprised of two tandemly arranged genes 
noted as esterase6 and esterase7 that encode the proteins esterase-6 (EST6) and esterase-7 
(EST7) (Table 3.1) (153, 154, 159). Both proteins are soluble, secreted and glycosylated 
with distinct expression patterns (153, 154, 159). The first mention of this cluster of 
enzymes in the literature was in 1963 and since then over 40 research papers have focused 
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on the enzymes (32, 160). The study of EST6 and EST7 has established a well-understood 
model of microevolution and has had a large impact on Drosophila genetics research (32). 
3.2.3. EST6  
EST6 in D. melanogaster has acquired a novel function involved with reproduction biology 
(56). In other Drosophila species (D. erecta), EST6 has a functional role in the hemolymph 
with unknown function (56). However, EST6 in D. melanogaster is highly expressed in the 
sperm ejaculatory duct of the adult male fly (161). The enzyme is transferred during 
copulation from the male to the female in the seminal fluid during the first few minutes of 
mating. The transfer results in the triggering of egg-laying and remating behaviour being 
repressed in the female fly (162, 163). After transfer, EST6 is translocated to the  
hemolymph of the female, where traces of the enzyme survives for several days (164, 165). 
It is unknown how the male-EST6 in the female hemolymph affects the female-EST6, 
however, it has been shown to affect the female’s subsequent reproductive behaviour in 
relation to EST6 activity (153, 165–168). 
EST6 is important in the reproductive biology of Drosophila as differences in enzyme 
expression in the male can affect the reproductive success of their mates (168). Also while 
EST6 is expressed in the ejaculatory duct, it is also expressed in the antennae (27, 157, 161, 
169, 170). The expression in the antennae has recently expanded EST6 to have a secondary 
role in the sensory physiological and behavioural dynamics of D. melanogaster. It has been 
proposed that EST6 acts as an odorant-degrading enzyme involved in 11-cis vaccenyl 
acetate (cVA) detection in the antennae (170, 171).  
3.2.4. EST6 Substrate Specificity and 11-cis vaccenyl acetate 
The mechanism of EST6 in the reproductive success of Drosophila is not well understood 
(32). EST6 shows activity against a broad range of substrates in vitro suggesting to be a 
non-specific CBE. However, the in vivo substrates are unknown (Figure 3.1) (168, 172). 
A proposed mechanism of how EST6 affects reproduction involves the pheromone cVA 
(Figure 3.1) (162, 173).  
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Figure 3.1. Structures of cVA, the sex aggregation hormone in Drosophila and short-chain 
esters (ethyl acetate, ethyl propionate, isobutyl acetate, methyl hexanoate) that are known 
odorants involved with Drosophila species (174). 
cVA is an oxygenated semi-volatile hydrocarbon and is the major sex and aggregation 
pheromone in D. melanogaster species (175). cVA is transferred from the ejaculatory bulb 
of the male to the female during copulation. After transfer, cVA reduces the attractiveness 
of the recently mated female to males which suppresses male mating behaviour (173, 175–
178). The mated female once copulated will rarely accept another male, resulting in cVA 
being an indicator of the mating status of the female (179). This reduces a potential loss of 
progeny for the female’s first mate (170).  
The evidence for EST6 inactivating cVA has been speculative (32). EST6 and cVA are 
both found in close proximity in the male reproductive system and both transferred to the 
female during copulation. Preliminary assays had led researchers to believe that in vivo, 
cVA is the substrate for EST6 and the mechanism of how EST6 affects reproduction (162, 
173). However, these claims have since been refuted (162, 180–183). Recent work 
involving electrophysiological investigations on the Drosophila antennae indicate that 
EST6 has a role in the deactivation of cVA despite the location of EST6 in the antennae 
not being responsive to cVA (170). Further characterization of EST6 suggests the enzyme 
acts on various short chain fatty acid food esters (32, 174). This raises the question of the 
substrate range of the enzyme, suggesting EST6 has the ability to turnover a large range of 
esters with carbon length ranging from 3 to 20. The evidence of the in vivo substrates of 
EST6, the role the enzyme plays in the antennae and the mechanism by which the enzyme 
influences female reproductive behaviour remains unknown. Likewise, the interaction 
between EST6 and cVA is not well understood and still under discussion (170, 173, 174, 
183). 
41 
3.2.5. Prediction of EST6 Structure 
Studies have modelled the structure of EST6 using the enzyme acetylcholinesterase (56, 
153). The structure of EST6 is predicted to contained three disulfide bonds and four N-
linked glycosylation sites which have been suggested to help the longevity of the protein 
during transfer from the male to the female (56, 153). The loop regions, substrate binding 
regions and active site gorge which are critical for functional differences in CBEs are 
unknown in the structure based on the EST6 homology model with only the main α/β 
hydrolase fold identified with high accuracy. 
3.3. Research Article 
3.3.1. Preface 
For the past 50 years, the β-cluster has been heavily studied, yet questions still remain on 
the structure/function relationships of enzymes in this cluster. The most studied member of 
this cluster, EST6 from D. melanogaster has been a major focus due to the important role 
the enzyme has in the reproductive success of Drosophila. EST6 has been modelled using 
the structure of AChE, but this protein has significant differences in substrate specificity 
and shares 30% sequence identity to EST6. Thus, only the highly conserved regions of 
EST6 have been modelled with reasonable certainty (56, 153). A structure of EST6 is 
important to understand the function of this protein and the role of this protein in D. 
melanogaster reproduction and in the antennae. The following article discusses the 
structure of EST6 in combination with enzyme kinetics and electrophysiological 
experiments to provide insight into the substrate range of the enzyme and predicted role of 
EST6 in Drosophila. 
3.3.2. Published Research Article: Molecular basis for the behavioral effects of the 
odorant degrading enzyme Esterase 6 in Drosophila 
Supplementary Information is found in Appendix B 
1Scientific RepoRts | 7:46188 | DOI: 10.1038/srep46188
www.nature.com/scientificreports
Molecular basis for the behavioral 
effects of the odorant degrading 
enzyme Esterase 6 in Drosophila
Faisal Younus1,2, Nicholas J. Fraser2, Chris W. Coppin1, Jian-Wei Liu1, Galen J. Correy2, 
Thomas Chertemps3, Gunjan Pandey1, Martine Maïbèche3, Colin J. Jackson2 & 
John G. Oakeshott1
Previous electrophysiological and behavioural studies implicate esterase 6 in the processing of the 
pheromone cis-vaccenyl acetate and various food odorants that affect aggregation and reproductive 
behaviours. Here we show esterase 6 has relatively high activity against many of the short-mid chain 
food esters, but negligible activity against cis-vaccenyl acetate. The crystal structure of esterase 6 
confirms its substrate-binding site can accommodate many short-mid chain food esters but not cis-
vaccenyl acetate. Immunohistochemical assays show esterase 6 is expressed in non-neuronal cells in 
the third antennal segment that could be accessory or epidermal cells surrounding numerous olfactory 
sensilla, including basiconics involved in food odorant detection. Esterase 6 is also produced in trichoid 
sensilla, but not in the same cell types as the cis-vaccenyl acetate binding protein LUSH. Our data 
support a model in which esterase 6 acts as a direct odorant degrading enzyme for many bioactive food 
esters, but not cis-vaccenyl acetate.
Insects’ olfactory systems are both primary drivers of their interactions with the environment and an emerging 
model for studying the molecular basis of eukaryote signaling processes. They are also of enormous interest in 
applied entomology because they are the targets for various pest control strategies based on mating disruption1. 
Many aspects of insects’ olfactory system have recently been elucidated but others, such as their odorant degrad-
ing enzymes (ODEs), are still poorly understood2,3. It is proposed that ODEs are vital in the maintenance of the 
ongoing sensitivity of the olfactory system to incoming signals through the rapid inactivation of the relevant 
pheromones and kairomones once they have activated their receptors2,4. However few of these have yet been 
characterized in any detail and fundamental questions remain about their modes of action. In particular there is 
ongoing debate, both about whether individual ODEs are specific for particular odorants or act generally against 
many2, and about whether they act alone or in combination with odorant binding proteins (OBPs)2,5. OBPs have 
been strongly implicated in the transport of incoming odorants through the sensillar lymph to their correspond-
ing receptors, but any subsequent role for them in the deactivation process remains controversial2.
Most of the work to date on ODEs has been done on certain Lepidoptera that have antennae large enough for 
classical biochemical and physiological studies4. One of the best characterized is the antennal specific esterase 
Apo1SE from the giant silk moth Antheraea polyphemus, which is estimated to have a kcat of 127 s−1 for its natu-
ral E6Z11-16:acetate pheromone substrate6, but little activity for other isomers of this compound or for several 
other volatile esters tested. Relatively high kcat values for their putative pheromone ester substrates have also been 
reported for a few other lepidopteran antennal esterases, although in at least two of these cases their substrate 
ranges seem be to less specific3,7,8, perhaps suggesting broad rather than specific ODE functions.
By far the best characterized ODE for the model insect Drosophila melanogaster is esterase 6 (EST6). This 
enzyme was originally reported to degrade the major volatile sex and aggregation pheromone cis-vaccenyl ace-
tate (cVA)9. Subsequent electrophysiological comparisons of EST6 wildtype and null flies on comparable genetic 
backgrounds have confirmed a role for the enzyme in the dynamics of cVA processing10. A specific OBP, LUSH, 
has been identified for cVA in D. melanogaster but the latest genetic evidence suggests that the interaction of 
cVA with its receptor OR67d is independent of LUSH11. Notably, the distribution of EST6 in the third antennal 
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segment also includes sensilla that are responsive to other odorants but not to cVA10, and further biochemical, 
electrophysiological and behavioral comparisons of the EST6 active and null strains indicate that the enzyme also 
acts on various short chain fatty acid food esters12,13. There is indeed some relationship between the level of EST6 
activity for the different esters and the size of the electrophysiological effect13, suggesting that EST6 does act as a 
general ODE with activities for several ester odorants.
As further evidence for pleiotropic effects of the enzyme, EST6 is also known to be expressed at high levels 
in the male ejaculatory duct, from where it is transferred to the female reproductive tract during mating14. It is 
then rapidly (within minutes) translocated to her hemolymph, where it remains for several days. Comparisons 
of females mated with null and wildtype EST6 males indicate it acts in the female to stimulate her egg-laying and 
delay her receptivity to re-mating15,16. Early claims that this effect was mediated by EST6 action on endogenous 
cVA9 have since been refuted17, but the substrate responsible for the effect nevertheless remains unknown.
EST6 is a member of the carboxyl/cholinesterase (CCE) family of proteins18, which is represented by 30–110 
different gene/enzyme systems encoding diverse functions in the insect genomes so far sequenced19. However, 
the juvenile hormone esterase from the moth Manduca sexta (MsJHE)20, an insecticide metabolizing carboxy-
lesterase from the blowfly Lucilia cuprina (Lcα E7)21 and acetylcholinesterase from D. melanogaster (DmAChE)22 
are the only insect CCEs for which crystal structures have been determined, so relatively little is known of the 
structure-function relationships underlying their diverse functions. The structural features of EST6 have so far 
been inferred from the structure of the D. melanogaster AChE or its orthologue from the electric ray Torpedo 
californica, but the low sequence similarity between EST6 and AChE (27%) means that the fine structural features 
of the enzyme responsible for its substrate specificity have not yet been understood23.
In this paper, we present a comprehensive analysis of the substrate range of semi-purified EST6, showing it has 
significant activity for a range of short chain fatty acid esters but negligible activity for long chain fatty acid esters. 
In particular, we find that EST6 is not active against cVA, either in the presence or absence of LUSH, but does 
degrade various volatiles emitted by rotting fruits and the yeasts therein on which the flies naturally live; these 
volatiles have recently been shown to be key regulators of Drosophila mating behavior24. We also present a crys-
tal structure for the enzyme which, together with in silico docking studies, supports the kinetic data and shows 
that its active site can readily accommodate short chain fatty acid esters, including the yeast and fruit volatiles 
above, but not long chain fatty acid esters like cVA. A unique active site location and entry is identified, which 
appears to explain the enzyme’s substrate preferences. Finally, we present data from immunohistochemical and 
behavioral assays with RNAi knock-down constructs that localize the expression of EST6 to a large proportion 
of non-neuronal cells surrounding the olfactory neurons of almost all the olfactory sensilla, but in different cells 
than those producing LUSH in the trichoid sensilla.
Results
Enzyme kinetics. Wildtype EST6 was tested for activity against 85 bioactive ester odorants and two model 
substrates; 4-nitrophenyl acetate (4 NPA) and 2-naphthyl acetate (2 NA). It showed detectable activity (gener-
ally, a specificity constant kcat/KMEst > 1.5 × 104 M−1.s−1) for 47 of the bioactive esters as well as the two model 
substrates (Fig. 1 and Supplementary Table S1). Specificity constants for most (42) of these 49 were above 
1 × 105 M−1.s−1, although none exceeded 1.3 × 106 M−1.s−1, consistent with typical kcat/KM values for enzymatic 
reactions in secondary metabolism25. The highest activities were seen with esters containing longer (C > 6) or 
more complex (branched, unsaturated or cyclic) leaving groups and acetate or propionate acid moieties, although 
a combination of mid-length leaving groups and acid groups (butyl decanoate) was also a relatively good substrate 
in these assays. The 38 compounds for which little or no activity could be detected were mainly methyl or ethyl 
esters or those with more complex acidic groups. cVA, which has a very long leaving group, was not hydrolysed 
at significant rates.
Precise KM values for most substrates could not be calculated because of low substrate solubility. However, 
estimates of KM values could be obtained for some of the more soluble esters (4 NPA, 2 NA, benzyl acetate, phe-
nyl acetate, phenethyl acetate) and were found to be in the range 121–880 μ M under these assay conditions, 
which included 5% ethanol (Supplementary Table S1). Previous kinetic analyses of EST6 with 2NA26 and 4 NPA 
(Supplementary Fig. S1) indicated the KM values were ~5–20 fold lower in the absence of 5% ethanol. The KM val-
ues that were obtained generally exceed the concentration of substrate in the reaction mixtures (200 μ M), which 
means that the kcat/KMEst calculated will be a reasonable approximation of the true kcat/KM value (in those cases 
where KM is lower than 200 μ M, the estimated value will underestimate the true kcat/KM for the assay conditions 
used – see Methods). Given the measured KM values are typically > 100 μ M, the measured kcat/KM values therefore 
imply relatively high kcat values (in some cases > 1,000 s−1). These results indicate that EST6 is a relatively “fast” 
enzyme (high kcat values) that displays broad specificity, working moderately efficiently with a very wide range 
of natural esters. In comparison, the related enzyme acetylcholinesterase catalyses acetylcholine hydrolysis with 
very high efficiency but has an extraordinarily narrow substrate range, essentially catalysing a single substrate18.
The assays with cVA were repeated in the presence of the cVA binding protein LUSH, which again indicated 
negligible activity, even in the presence of a great excess of EST6 (57 nM compared with the 3 nM used previ-
ously). The only other known pheromone among the compounds tested was the fatty acid ester methyl myristate, 
which is also a plant volatile and functions as an attractant to D. melanogaster27. EST6 also had relatively little 
activity with this compound (~1.5 × 104 M−1.s−1).
Apart from the two pheromones and two model substrates, all the esters tested for which EST6 was found 
to have significant activity are food odorants that are known to be bioactive against D. melanogaster in in vivo 
(behavioral) and/or in vitro (receptor binding) assays (Supplementary Table S2)27–29. Five of the major odorant 
receptors in this species that are known to have affinity for ester ligands (Or10a, Or22a, Or35a, Or67a and Or98a) 
all bind a variety of such esters, with substantially overlapping ranges30,31. Notably, many of the alcohol and alde-
hyde metabolites of these esters are also known ligands for various D. melanogaster odorant receptors32.
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Structure determination of EST6. One of the main barriers to crystallizing EST6 was its very low soluble 
expression in Escherichia coli. To address this, we used the same approach as we did to solve the structures of the 
α -Esterase 7 carboxylesterase from Lucilia cuprina21. Briefly, we utilized directed evolution to screen libraries 
of EST6 variants lacking the N-terminal signal peptide33 for enhanced activity (as a result of enhanced soluble 
expression) in E. coli (Supplementary Fig. S2). After six rounds of directed evolution, the EST6 variant with great-
est soluble expression (EST6-1) contained 16 mutations; K15V, V145L, R208K, G229E, N237S, T247A, D290G, 
I292F, I335V, E383G, S400G, A416V, F450S, F456S, N485D, I511T (note that amino acids are numbered from 
the first residue of the mature EST6 protein as it would be processed in its native form within the fly33 and omits 
the start methionine included to permit heterologous expression in E. coli). Four of these mutations have been 
found in EST6 from several Drosophila species (V145A, R208K, T247A and I292F)23,34. Importantly, the catalytic 
activity of EST6-1 was very similar to that of EST6-WT (Supplementary Fig. S3), suggesting that the 16 mutations 
principally affected folding, rather than function, consistent with their being located remote from the active site.
Using the Origami B strain of E. coli, a cell line that has been designed to enhance disulfide bond forma-
tion in the cytoplasm in prokaryotic systems35, high levels of soluble EST6-1 were expressed (~20 mg. l−1) 
(Supplementary Fig. S4). Expression of EST6-WT in E. coli Origami B cells resulted in substantially lower sol-
uble expression (~0.5 mg. l−1). Size exclusion chromatography showed EST6-1 eluted primarily as a monomer, 
although there was secondary peak present that indicted a small amount of dimer (Supplementary Fig. S4). 
Crystallization trials of the EST6-1 monomer fraction at two different concentrations did not yield crystals. We 
then performed surface lysine methylation, which has been shown to increase the propensity of proteins to crys-
tallize36, which yielded crystals in conditions of 0.2 M ammonium acetate, 0.1 M Tris pH 8.5 and 25% w/v PEG 
3,350 that diffracted to 2.1 Å resolution.
The structure of EST6-1 contains 520 amino acids, 353 water molecules, 32 surface carboxylated lysines and 
one monomer per asymmetric unit. All but the first four N-terminal amino acids are present in reasonable elec-
tron density. EST6-1 adopts an α /β -hydrolase fold, including the conserved catalytic triad and oxyanion hole 
(Fig. 2a,b). The eight-stranded β -sheet (β 1–8) surrounded by six α -helices (A-F), that comprises the canonical 
fold is present, along with the two antiparallel β -strands at the start and two antiparallel β -strands at the end of the 
structure that are found in the other three insect carboxylesterases whose structures have been solved20–22. The 
Figure 1. EST6 kcat/KMEst and biological source of the most active substrates tested and other substrates of 
particular structural or physiological significance. Alcohol moieties are listed on the vertical and are grouped 
according to structural similarity. Acid moieties are listed on the horizontal. An ellipsis (… ) demarcates 
a break in an otherwise incremental series. Data on the biological source of the substrates are taken from 
Supplementary Table S2. Activity results for all 87 compounds tested are given in Supplementary Table S1.
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entrance of the active site is formed by loops following β 1, loops and two helices following β 4, and loops following 
β 8, including helix F that makes up part of the canonical α /β hydrolase fold. The active site itself is formed from 
the catalytic triad (Ser188, His445 and Asp319), oxyanion hole (Gly108, Gly109 and Ala189) and additional resi-
dues (Tyr322 Tyr449, Phe450, Asn455, Phe456 and Val457) from a helix after β 7 and a loop following β 5 (Fig. 2c). 
There are three intramolecular disulfide bonds present (65–84, 240–252, and 493–514) on surface loop regions. 
The first two disulfide bonds are also seen in the other two insect carboxylesterase structures containing disulfides 
(AChE, JHE), but the third disulfide is unique to EST6, which also has a shortened C-terminus relative to the 
other three carboxylesterases structures.
Comparison to known structures. Analysis of the ESTHER database37, which comprehensively 
describes the α /β hydrolase fold across a wide range of organisms, reveals that EST6-1 falls into Block C, which 
also includes the other three known insect carboxylesterase structures. Amongst the insect carboxylesterases, 
Figure 2. The structure of EST6 from D. melanogaster. (a) Topology representation of EST6 displaying the 
conserved α /β -hydrolase fold (grey), secondary structure found in the structurally similar proteins (blue) and 
unique secondary structure (red). S, D, H represent the Ser188, Asp319 and His445 residues that make up 
the catalytic triad. The oxyanion hole is located in the loop following sheet 4 (marked by a red x). (b) Cartoon 
diagram of EST6 with features shown in the topology model similarly coloured. The location of the active 
site is indicated. (c) The active site of EST6 with 2mFo−dFc electron density contoured at 1.5 σ . The active site 
serine and histidine from the catalytic triad are coloured cyan, the oxyanion hole (Gly108, Gly109, Ala110) is 
coloured green. (d) An overlay of EST6 (cyan), Lcα E7 (tan; 4FNM), DmAChE (green; 1QO9) and MsJHE (pink; 
2FJ0). Conservation of the core β -sheet and conserved α -helices is apparent, but the structures diverge in the 
region that forms the active site entrance. These regions, either side of the active site, are boxed for clarity. (e) A 
superposition of EST6, LcαE7, DmAChE and MsJHE, with cut-aways through the middle of the active site. The 
location of the active site entrance difference between EST6 (cyan) and the other related insect carboxylesterases 
Lcα E7 (tan; 4FNM), DmAChE (green; 1QO9) and MsJHE (pink; 2FJ0).
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which Oakeshott et al.18 have divided into 14 Clades, EST6-1 falls into Clade E, with Lcα E7 (PDB - 4FNM) in 
Clade B, MsJHE (PDB - 2FJO) in Clade G and DmAChE (PDB - 1QO9) in Clade J. Application of the SALAMI 
server38 confirmed there were no structural homologues in PDB closer to EST6-1 than these three enzymes 
(Supplementary Table S3). The four clades are well separated from one another phylogenetically (26–29% amino 
acid identity) but all four structures superimpose well over the canonical fold (2.27, 2.09 and 2.41 Å C-α r.m.s.d. 
for the other three compared with EST6-1, respectively). In contrast, in the loop regions above the canonical 
β -sheet and α -helices, there is significant variance between the structures (Fig. 2d).
Closer inspection of the structures and alignment revealed that EST6-1 is missing the C-terminal helix present 
in DmAChE, Lcα E7 and MsJHE. Another feature of interest is the length and composition of the surface-exposed 
loop regions after strands β 1, β 6 and β 8, which contribute to the active site entrance in the other three proteins. 
In the latter three, the opening of the active site is formed from helices after β 6 and β 7 and loops and helices after 
β 1 and β 8, but this region has closed over in EST6-1. Its active site entry is instead formed by loops and helices 
after β 1, β 4, and β 8 on the opposite face of the protein (Fig. 2e). The result is a narrower and shorter active site 
entrance in EST6-1 in comparison to the open and accessible active site in Lcα E7 and the deep gorges leading to 
the catalytic triads in AChE and JHE.
A comparison of the four structures using the CASTp server39 also revealed that the active site volume of 
EST6-1 was significantly less than in Lcα E7 (Table 1). The relative sizes of the active sites of DmAChE, Lcα E7 and 
MsJHE reflect their native substrate preferences: Lcα E7 natively hydrolyses a wide range of medium chain fatty 
acid methyl esters and has a large active volume (2727 Å3)21, while AChE and JHE both have narrower substrate 
specificities, for the smaller acetylcholine and juvenile hormone molecules respectively, and have much smaller 
active site volumes, of 782 and 1308 Å3, respectively. The active site volume of EST6-1 is estimated to be 935 Å3, 
which is consistent with the observed preference of EST6 for smaller substrates than Lcα E7 (Fig. 1).
The substrate binding pocket. Given that EST6-1 is ~97% identical to EST6-WT, and the mutations dis-
tinguishing them are all remote from the active site, it is highly likely that the structures will be essentially iden-
tical in this region. Nevertheless, for analysis of the substrate binding site, a model of EST6-WT was produced 
using the empirical structure of EST6-1 and the FoldX force field, which has been developed to allow accurate 
modeling of point mutations, among other things40. As noted above, the conserved catalytic triad of EST6 con-
sists of Ser188, His445 and Asp319, while the backbone NH groups of Gly108, Gly109 and Ala189 create the 
oxyanion hole (Fig. 2c). His187 is adjacent to the catalytic serine and as with the other three structures its side 
chain extends into the active site; in the others it has been suggested to affect substrate specificity26. EST6 has an 
asymmetrical binding pocket with a very small, hydrophobic and buried sub-site consisting of Ala110, Trp221, 
Phe276, Tyr322, Phe397 and His445 that could accommodate the carboxyl group. Opposite this, there is a larger 
cavity (the putative alcohol leaving group site) that extends into the active site exit/entrance and is slightly less 
hydrophobic, consisting of Gln70, Phe71, Phe113, Gly114, Gln118, Asn119, Ile429, Tyr449, Phe450, Asn455, 
Phe456 and Val457 (Fig. 3a).
A representative range of potential substrates that EST6 was tested with were docked into the active site of EST6 
using flexible docking with DOCKovelent41, which is able to screen binding modes for substrates or inhibitors 
that form covalent bonds with the target enzyme (Fig. 3b, Supplementary Fig. S5 and Supplementary Table S4). 
The docking results are entirely consistent with the kinetic data, in so much as acylated enzyme intermediates 
for substrates that were hydrolyzed at significant rates were well accommodated by the substrate binding pocket, 
whereas no suitable binding poses (without steric clashes) could be obtained for the acylated enzyme intermedi-
ates that would result from reaction with compounds that were shown not to be substrates of EST6 (such as cVA). 
A clear trend is evident: the small sub-site can easily accommodate chains of 1–6 carbons, while the leaving group 
site has a preference for longer saturated chains, such as hexyl and octyl, over smaller chains, such as methyl and 
ethyl, but not as large as cVA (C18). This is also consistent with the high activity and complementary binding 
of geranyl and neryl acetate, with the short carboxyl side chains being accommodated in the small sub-site and 
the unsaturated leaving group being accommodated in the leaving group site. Likewise, those substrates with 
aromatic leaving groups and short carboxyl groups are also well accommodated (Supplementary Fig. S5). This 
analysis provides a molecular explanation for the observed substrate preference for typical food odorants with 
carboxyl groups of 0–6 carbons and leaving alcohol groups up to ~10 carbons, including branched and aromatic 
moieties. This structural analysis also strongly supports the kinetic analysis and the initially surprising observa-
tion that cVA does not appear to be a physiological substrate for EST6, in that it is clearly far too large for the EST6 
substrate binding pocket.
Protein
Active Site 
Volume (Å3)
Distance from surface 
to active site Serine 
(Å)
EST6 WT FoldX Model 408 15.1
EST6-1 Crystal Structure 935 15.1
Lcα E7 (4FNG) 2727 20.2
DmAChE (1QO9) 782 17.2
MsJHE (2FJ0) 1308 18.1
Lipase (1AQL) 3074 17.4
Table 1.  Active site volume calculated using the CASTp server.
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Localization of EST6 in the antennae. Est6 is known to be highly expressed in the antenna8, in particu-
lar in the third antennal segment10, but its expression in this tissue at the cellular level was unknown. Labelling 
of EST6 with anti-EST6 antibody and of Red Fluorescent Protein (RFP) under the control of the Orco promoter 
(Orco encodes the universal odorant co-receptor Orco) in transgenic adults showed EST6 immunoreactivity in 
numerous cells at the base of olfactory sensilla throughout the third antennal segment whereas, as expected42, 
the Orco promoter directed expression in numerous olfactory receptor neurons (ORNs) and in cilia entering the 
sensillar lumen (Fig. 4). As was earlier suggested by Chertemps et al.10, there was thus no co-localization of the 
two signals, showing that EST6 is not expressed in ORNs. Similarly, a complementary experiment showed no 
co-localization of EST6 and the neuron-specific expression of Green Fluorescent Protein (GFP) under the con-
trol of the elav promoter43 (Supplementary Fig. S7). Given that EST6 is a secreted enzyme, this confirms that the 
enzyme surrounds the Orco+ dendrites within the sensillar lymph of various sensilla.
Co-labelling of EST6 and lush was then performed to investigate whether the location of EST6 in the sensillar 
lymph includes the T1 trichoid sensilla involved in cVA detection. LUSH is known to be expressed in all trichoid 
types44. Labelling of EST6 with anti-EST6 antibody and of RFP under the control of the lush promoter in trans-
genic adults found that both signals were closely associated but with no co-localization of the two. RFP was found 
at the base of trichoid sensilla in accessory cells (Supplementary Fig. S8) that could correspond to trichogen and 
tormogen cells44, whereas EST6 was apparently produced by different support cells for the trichoid sensilla than 
the LUSH-producing cells45, and possibly also by the epidermal cells surrounding the sensilla. To corroborate this 
result we also performed RNAi knock-down experiments. These results are also consistent with Est6 is not being 
co-expressed with lush (Supplementary text).
Altogether, these data show that EST6 is produced by non-neuronal cells in the olfactory sensilla, most proba-
bly in a large population of accessory cells surrounding ORNs. It localization in the sensillar lymph is compatible 
with a function of a general ODE in the basiconic sensilla involved in the detection of almost all the substrates 
tested here46. Its function in the T1 trichoid sensilla is not yet clear but its effect on cVA processing in the absence 
of any direct hydrolytic activity for the compound may reflect a general scavenging role for other ester odorants 
which might otherwise impede the processing of cVA by its own, as yet unknown, ODE. It is possible that it also 
plays an equivalent broad scavenging role in some of the other sensilla where it is abundant, although its strong 
hydrolytic activity for many ester kairomones suggests it has a direct ODE function for several of them.
Discussion
Notwithstanding the genetic evidence that EST6 contributes to cVA processing in vivo10, we find that the enzyme 
has negligible activity (< 1.5 M−1.s−1) for this substrate in vitro, with or without LUSH in the assay mix. Our 
results in fact confirm the only other direct measure of its in vitro activity, by Mane et al.9; their estimation of 55 
picomoles of cVA per min per g of purified EST6, or 3.4 M. min−1.M−1, (in the absence of LUSH) is in the range 
that was too low to measure accurately in our assays. We concur with Vandermeer et al.17 that activity in this 
range is most unlikely to be physiologically relevant. This indicates that the in vivo effects of EST6 on cVA pro-
cessing seen by Chertemps et al.10 must be indirect.
While we found that EST6 had low activity against cVA, it clearly has physiologically significant 
(kcat/KM > 105 M−1.s−1)25 activity with a wide range of esters with acyl chains up to six carbons in length and 
alcohol groups from mid length (3–10 carbon atoms), aliphatic moieties to branched, secondary, unsaturated, 
Figure 3. The substrate binding site of EST6. (a) The surface of the substrate binding site is shaded grey 
and the residues that comprise the small and large pockets are shown (grey) as is the catalytic serine (orange). 
The small site consists of Ala110, Trp221, Phe276, Tyr322, Phe397 and His445, and the large site consists of 
Gln70, Phe71, Phe113, Gly114, Gln118, Asn119, Ile429, Tyr449, Phe450, Asn455, Phe456, and Val457. (b) An 
overlay of representative acylated enzyme intermediates covalently docked into EST6: the efficiently hydrolyzed 
substrates pentyl butyrate (magenta), octyl propionate (cyan), geranyl acetate (green) and phenethyl acetate 
(yellow) all produce acylated intermediates that are accommodated by the substrate binding site.
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cyclic and aromatic groups. These substrates include many fruit and yeast volatiles that are known to be bioactive 
against Drosophila, consistent with the results of electrophysiological and behavioural comparisons of wildtype 
and EST null flies by Chertemps et al.10, which show that the enzyme contributes to the processing of many such 
molecules in vivo. As such, our biochemical data support the proposition that EST6 is a general, rather than spe-
cific, odorant degrading enzyme (ODE), but with a substrate range tuned to various volatile esters with relatively 
short chain acyl groups that are commonly emitted by the food sources for the flies.
Significantly, the bioactivity of many of these better substrates for EST6 involves attraction behaviours47. For 
example, fruity smelling acetate esters such as isopentyl and pentyl acetate, which are produced by both plants 
and yeasts, are highly attractive to Drosophila48, wherein they activate several fairly broadly tuned odorant recep-
tors, such as Or43b, Or47a and Or85b46,49. Likewise, the phenolic yeast volatile phenethyl acetate elicits an attrac-
tion response from the fly50 and activates its Or85d receptor49. Notably, some of these attraction behaviors also 
manifest as effects on reproductive traits; for example, citrus fruits emit many short-mid chain volatile acetates 
(e.g. propyl, hexyl, heptyl, nonyl, decyl, neryl and geranyl acetates51), which attract females to lay eggs28.
It has been shown that several food odors, including ester substrates for EST6, can act synergistically with cVA 
in both aggregation and courtship bioassays52–55. Indeed, some evidence suggests that cVA only acts as an aggre-
gation pheromone in the presence of attractive food odors55. It is suggested that the co-processing of pheromonal 
and kairomonal stimuli would help coordinate feeding and oviposition site selection with reproductive behav-
iors53. However, we cannot see how this synergism would explain the indirect effects of EST6 activity on cVA pro-
cessing observed by Chertemps et al.10. One reason is that the experimental design of that previous study meant 
Figure 4. EST6 and Orco expression in the third antennal segment, longitudinal sections. (a) Membrane-
tethered RFP expressed with the Orco promoter (OrcoGal4 /UAS-mCD8::RFP transgenic flies). (b) EST6 protein 
localization in the same section. (c) Merge image of (a,b): Est-6 and Orco are not expressed in the same cells. 
(d) Higher magnifications of (c): EST6 protein surrounds the Orco+ dendrites. Arrows indicate the dendrites 
of Orco expressing ORNs. Western blots and immunohistochemistry showing the specificity of the anti-EST6 
antibody are shown in Supplementary Fig. S6.
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that food odors would not have been present in the cVA atmospheres they tested. Furthermore, the co-processing 
of the signals from cVA and the food odors must occur downstream of their receptors, since they have different 
receptors and the signals from their receptors are transmitted to different glomeruli in the brain, but the effects 
of EST6 on EAG responses to cVA seen by Chertemps et al.10 must occur prior to or at the time when the cVA 
interacts with its receptors. Other indirect effects of EST6 on cVA processing must therefore explain the data of 
Chertemps et al.10. For example, as noted above, EST6 may facilitate cVA processing simply by removing other 
potential substrates (or inhibitors) of the ODE that does degrade cVA. As noted, the latter ODE may be a lipase, 
and indeed, with an 18-carbon leaving group, cVA is more like a typical lipase substrate than an esterase substrate. 
Our localization studies would certainly allow for that, given the broad distribution of the enzyme through the 
sensillar lymph. Further work is needed to elucidate the molecular basis for the effects seen by Chertemps et al.13.
Our biochemical studies also bear on the question of the molecular basis for the effects on female oviposition 
and remating behaviors due to the ejaculatory duct EST6 transferred from their mates15,16. This enzyme is known 
to be transferred from the female’s reproductive tract to her haemolymph within minutes of mating14, but its 
fate from there and its substrate in the female are unknown. Our results indicate that a wide variety of esters of 
terpene or aromatic alcohol groups and short-mid chain acids could be candidate substrates. Notably, some such 
compounds are precursors for various hormones and other key molecules in the fly56,57. Modern metabolomic 
technologies may be useful in identifying the in vivo substrate for the transferred EST6, particularly given the 
availability of the Est6° flies and wildtype revertants on the same genetic background10.
EST6, in Clade E of the carboxylcholinesterase gene family, is not closely related in sequence (26–29% amino 
acid identity) to any of the three insect esterases for which structures have been solved previously (in Clades B, G 
and J). While it’s overall structure is similar to the other three, we noted several significant differences in relation 
to its active site. Of particular note was the appearance of an active site entrance on the opposite face of the protein 
to that containing the active site entrance in the other three structures. Interestingly, the entrance in EST6 corre-
sponds to the alternative ‘back door’ entrance that has been proposed for AChE58. Moreover, the corresponding 
surface of the catalytically inactive ligand-binding ‘esterase’ neuroligin is the site to which its ligand binds59.
Transcriptomic analyses of sensory tissues in various insects have shown as many as half of the catalytically 
competent carboxyl/cholinesterases in some insects may be expressed at readily detectable levels in their sen-
sory tissues8,60. The few for which there is any empirical support for ODE functions have spanned four major 
Clades (A, D, E and G)18,61, suggesting that esterase ODEs may have evolved independently on several occasions. 
However, there is a concentration of putative esterase ODEs in the particular lineage within Clade E that contains 
EST6 (31% amino acid identity)18. This lineage contains esterases from at least four insect orders, including one 
of the best-understood ODE’s at a physiological level, the Apo1PDE from the silkmoth Antheraea polyphemus. 
Apo1PDE is highly specific ODE for a particular sex pheromone substrate62, whereas we find EST6 has both 
broad activity for many kairomones and an indirect effect on cVA processing whose mechanism we currently do 
not understand. Further work on this lineage could elucidate a range of biochemical, physiological and evolution-
ary phenomena concerning the function of esterases in insect antennae.
Methods
EST6 activity assays. The expression of wildtype EST6 and an inactive EST6 variant in the baculovirus sys-
tem has been described previously13. These two enzymes were assayed here for activity against 85 ester odorants 
of potential ecological relevance49,63,64 and two other model substrates (listed in Supplementary Table S1). All 
these esters were purchased in the highest available purity.
Eighty two of the esters were first subjected individually to gas chromatography-mass spectrometry (GC-MS, 
7890 series, Agilent Technologies, USA) to determine their respective retention times. A J&W DB-WAX column 
(30 m × 0.25 mm × 0.25 μ m, Agilent Technologies, USA) was used with He (2 ml. min−1) as the carrier gas. The 
oven temperature was initially set at 50 °C for 2 mins and then subsequently increased over a gradient of 10 °C to 
275 °C and held for 10 mins. The injector and detector temperature was set at 250 °C with a 10:1 split ratio.
Mixtures of up to 17 compounds with non-overlapping GC-MS retention times were then made in Tris HCl 
buffer pH 8.0 for a set of preliminary ‘group assays’. Each group included pentyl acetate as a common ester sub-
strate standard. All compounds had been dissolved in ethanol to give a 5% v/v final solvent concentration; pre-
liminary assays on some of the more water-soluble esters showed that this ethanol concentration increased KM 
by 5–20 fold (see below) but lower concentrations of ethanol were insufficient to solubilize some compounds and 
equivalent concentrations of other organic solvents tested were more disruptive to EST6 activity. Several reactions 
were set up at 25 °C in Tris-HCl buffer pH 8.0 with each ester in the mixture at a final concentration of 200 μ M 
and the enzyme (added last) at 8.2 nM. Individual reactions were then stopped by the addition of 0.5 volumes of 
ice-cold hexane containing 200 μ M heptanone as an internal non-ester standard at intervals from 5 to 65 mins. 
The concentrations of the various esters remaining were then determined by GC-MS as above. EST6 activity was 
calculated from the difference in substrate usage between the wildtype and null enzymes, but all values for the 
latter were essentially negligible.
Subsequently, 43 substrates from the group assay, including all the better substrates, were assayed individually 
in order to obtain estimates of kcat/KM using equation (1):
= .k K V/ /([E] [S]) (1)cat M
Est
0
where [E] and [S] are the starting enzyme and substrate concentrations respectively, and V0 is the initial velocity 
of the reaction65.
Aside from the single substrate, these assays were the same as those for the group assays, except that a lower 
enzyme concentration was used (0.1 to 3.6 nM). The appropriate enzyme concentration was inferred from the 
enzyme’s activity towards each substrate in the group assay. Three other esters that were not included in the 
49
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group assays but with closely similar chain lengths and structures to some of the best substrates were also assayed 
individually in this way. Individual substrate assays with two model esters, 4 NPA and 2 NA, were also carried out 
using previously described 420 and 390 nm UV/vis protocols for monitoring substrate loss8,21. KM estimates could 
be obtained from these data for a few substrates and a few were also obtained using the competitive inhibition 
method with 4 NPA as substrate as described in Younus et al.8. All the above assays were conducted in triplicate.
Assays with LUSH. Some assays were also conducted in the presence of the odorant binding protein LUSH. 
In preparation for this the lush coding region was synthesized by Invitrogen and cloned into the expression vector 
pETMCSI66. The LUSH protein was overexpressed in inclusion bodies of E. coli BL21 (DE3) star (Invitrogen) cells 
after overnight growth in Lysogeny Broth (LB) broth containing 100 mg. l−1 of ampicillin at 37 °C. The cells were 
harvested by centrifugation at 5,000 g for 5 min at 4 °C, the cells lysed by three passages through a French Press, 
and the inclusion bodies collected by centrifugation at 10,000 g for 20 min at 4 °C. The inclusion bodies were then 
solubilized and refolded following the method of Kruse et al.67 using a cysteine-cystine redox reaction in the 
presence of 1% v/v ethanol. The only modifications to this method were that 8 M urea was used to solubilize the 
inclusion bodies and the soluble protein was dialyzed in 20 mM Tris pH 7.4, 50 mM NaCl. The soluble LUSH was 
further purified by using a Superdex 200 preparation size exclusion column (GE Healthcare, UK) and assayed for 
binding activity with the model ligand N-phenyl-1-naphthylamine (NPN) according to the method described 
by Katti et al.68. This involved titrating LUSH (1 μ M) with increasing amounts of NPN to final concentrations 
ranging from 0.5 μ M to 20 μ M. A saturable NPN fluorescence change was recorded by a fluorometer and the 
dissociation constant was found to be 2.39 μ M. Katti et al.68 showed that LUSH does not display a saturable NPN 
fluorescence change if it is not fully refolded.
Assays to investigate the activity of EST6 towards cVA in the presence of LUSH were set up the same as those 
for the group assays except for changes to the substrate (150 μ M) and enzyme (3 and 57 nM) concentrations, and 
the addition of LUSH (300 μ M). Duplicate reaction mixtures were set up without LUSH as controls. Equivalent 
reactions using a better, mid-chain ester substrate, decyl acetate, were also set up as further controls.
Protein engineering and expression. Six generations of directed evolution were undertaken to improve 
the soluble expression of E. coli-expressed wildtype EST6. The method followed Jackson et al.21, but in this case the 
coding region of Est6 from the iso-1 y1cn1bw1sp1 reference strain (http://flybase.org/reports/FBsn0000272.html), 
omitting the 63 bp encoding the N-terminal signal peptide33, was cloned into the expression vector pETMCSIII66 
between the NdeI and EcoRI sites in frame with the ATG start codon of the NdeI site. Adequate expression of Est6 
could be achieved by ‘leaky expression’ because of the presence of trace amounts of lactose in the LB media used. 
The error-prone PCR protocol used to construct the initial mutant library involved a reaction mixture comprising 
100–200 ng of pETMCSIII-Est6, 1 μ M primers pET3 and pET4 (5′ CGACTCACTATAGGGAGACCACCAC3′ 
and 5′ CCTTTCGGGCTTTGTTAGCAG3′ ), 1 × Taq DNA polymerase buffer, 5 mM MgCl2, 0.1–0.4 mM 
MnCl2, 0.5 mM dNTPs, 5U Taq DNA polymerase, and milliQ H2O to a final volume of 50 μ l. Thermocycling 
involved 30 cycles of 94 °C for 10 s, 45 °C for 10 s and 30 s at 72 °C. The NdeI- and EcoRI-digested PCR product 
was gel extracted, ligated back into pETMCSIII, and then used to transform competent BL21 (DE3) star cells. 
Transformed cells were plated onto LB plates containing 100 mg. l−1 ampicillin. After incubation at 30 °C over-
night, the colonies were blotted onto 3 M filter papers and esterase activity was assayed by staining the filter paper 
with a solution consisting of 10 ml of 0.1% w/v Fast Red and 0.2 ml of 1% w/v 2 NA in 0.1 M Tris pH 7.0. Between 
200–300 (approximately 1%) of the colonies generating the most intense red colour were then picked by hand and 
grown overnight in 500 μ l of LB, 100 mg. l−1 ampicillin, in 96-well culture plates. 50 μ l of each of these cultures 
was then added to the corresponding well of a 96-well assay plate that contained 250 μ l of a reaction mixture con-
sisting of 0.5 mM 2 NA, 0.5 mM Fast Red, and 0.1 M Tris pH 7.0. The reaction was monitored with a spectropho-
tometer at 490 nm, and the 10–20 colonies generating the highest activities were sequenced and used as parents 
for the next generation of mutation and selection. The protocols for generations 2 to 6 followed those above. The 
sixth generation mutant generating the highest activity in the spectrophotometric assay, denoted EST6-1, was 
used for crystallization.
EST6-1 Crystallization and Computational Analysis. EST6-1 was expressed in E. coli Origami B (DE3) 
pLysS Cells (Merck) grown in LB media with 100 μ g.ml−1 ampicillin to an optical density of 0.6. The cells were 
induced with 700 μ M IPTG and harvested after 18 hours at 25 °C. The cells were then lysed by sonication in 
50 mM Hepes (pH 7.5), 300 mM NaCl, 10 mM imidazole (buffer A). The soluble lysate was separated by centrifu-
gation at 23,000 g and filtered with a 0.45 μ M filter before being loaded onto a 5 ml Ni-NTA column. The protein 
was eluted from the column with buffer A supplemented with 300 mM imidazole. Fractions were pooled after 
confirmation by SDS-PAGE and further purified by size exclusion chromatography in 20 mM Hepes (pH 7.5) and 
50 mM NaCl (buffer B) using a Hiload 26/600 Superdex 200 pg column (GE Healthcare). The concentration of 
EST6-1 was determined at 280 nm with the Nanodrop 1000 (Thermo Scientific) using an extinction coefficient of 
74,635 M−1 cm−1 estimated by the ProtParam server69.
Surface lysine residues of purified EST6-1 (1 mg. ml−1) were methylated following the protocol of Walter 
et al.36, and the reaction was quenched with 1 M glycine, followed by concentration of methylated EST6-1 to 
18.2 mg. ml−1 and dialysis into buffer B. Crystals of methylated EST6 were grown by the sitting drop diffusion 
technique with a reservoir solution containing 0.2 M ammonium acetate, 0.1 M Tris pH 8.5 and 25% w/v PEG 
3,350. 35% w/v PEG 3,350 was used as a cyroprotectant during flash cooling of the crystals in nitrogen at 100 K. 
Diffraction data were collected at the MX2 beamline at the Australian Synchrotron, Victoria, Australia with a 
wavelength of 0.9655 Å. Data collection methods and statistics as well as details of the informatics methods used 
to solve the enzymes structure are given in Supplementary Table S5.
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A model EST6-WT was built from the 97% identical structure of EST6-1 using FoldX40. Covalent docking was 
performed with DOCKovalent, a covalent version of DOCK3.741. The program pre-generates a set of conforma-
tions for each ligand, covalently attaches the ligand to a receptor, and exhaustively samples ligand orientations 
around the covalent bond. Ligands are then ranked via a physics-based scoring function. Esters investigated in 
this work were represented as SMILES strings with the covalent attachment to the catalytic serine Oγ marked 
with a dummy atom. The esters were docked in the form of a tetrahedral intermediate, after nucleophilic addition 
of the serine Oγ to the carbonyl carbon and prior to departure of the alcohol, with the carbonyl oxygen bearing a 
negative charge. The generation of ligand conformations and preparation of the receptor (EST6-WT model) was 
carried out as described previously41. The catalytic histidine was represented in its doubly protonated form. The 
selected esters were covalently docked onto the Ser188 Oγ with a Oγ -ligand bond length of 1.6 ± 0.1 Å sampled 
at 0.05 Å increments and with the Cβ -Oγ -ligand and Oγ -ligand-ligand bond angles set to 109.5 ± 5° and sampled 
at 1° increments. The lowest energy pose for each ligand was selected for analysis. Protein structure images were 
produced with PyMol V 1.3 and a topology diagram was generated using TOPDRAW70.
Immunohistochemistry. Flies. OrcoGal4 flies were generously provided by G. Galizia (University of 
Konstanz, Germany), lushGal4 flies (originally from R Benton, Université de Lausanne, Switzerland) from J-F. 
Ferveur (CSGA, Dijon, France) and elavLexA, LexAOP-mCD8::GFP, UAS-mCD8::RFP and Est6 null mutant flies 
from the Bloomington Stock Center (stocks 52676, 32203, 27392 and 4211 respectively). All flies were raised at 
25 °C on standard yeast/cornmeal/agar medium in a 12-hr light/12-hr dark cycle, 50–60% relative humidity.
Generation of anti-EST6 antiserum. Preparation of denatured EST6 antigen and production of polyclonal anti-
body followed the methods of Han et al.71. Briefly, wildtype EST6 was overexpressed in inclusion bodies in E. 
coli using the expression vector pETMCS III as above. Cells were harvested and lysed and inclusion bodies col-
lected as above. The latter were then dissolved in 6 M guanidine HCl in a buffer containing 20 mM phosphate 
pH 7.4 and the solubilized denatured proteins loaded onto a 5 ml Ni-NTA column. The EST6 was eluted from 
the column with a gradient of buffer containing 6 M guanidine HCl, 20 mM phosphate, 0.5 M imidazole, pH 7.4. 
Fractions containing EST6 were identified from the presence of a 59.7 kDa band on denaturing PAGE and then 
pooled and loaded onto a Superdex 200 preparative scale exclusion column (GE Healthcare) equilibrated with 
6 M of guanidine HCl, 20 mM phosphate buffer, pH 7.4. EST6 fractions from this column were concentrated to 
1 mg. ml−1 using an Amicon Ultra-15 centrifugal device (Millipore, US) and the guanidine HCl removed by dial-
ysis in 20 mM phosphate buffer, pH 7.4. The purified denatured EST6 was used as antigen for polyclonal antibody 
production by IMVS Veterinary Services, South Australia. Four doses of 0.5 mg antigen were administrated to a 
rabbit at 3 weekly intervals. The polyclonal antibodies were purified from antiserum using an IgG affinity column 
and the protein concentration was estimated at 3 mg. ml−1.
The specificity of the antiserum was then tested by western blotting against extracts from heads of wild-
type (Canton S) and Est6° null mutant flies. Mass homogenates of heads from each strain in 20 mM Tris-HCl 
buffer (pH 7.4) were briefly sonicated, centrifuged at 8,000 g for 10 min and the supernatants isolated. Twenty 
μ g of protein from each homogenate were then separated by SDS-PAGE and blotted onto a polyvinylidene 
fluoride (PVDF) membrane. After blocking in Tris Buffered Saline-Tween 10% (TBST-10%) blocking reagent 
(Invitrogen), membranes were incubated overnight at 4 °C with the anti EST6 antibody (1:3,000), then incubated 
with rabbit-peroxidase-labelled antibody (1:10,000). Blots were then washed and incubated with chemilumines-
cent substrate (ECL Plus Western Detection Kit, GE Healthcare).
Localization of EST6 within antennae. To localize EST6 in the antenna, we performed immunohis-
tochemistry with the anti-EST6 antibody above on transgenic flies expressing RFP under the control of either 
the Orco or lush promoter or GFP under the control of the elav promoter. Est6 null mutant flies were used as a 
control for the specific labelling of the antibody. Specifically, heads with antennae still attached from 5-day-old 
OrcoGal4/UAS-mCD8::RFP, elavLexA/LexAOP-mCD8::GFP, lushGal4/UAS-mCD8::RFP or Est6 null mutant males 
were fixed for 3 h in 4% paraformaldehyde with 0.2% Triton X-100, then washed for 1 h with PBS containing 
0.2% Triton X-100 (PBST). The heads were then embedded in Tissue-TekTM (CellPath) and cryosections (15 μ m) 
were set in cell culture insert (Greiner Bio-one). After blocking with 3% normal goat serum and 1% BSA in 
PBST (1 h at room temperature), the anti-EST6 antibody was diluted from 1:3,000 to 1:750 (v:v) in the blocking 
solution (3% normal goat serum in PBST) and incubated overnight at room temperature. After a brief rinse in 
PBST, an anti-mouse conjugated Alexa-488 or Alexa-596 (Invitrogen) was applied at a concentration of 1:800 
(v:v) in the blocking solution for 4 h at room temperature. Tissues were mounted in Slowfade reagent with DAPI 
(Invitrogen). Images were captured on a Leica SP5 confocal microscope and analysed using ImageJ 1.47 v (http://
imagej.nih.gov/ij).
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4.2. Introduction 
4.2.1. Insects 
Insects are one of the most abundant group of animals on the planet, some of which are 
associated with detrimental effects on human health and the environment (184). Insects are 
also a major agricultural pest, which results in billions of dollars of damage to agriculture 
every year (14). There are a number of ways to deal with insects such as mechanical (traps, 
barriers) or biological controls (promoting beneficial insects to eat target pests), but most 
control programs rely on the use of insecticides to control the insect population (14). It has 
been estimated that 4 million tons of pesticides are used on world crops annually for pest 
control, with the market estimated to be in the order of $11 billion US (185, 186). 
4.2.2. Organophosphate insecticides 
Five major classes of insecticides have been widely used, including: organochlorines, 
carbamates, pyrethroids, organophosphates and neonicotinoids (Figure 4.1) (185, 187). All 
of these insecticides are neurotoxins that target the central nervous system of the insect and 
aim for one of the following targets: acetylcholinesterase, GABA receptors, sodium 
channels or nicotinic acetylcholine receptors (188). These insecticides, with the exception 
of organochlorines and neonicotinoids, are susceptible to cleavage as they contain ester 
bonds. This has led to resistance by detoxification and interaction with carboxylesterases 
(CBEs)  (16, 68, 69, 185, 187–191). Two alternative insecticide types have been introduced 
in recent years including: biopesticides (Bacillus thuringiensis) and insect growth 
regulators (methoprene) (192–195). 
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Figure 4.1. A selection of insecticides from the five major classes: organochlorides, 
organophosphates, carbamates, pyrethroids and neonicotinoids (185). 
Organophosphate (OP) insecticides are covalent, irreversible inhibitors of 
acetylcholinesterase (AChE) and are used worldwide (17, 196, 197). They contain triesters 
of phosphoric acid with two short alkyl side chains (o-methyl or o-ethyl), a variable leaving 
group and a terminal oxygen (Figure 4.2) (17, 196–198). The leaving groups of OPs are 
electron withdrawing groups, which are displaced in the first step of the mechanism by the 
catalytic serine residue (17, 198). Over 30 commercial OP insecticides are in use and are 
often synthesised as “thion” analogs form, containing a sulphur at the phosphoryl oxygen 
position, which are activated to the active oxon form by P450 enzymes during metabolism 
(199). The oxon form of the OP is a much more effective inhibitor of AChE (200).  
Figure 4.2. A generic OP insecticide. X is either an oxygen or sulfur and R1 and R2 are typically 
a methyl or ethyl group. R3 is the variable leaving group (197). 
OPs disrupt the function of cholinergic synapses in higher eukaryotes, which is the basis of 
their insecticidal effect (17, 197). The target, AChE is an essential enzyme that terminates 
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signal transduction at nerve synapses by hydrolysis of acetylcholine (Ach) (17, 201, 202). 
Insects are able to survive a high amount of AChE inhibition until a certain threshold, at 
which interminable signal transduction occurs at the cholinergic synapse leading to 
cholinergic nerve failure, paralysis, and death (72, 203, 204). Insect AChE is more 
susceptible to inhibition compared to human AChE leading to the popularity and 
widespread use of OPs (205–207). 
 
Figure 4.3. Mechanism of AChE inhibition by OPs. The enzyme can go either two pathways: 
aging to an irreversibly inhibited enzyme or can be slowly regenerated by the solvent to active 
protein. Figure adapted from Jackson et al (208). 
 
The central phosphotriester moiety of OPs is important to their mode of action as inhibitors 
(208). In the initial steps of inhibition by OPs, the hydrolytic attack of the central 
phosphorous leads to the departure of the leaving group and the stable phosphor-Ser 
intermediate is formed (Figure 4.3) (32, 208). The first step of the reaction mechanism 
proceeds fast but the OP is a poor substrate for the second step and proceeds extremely 
slowly, rendering the enzyme essentially catalytically inactive (32, 208). The phosphor-Ser 
intermediate is tetrahedral, not planar like in the acyl-Ser intermediate. This causes steric 
constraint and prevents nucleophilic attack from an activated water molecule to regenerate 
the enzyme as in the acylated intermediate (209).  
 
The enzyme can have two fates after the phosphor-Ser intermediate is formed – either (i) 
be slowly deactivated by non-activated water molecules, which is a very slow hydrolytic 
process or (ii) an aging reaction (Figure 4.3) (208). The aging reaction is from dealkylation 
of one of the side chains of the phosphor-Ser intermediate that leads to irreversible 
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inhibition of AChE (210, 211). Inhibition by OPs occurs to a certain degree with various 
CBEs due to the similarity in structure and catalytic mechanism (208, 212, 213). However, 
CBEs are resistant to the aging reaction due to subtle differences in structure (208, 212, 
213).  
4.2.3. Insecticide Resistance 
Living organisms have evolved to adapt to xenobiotics and insecticide resistance is a well-
documented example (32, 214). Insecticides are the preferred control method for 
agricultural and disease vector insect pests, yet the widespread use of insecticides 
worldwide creates a strong selection pressure (32, 214). This has led to a global increase of 
insecticide resistance due to the evolutionary adaptability of insects (215, 216). This 
resistance has made insecticide use ineffective and limited the available options for 
controlling arthropod populations, resulting in the re-emergence of diseases and a decrease 
in crop yields and profitability (217, 218). This resistance has caused disruption to 
arthropod control programs and is an ever growing and complicated global problem (14). 
Insects exposed to these insecticides have evolved altered physiology and unique metabolic 
mechanisms in order to survive under the strong selection pressure imposed (32, 69, 187, 
214, 219, 220). Currently, there are over 500 insect species that are reported to have 
resistance to at least one of the five classes of insecticides (Table 4.1) (193, 195, 221). 
Some of the most famous examples of insecticide resistance are from the house fly (222, 
223),  the cotton bollworm (224–226) and several mosquitoes species (227–229). Research 
worldwide is focussed on elucidating the mechanisms involved with the development of 
insecticide resistance, which is necessary for the creation of more effective strategies to 
hinder resistance, to control resistant species and to reduce the prevalence of disease and 
crop loss (230). To combat resistant arthropod populations, alternative techniques are being 
implemented such as using multiple insecticides on rotation at an increased concentration 
(217, 231).  
Insecticide resistance in arthropod species has evolved by two main routes: by a decrease 
in sensitivity of the target site, or by upregulation of proteins able to sequester or break 
down the insecticide (32, 219). Metabolic resistance occurs through one or a combination 
of either quantitative (sequester) or qualitative (breakdown) and CBEs are most commonly 
responsible for this type of resistance (Table 4.1) (14, 19, 44, 187, 208, 215). CBEs are an 
abundant protein family in insects, with up to 76 CBE encoding genes identified in the 
60 
 
genomes of insect species (232). Two other major enzyme families are also involved in 
metabolic resistance: glutathione S-transferases (GST) and cytochrome P450 
monoxygenases (P450s) (Table 4.1) (77, 187, 228). Metabolic resistance mediated by 
CBEs has rapidly evolved and has been shown to give resistance to three major insecticide 
classes (pyrethroids, carbamates, OPs) (69, 187, 208, 230). 
 
Table 4.1. Summary of insecticide resistance to five types of insecticides (organophosphates, 
organochlorines, pyrethroids, carbamates and neonicotinoids) (32, 233). 
 
Type of 
Resistance 
Insecticide Target Site (s) Mechanism of 
Resistance 
Desensitivity OPs Acetylcholinesterase G117S 
Pyrethroids Sodium Channels/GABA 
Receptors 
L1014F 
Carbamates Acetylcholinesterase G117S 
Neonicotinoids Nicotinic Acetylcholine 
Receptors 
Y151S, R81T 
 Organochlorines Sodium Channels L1014F 
Metabolic 
Resistance 
OPs Acetylcholinesterase CBEs 
Pyrethroids Sodium Channels/GABA 
Receptors 
P450s, GSTs, 
CBEs  
Carbamates Acetylcholinesterase CBEs 
Neonicotinoids Nicotinic Acetylcholine 
Receptors 
P450s, GSTs 
 Organochlorines Sodium Channels - 
 
4.2.4. Organophosphate Resistance 
OP insecticides are commonly used worldwide, and have superseded organochlorine 
insecticides since they were mostly banned in 1972 (208). There have been over 150 
separate cases of OP resistance reported with the earliest reports coming in 1963 (14, 234). 
Insects have three main resistance mechanisms to OP insecticides associated with CBEs 
(14, 32). 
(1) Evolution of AChE (target) for lower sensitivity towards OPs. 
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(2) Upregulation of CBE genes that are able to bind and sequester the insecticide – 
potentially turning it over very slowly. 
(3) Evolution of CBEs to catalyse hydrolytic detoxification of the OP insecticide. 
4.2.5. Mechanisms of Resistance to Organophosphates 
(1) Desensitivity of Acetylcholinesterase. Most insects have two forms of cholinesterase; 
one (AChE) is involved in neurotransmission and the target of insecticides. The other form 
(butylcholinesterase) is not discussed in further detail here (235–237). Amino acid 
substitutions in AChE cause a change in the structure that results in an enzyme that is less 
sensitive to inhibition by OPs (238–241). The amino acid position and the nature of 
resistance conferring mutations vary depending on the organism. For example, the 
Gly151Ser mutation is commonly found in the mosquitoes Culex pipiens and Anopheles 
gambiae, however, the Ser371Phe mutation is observed in the aphid, Myzus persicae (237, 
238, 242–246). In both cases, resistance is achieved from a smaller residue to a bulkier one 
that constricts space in the active site gorge for the OP. This limits access for the OP to the 
catalytic residues that results in a reduction of AChE sensitivity (32). The substrate, Ach 
can still enter for normal cholinergic function, however, in some cases with reduced 
efficiency (247, 248). The mutation that appears depends on the particular insecticide, 
slight structural differences and genetic constraints (codon usage and variability). There are 
over 10 mutations that have been reported to be involved in resistance throughout multiple 
species (249–252).  
  
(2) Quantitative changes involving carboxylesterases as a mechanism of metabolic 
resistance. This mechanism of resistance is from the overproduction of CBEs through gene 
amplification (multiple copies of the same gene being found on the same genome). This 
results in CBEs effectively acting as an OP sink, minimising the inhibition of AChE (28, 
32, 187, 188). In some cases, the CBEs genes can be amplified up to 200 copies, which 
results in the overexpression of the protein (34, 253, 254). This mechanism is found in 
several orders including Hemiptera (aphids and whiteflies), Hymenoptera, Lepidoptera and 
lower dipteran species (Culex mosquitoes). The quantitative mechanism has been utilized 
in insect species for resistance against OPs, carbamates, and pyrethroids insecticides (32, 
34, 35, 188, 253, 255–259). The sequestration mechanism is effective because of the 
similarity in structure and catalytic mechanism of CBEs to AChE, which results in CBEs 
having high affinity for OPs (260). Despite the negligible OP hydrolase activity, the 
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overabundance of the CBE is able to sequester the OP sufficiently to confer resistance to 
the organism (261–263).  
(3) Qualitative changes in carboxylesterases by mutations for increased activity.
Instead of a change in copy number, a favourable structural mutation in a CBE can provide 
resistance. A mutation can enhance OP hydrolysis resulting in an increased capability for 
insecticide metabolism (2, 208). This mechanism of resistance by catalytic improvement is 
a successful detoxification strategy because of the high affinity for OPs observed in CBEs 
(2, 223, 264). The turnover rates of the OP are typically slow for an enzyme but are 
sufficient for resistance (2, 223, 264). The most studied CBE for this strategy is the protein 
αE7 from the Australian sheep blowfly (Lucilia cuprina) (2, 264). A single point mutation 
was identified to give increased activity towards OP insecticides, however, the mutation 
resulted in a decrease in CBE activity (72, 223, 264–266).  
4.2.6. Qualitative Resistance in Diptera 
In higher Diptera, resistance to OPs is achieved by a structural change that reduces CBE 
activity for OP hydrolase activity (2). Resistance by this mechanism has been observed in 
multiple Diptera species including Lucilia cuprina (Australian sheep blowfly), Lucilia 
sericata, Musca domestica (Common housefly), Cochliomyia hominivorax (New World 
screw-worm fly), and one Hymenopteran species, Anisopteromalus calandrae (Howard 
Parastic Wasp) (2, 223, 267–269). In blowfly species, the CBE involved has been identified 
as αE7 with a single amino acid substitution found in the active site (Gly137Asp or 
Trp251Leu). The single mutation Gly137Asp results in broad-spectrum OP resistance in 
preference to diethyl OPs. The Trp251Leu substitution results in broad-spectrum resistance 
in preference to dimethyl OPs and malathion specific resistance (264, 270). This has been 
identified as an example of the ali-esterase mechanism, as there is a characteristic shift in 
substrate specificity from carboxylesters to OPs (2, 223, 265, 267). 
As mentioned, the best characterized mutant CBE involved in the qualitative resistance 
mechanism is αE7 from the species L. cuprina (2, 72, 271, 272). The Gly137Asp mutant 
enzyme has a 55-fold increase in hydrolase activity for diethyl OPs and a 33 fold increase 
for dimethyl OPs compared to the wild-type enzyme (72). The turnover number is poor, 
with approximately three turnovers per hour per molecular enzyme (72, 264, 270). The 
poor catalytic efficiency (kcat/KM of 102 s-1M-1) is low for a typical naturally evolved 
enzyme (104- 107 s-1M-1), however, the system has been present for less than 70 years rather 
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than millions of years for evolution to take place (32). The Trp251Leu mutant enzyme 
provides a 130 fold increase in activity against malathion compared to the wild-type 
enzyme (264, 270). The selective pressure and protective benefit has resulted in alleles with 
the Gly137Asp substitution becoming dominant over the Trp251Leu mutant in L. cuprina 
populations (11, 273). The opposite trend (Trp251Leu dominant over Gly137Asp) has been 
observed with M. domestica populations in Turkey where malathion is commonly used 
(274). The two mutations are not found together in nature, each conferring resistance 
independently (69). 
 
A full understanding of the mutations has been achieved with the structure of αE7 from L. 
cuprina (55). For the Gly137Asp mutation, the non-conservative replacement of Gly to Asp 
disrupts the oxyanion hole in the active site. This compromises function, resulting in a 
reduction of CBE activity (2, 55, 223). However, the introduction of Asp at position 137 
increases OP turnover by Asp acting as a general base. This allows for the activation of a 
water molecule in a suitable position to attack the phosphor-Ser intermediate that is formed 
between the catalytic serine and the OP (2, 72). The hydrolysis of the intermediate 
regenerates the enzyme and is similar to the second step of native carboxylester hydrolysis 
activity (32). A new activation site is necessary for OP hydrolysis, as the intermediate has 
tetrahedral rather than planar trigonal geometry that is found with carboxylester substrates 
(233). A similar mechanism for an increase in OP hydrolase activity has been observed in 
human BChE during a directed evolution experiment. However, in this experiment, a 
histidine residue was found at this position instead of an aspartate residue (275).  
 
The Trp251Leu mutation is found in the acyl pocket of the active site (P2 subsite). The 
presence of a bulky tryptophan residue at this position limits the hydrolysis of the phosphor-
Ser bond (55, 264, 270). The change from Trp251 to a smaller residue (Leu) provides more 
space for the OP by opening up the acyl binding pocket. This reduces steric hindrance for 
the hydrolysis of the phosphor-Ser bond (55, 223, 264). There is also a loss of a stabilising 
interaction between the phosphorylated serine and the protein that leads to an increase in 
active site regeneration (208). This mutation has been found before the introduction of 
insecticides, suggesting it could be neutral in regards to native function (264, 268). 
 
A further understanding for how the OP resistance is conferred by CBEs can be gained from 
the comparison between CBEs and AChE. The high active site complementary between 
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CBEs and AChE can result in CBEs having a tighter affinity to OPs than AChE (2, 55, 206, 
208, 212). Furthermore, the resistance to the aging reaction and a high abundance results 
in CBEs acting as effective catalytic bioscavengers (55, 212, 272, 276, 277). 
 
4.2.7. Evolutionary Contingency and Insecticide Resistance 
There are a larger number of examples of the quantitative resistance mechanism in insects 
compared to the qualitative resistance mechanism (193, 195, 221). There are several 
proposed reasons for why certain insect species favour the quantitative mechanism over the 
qualitative mechanism of resistance. These include: 
 
- Two or more base pairs changes from Gly to Asp results in a low chance of evolution to 
occur (278). 
- Subtle differences in structure limits the ability for OP hydrolase activity to evolve (55). 
- The loss of wild-type function with the introduced mutation leads to a loss of fitness (278, 
279). 
- The sequestration ability confers resistance to a wider range of insecticides, therefore, 
provides greater protection than the qualitative resistance mechanism (32, 278, 279). 
 
Despite the large amount of effort in showing the critical role of CBEs in the evolution of 
insecticide resistance, the molecular principles regarding the evolution of new enzyme 
function have not been fully elucidated. Furthermore, there is no full understanding of what 
dictates the evolution of qualitative or quantitative mechanism in insect species (32, 279). 
The understanding of resistance could lead to the ability to engineer a protein for an 
increase in OP hydrolase activity to treat OP poisoning (72, 208). However, without 
structural and biochemical information on a large number of insect proteins, it is difficult 
to understand what factors dictate a protein’s ability to hydrolyse OPs effectively. 
 
Subtle differences between the CBEs could explain why some proteins cannot confer 
resistance by the qualitative mechanism. This could be caused by neutral drift, which is 
related to the concept of evolutionary contingency (280). The key evolutionary concept of 
historical contingency was first mentioned by Stephen Jay Gould, who describes historical 
contingency as the constriction of evolutionary paths by historical events that are often 
random (281–284). In other words, the initial state influences the evolutionary outcome. 
During the selection process, small genetic differences can cause major changes in the 
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evolutionary outcome (285). Genetic differences can be due to past selective pressures and 
to random changes in alleles, which is related to the sampling processes (286–289). 
The fundamentals of evolution involve a balance between random and deterministic 
processes (284, 290–295). The deterministic processes of evolution will produce the most 
accessible form in the fewest possible steps, regardless of random events (296, 297). When 
non-deterministic processes (genetic drift) play a strong part in evolution, chance events 
determine the outcome of evolution (298). This results in the unpredictability when history 
is repeated, with different results despite identical environmental conditions (299). Non-
deterministic processes are important for the generation of new beneficial mutations (299). 
In some cases, beneficial mutations can be dependent on prior mutations that are neutral 
when isolated but must be present for beneficial mutations to take effect (284, 300–306). 
These mutations cannot be fixed by selection processes and must be acquired independently 
(298). Therefore, the chance of a mutation appearing in a population may be contingent on 
past mutations (282, 284, 307, 308). These historical contingencies or differences in initial 
conditions that are a universal property of dynamic systems, make evolution largely 
unpredictable (282, 309).  
In most studies, the conditions that facilitate the evolution of new function are destroyed 
during the evolutionary processes (307). However, the recent example of OP resistance in 
insects presents a modern example where the past is able to be recovered (310–313). 
Understanding how random historical events shape evolutionary processes is a main goal 
of evolutionary biology and it is difficult to characterize other potential pathways from the 
past (284, 297, 305, 308). However, as insecticide resistance is a relatively recent event, 
direct insights into evolutionary contingency can be investigated. 
There has been a suggestion of contingency previously with Diptera αE7 orthologs. The 
Drosophila αE7 protein has a lower affinity for OPs compared to LcαE7, despite few 
changes in the active site residues (206, 272, 277). Development of prediction strategies is 
required to look at the active site and second or third shell residues. These residues are 
important for shaping the active site and influencing the correct orientation of Asp137 for 
OP hydrolysis (314–316). To investigate OP resistance in Diptera species, the role of 
evolutionary contingency in Diptera and why OP resistance is not widespread by the 
qualitative mechanism, multiple genes were ordered of LcαE7 orthologs with and without 
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the Gly137Asp mutation. The orthologs would be characterized biochemically and 
structurally to analyse their ability to turnover OPs. 
4.3. Preface 
How enzymes evolve new functions has been of great interest and insecticide resistance is 
a valuable model system to study this. While a large number of insect pests have evolved 
resistance, there appears to be limited options for CBE-based metabolic resistance. 
Studying the evolution of resistance is important for designing new effective control 
strategies for insecticide resistance and the creation of new insecticides to make resistance 
difficult to evolve. A large amount of effort has been focussed on resistance at the genetic 
level with protein analysis been relatively unexplored. The difficulties of recombinant 
expression of eukaryotic proteins in E. coli has been a major hurdle in the characterization 
of resistance proteins. There are still a few questions that remain to be answered with 
resistance proteins including if there are limited routes for resistance by the qualitative 
resistance mechanism for CBEs and can the Asp137 residue hydrolyse OPs in close 
orthologs of LcαE7? This could show that resistance by the qualitative resistance 
mechanism is a general characteristic or a unique feature in dipteran species. The following 
research also intends to understand if evolutionary contingency plays a role in the 
development of insecticide resistance involving CBEs. In this chapter, work has been 
focussed on the evolution of qualitative resistance in LcαE7 orthologs. The Gly137Asp 
mutation in the protein LcαE7 has been found to give resistance to the blowfly against OPs. 
Analysis of this mutation on OP hydrolase activity in LcαE7 orthologs can establish if 
contingency plays a role in the evolution of insecticide resistance in Diptera species. 
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4.4. Materials and Methods  
 
4.4.1. Cloning  
Genes encoding αE7 orthologs bearing the Gly137Asp mutation were synthesized by 
Integrated DNA Technologies (IDT, USA). The genes were cloned by the DNA-fragment 
assembly method described by Gibson and coworkers into the pETMCSIII vector (317, 
318). The mutations Asp137Gly or Gly137Asp were introduced into the vectors by Gibson 
assembly using the primers listed in Appendix F. The resulting vectors were sequenced at 
the Biomolecular Resource Facility, Australian National University, Australia. Plasmids 
encoding L. cuprina αE7 were described previously (315). Plasmids and sequence 
information was submitted to the Addgene vector database. 
4.4.2. Protein Expression and Purification 
The proteins were expressed in BL21 (DE3) Escherichia coli at 24 °C for 22 hours with 
autoinduction in lysogeny broth (LB). Cells were collected by centrifugation and 
resuspended in buffer A (50 mM HEPES pH 7.5, 300mM NaCl, 10 mM imidazole) and 
lysed by sonication. Cell debris was pelleted by centrifugation, and the soluble fraction was 
applied to a HisTrap-HP Ni-Sepharose column (GE Healthcare, USA). Protein was eluted 
in buffer B (50 mM HEPES pH 7.5, 300 mM NaCl, 300 mM imidazole). The major fraction 
containing the protein of interest was applied to a HiLoad 26/60 Superdex-200 size-
exclusion column (GE Healthcare, USA), pre-equilibrated in buffer C (20 mM HEPES pH 
7.5, 150 mM NaCl). The protein CcαE7 was purified in the same buffer conditions but with 
the pH adjusted to 8.5. Protein elution was monitored at 280 nm, and fractions containing 
the monomeric protein were pooled for enzyme assays. Protein concentration was 
calculated from absorbance at 280 nm with the extinction coefficient. The extinction 
coefficient and molecular mass for each protein was calculated using the Protparam online 
tool (319). Molecular weights of the oligomeric species were estimated using a gel filtration 
HMW calibration kit (GE Healthcare, USA) following the manufacturer’s instructions. 
Protein purity was assessed by SDS-PAGE using precast ExpressPlus 4 to 20% PAGE gels 
(GenScript) and visualized by staining with Coomassie brilliant blue (Sigma, USA.)  
4.4.3. Carboxylesterase Activity 
Hydrolysis of the ester substrate 4-nitrophenyl butyrate (4-NPB; Sigma-Aldrich, USA) was 
monitored at 405 nm in buffer C at 25 °C using an Epoch microplate spectrophotometer 
(BioTeK Instruments, USA). Buffer C was supplemented with 0.4 mg/mL bovine serum 
albumin in the assays (Sigma-Aldrich, USA) to increase the stability of the enzyme. 4-NPB 
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was serially diluted 1:2 from 1000 to 7.81 μM and the assays were measured in triplicate. 
Velocities were obtained from the initial linear portion of the reaction progress curves, and 
product concentration was determined with the extinction coefficient calculated from a 
standard curve of 4-nitrophenol (Sigma-Aldrich, USA). KM and kcat were determined by 
nonlinear regression to the Michaelis−Menten equation using GraphPad Prism 6.0 
(GraphPad Software, USA). 
4.4.4. Organophosphate Hydrolase Activity 
The measurement of OP hydrolase activity of the proteins was followed by the protocol 
developed by Mabbitt et al. 2016 using the substrate diethylumbelliferyl phosphate (DEUP, 
Sigma-Aldrich, USA) (315). DEUP hydrolysis was monitored fluorometrically (excitation 
at 330 nm and emission at 450 nm) with a Cary Eclipse Fluorescence spectrophotometer 
(Agilent Technologies, USA). The assay was carried out at 25 °C and pH 7.5. Product 
formation was quantified using a standard curve of 4-methylumbelliferone (Sigma-Aldrich, 
USA) in the assay buffer C. The proposed scheme for hydrolysis of DEUP is presented in 
scheme 1.  
E + S
𝑘1
⇌
𝑘2
ES
𝑘3
⟶ EPQ
𝑘5
⟶ E + P + Q  (scheme 1). 
where E, S, P, Q are the enzyme, substrate, product and fluorescent umbelliferone leaving 
group, respectively. k1 and k2 are the rate constants for the formation of the Michaelis 
complex (ES), k3 is the rate constant for the formation of the phosphorylated intermediate 
(EP), and k5 is the rate constant for dephosphorylation. 
The rate constant describing the pre-steady state burst was determined by solutions 
containing DEUP serially diluted 1:2 from 500 to 1.5 μM, and 0.75 μM αE7. The solution 
was mixed in a 1:1 ratio using a RX2000 rapid mixing stopped-flow unit fitted with a 
RX/DA pneumatic drive (Applied Photophysics, UK). The values of k3 and KM were 
determined from the concentration dependence of the pre-steady state burst (315). The 
apparent values of k5 were determined from the linear portion of the fluorescence trace. 
Curve fitting was conducted using GraphPad Prism 6.0 (GraphPad Software, USA).  
4.4.5. Structure Modelling 
Models of the orthologs were generated using the I-TASSER server with the structure of 
LcαE7 (PDB ID: 4FNG) and the unpublished structure of CqB2 (55, 320). AaA2 and AgB2 
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models were generated with the structure of CqB2 and the other ortholog models were 
generated with the structure of LcαE7. 
4.4.6. Native-PAGE 
Peaks from the size exclusion chromatography were concentrated to 2 mg/mL and loaded 
onto NativePAGE Novex 4-16% Bis-Tris protein gels (Invitrogen) according to the 
manufacturer’s instructions. Protein samples were visualized by staining with Coomassie 
brilliant blue (Sigma, USA). 
 
4.5. Results 
4.5.1. Expression and Purification 
The proteins for analysis were selected on their similarity to LcαE7 from a BLAST search 
(Table 4.2). The protein, B2 from the species Culex quinquefasciatus (Southern house 
mosquito) was used as the end point in the search, as the introduction of the Gly137Asp 
mutation in the Culex protein resulted in no change in the rate of OP turnover (278). The 
structure of this protein was recently solved in Dr. Colin Jackson’s research group (work 
unpublished). This structure can be used to understand the structural differences that affect 
OP kinetics. The pairwise identities of the orthologs from the 11 species range from 38% 
to 89% compared to LcαE7 (Table 4.3).  
The amino acid residues for the orthologs corresponding to position Gly137 found in the 
L. cuprina CBE are shown in Table 4.4. The targeted position 137 was Ala in the enzyme 
from Aedes aegypti, appears as Asp in the Musca domestica and Cochliomyia hominivorax 
proteins and is found as Gly for the other proteins (Table 4.4). The proteins share similar 
molecular weights and pIs with the exception of CcαE7 with a pI approximately 1 unit 
above the other orthologs. 
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Table 4.2. Summary of the Diptera α-esterases selected for analysis. GenBank codes are 
listed for each protein. 
Species Common Name Protein (GenBank) Name 
Lucilia cuprina Australian sheep blowfly AAB67728.1 LcαE7 
Calliphora stygia Brown blowfly AID61335 CsαE7 
Cochliomyia hominivorax New World screw-worm fly ACR56068.1 ChαE7 
Musca domestica Common house fly NP_001295905 MdαE7 
Haematobia irritans Horn fly AF139082_1 HiαE7 
Stomoxys calcitrans Biting house fly XP_013116190 ScαE7 
Bactrocera dorsalis Oriental fruit fly AKN90083.1 BdB1 
Ceratitis capitata Mediterranean fruit fly NP_001266341.1 CcαE7 
Aedes aegypti Yellow fever mosquito XP_001654509.1 AaA2 
Anopheles gambiae African malaria mosquito XP_316296.3 AgB2 
Culex quinquefasciatus Southern house mosquito CAA83643.1 CqB2 
 
Table 4.3. Percentage identity (%) between the Diptera orthologs. The range of identity varies 
between 89% and 36%. 
 
  
 
LcαE7 CsαE7 ChαE7 MdαE7 HiαE7 ScαE7 BdB1 CcαE7 AaA2 AgB2 CqB2 
LcαE7 100 89 88 76 74 73 58 57 41 39 38 
CsαE7 89 100 86 74 71 70 56 55 39 39 36 
ChαE7 88 86 100 76 73 73 57 56 40 40 37 
MdαE7 76 74 76 100 75 75 57 55 39 41 37 
HiαE7 74 71 73 75 100 77 56 53 39 39 36 
ScαE7 73 70 73 75 77 100 55 55 39 39 37 
BdB1 58 56 57 57 56 55 100 59 40 42 38 
CcαE7 57 55 56 55 53 55 59 100 38 39 36 
AaA2 41 39 40 39 39 39 40 38 100 49 51 
AgB2 39 39 40 41 39 39 42 39 49 100 63 
CqB2 38 36 37 37 36 37 38 36 51 63 100 
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Table 4.4. Summary of the general characteristics of the Diptera esterases analysed including 
the calculated molecular weight, theoretical pI, equivalent position number to 137 in LcαE7, 
codon found at this site and the resistance found in the species mentioned. 
Protein MW (kDa) Theoretical pI Position 
Equivalent to 137 
in LcαE7 
Codon at 
137 
Observed OP Resistance 
involving esterases in 
Diptera species 
 
LcαE7 65.4 6.27 137 GGT/GAT 
(Gly/Asp) 
Gly137Asp, Trp251Leu 
(2) 
 
CsαE7 65.6 6.13 137 GGT (Gly) Unknown  
ChαE7 65.2 6.56 137 GAC (Asp) Gly137Asp, Trp251Leu 
(267) 
 
MdαE7 65.4 6.27 137 GAT (Asp) Gly137Asp, Trp251Leu 
(223) 
 
HiαE7 65.7 6.35 137 GGT (Gly) Upregulation (321)  
ScαE7 65.5 6.69 137 GGT (Gly) Unknown  
BdB1 65.3 6.09 145 GGC (Gly) Upregulation (322)  
CcαE7 65.7 7.52 145 GGA (Gly) Unknown  
AaA2 62.2 5.34 118 GCT (Ala) Upregulation (323)  
AgB2 61.1 5.26 118 GGA (Gly) Unknown  
CqB2 61.7 5.70 118 GGC (Gly) Upregulation (262)  
       
The genes of the dipteran esterases were ordered as WT or with Asp at the equivalent 137 
position. Cloning by Gibson assembly introduced the genes into the pETMCSIII expression 
vector. The reverse mutation Asp137Gly or the Gly137Asp mutation were mutated into the 
Diptera esterases genes by Gibson assembly. The wild type and variant (Gly137Asp) CBEs 
were expressed and purified in similar conditions to the expression of LcαE7 (324). There 
was a significant absorbance reading (>1000 mA) following affinity chromatography that 
indicates a high amount of soluble expression for the recombinant CBEs (Figure 4.4). The 
exception was with the ortholog, HiαE7, where after affinity chromatography a low 
absorbance was observed (<300 mA). This suggests the protein is largely insoluble or does 
not express and was subsequently not analysed in further detail. There was no change in 
soluble expression of HiαE7 with variations in expression media and temperature.  
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Figure 4.4. Chromatogram of the 11 orthologs after nickel affinity chromatography. Blue lines 
represent the 10 proteins that express in large amounts. The red line represents HiαE7 that 
was found to not express in high amounts. 
 
Following affinity chromatography, the proteins were subjected to size exclusion 
chromatography (SEC). This revealed a large variation in the amounts of soluble protein, 
aggregation and oligomeric states between the proteins (Table 4.5) (Figure 4.5). The 
mosquito proteins (AaA2, AgB2, and CqB2) expressed in high amounts compared to the 
blowfly orthologs (Table 4.5). The three mosquito orthologs lack the amphipathic α-helix 
that is found in the other seven blowfly orthologs. The missing α-helix in the mosquito 
orthologs could explain the high amounts of expression and low aggregation associated 
with the three mosquito enzymes (Figure 4.5). 
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Table 4.5. Summary of the average peak size, area and average concentration of the orthologs 
after SEC. 
 
Protein Average Monomer 
Peak Absorbance 
(mA) 
Total Peak 
Area 
(ml*aMU) 
Estimated Monomer 
Concentration of a single 
main peak fraction (mg/mL) 
LcαE7 180 ±50 4900 ± 900 1 
CsαE7 105 ± 10 5200 ± 900 0.5 
ChαE7 300 ± 50 8200 ± 1200 1.5 
MdαE7 490 ± 40 11000 ±2000 2 
ScαE7 160 ± 30 5800 ± 2600 1 
BdB1 50 ± 30 4800 ± 1100 0.5 
CcαE7 40 ±10 3700 ± 900 0.3 
AaA2 880 ± 500 14000 ± 7000 3  
AgB2 1500 ± 200 24000 ± 3000 4  
CqB2 960 ± 100 17000 ± 3000 3  
 
To analyse in further detail the oligomeric states of the proteins, the absorbance peaks were 
compared to protein standards subjected to SEC. It is surprising the differences in 
oligomeric state between the orthologs, given the close similarity of the proteins to each 
other. Proteins sharing a sequence identity level of 90% have a 93% likelihood of 
quaternary structure conservation (114). Furthermore, when proteins share 30-40% 
sequence identity, the likelihood of the proteins sharing similar quaternary structure is 70% 
(114). This indicates the orthologs have a high likelihood of sharing quaternary structure, 
however, this was not the case. Comparing the elution volume of the orthologs to protein 
standards and using previous work on the identified oligomeric peaks of LcαE7, the 
different oligomeric species can be analysed (Table 4.6) (324).  
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Figure 4.5. Chromatograms of the 10 purified orthologs after SEC (A) AaA2 (B) AgB2 (C) 
BdB1 (D) CcαE7 (E) ChαE7 (F) CqB2 (G) CsαE7 (H) LcαE7 (I) MdαE7 (J) ScαE7. 
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Four of the orthologs show similar quaternary structure to LcαE7 (CsαE7, ScαE7, CcαE7, 
ChαE7). The surprising difference is observed with MdαE7 (Figure 4.6, Panel I), as the 
appearance of the main peak is at the similar position to the dimer peak in LcαE7 (Figure 
4.6, Panel H). To investigate the peak at this position, the main fractions of MdαE7 and 
LcαE7 were subjected to native-PAGE. This revealed that for LcαE7 there is a band at 66 
kDa, consistent of a monomeric species. However, for the main peak of MdαE7, there 
appears to be no band at this position. A major band for MdαE7 is present at 130 kDa 
suggesting MdαE7 appears as a dimer species (Figure 4.6). This is consistent with the 
protein standards that estimated the main peak of MdαE7 to be at 135 kDa. A variant of 
MdαE7 (Lys557Pro) resulted in a large amount of aggregation and a shift in the oligomeric 
state of MdαE7. The variant displayed similar amounts of dimer and monomer species that 
indicates the oligomeric state equilibrium of MdαE7 is dynamic (Figure 4.7). BdB1 elutes 
in a similar position to MdαE7 and suggests the protein is mainly found as a dimer species 
similar to MdαE7. The orthologs from the mosquito species (AaA2, AgB2, and CqB2) 
express in high amounts and are predominantly found as monomers (Tables 4.5, 4.6) 
(Figure 4.5). After affinity chromatography and SEC, the proteins with the exception of 
CcαE7 were >90% purity for further analysis by kinetic assays (Figure 4.8).  
 
Table 4.6. Summary of the predicted oligomeric states of the Diptera esterases estimated from 
protein standards.  
 
Protein Estimated Sizes of Peaks (kDa) Monomer Dimer Tetramer 
LcαE7 55, 89, 176 Yes Yes Yes 
CsαE7 59, 91, 165 Yes Yes Yes 
ChαE7 58, 165 Yes Possible Possible 
MdαE7 63, 145 Yes Yes No 
ScαE7 69,100, 224 Yes Yes Yes 
BdB1 49, 88 
 
Yes Yes No 
CcαE7 52, 76, 180 Yes Yes Yes 
AaA2 50, 132 Yes Possible Possible 
AgB2 47, 132 Yes Possible Possible 
CqB2 46 Yes No No 
              *Bold text highlights the predominant oligomeric species for each protein 
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Figure 4.6. Native-PAGE gel of MdαE7 and LcαE7 displaying the change in oligomeric state 
between the two proteins. There is an absence of a protein band at 66 kDa for MdαE7 (A) 
LcαE7 (B) MdαE7 (M) Marker. 
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Figure 4.7. Size exclusion chromatogram displaying the difference in oligomeric species 
between MdαE7 WT (red) and MdαE7 Lys557Pro (blue). 
 
 
Figure 4.8. SDS-PAGE gel of the 10 orthologs (WT and Gly137Asp variants) after size 
exclusion chromatography that was further used for kinetic analysis. 
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4.5.2. Kinetic Assays – Esterase Activity 
To understand a potential trade-off between CBE activity and OP hydrolase activity, the 
orthologs were first characterized using a model ester substrate 4-nitrophenyl butyrate (4-
NPB) (Figures 4.9, 4.10) (Table 4.7). The WT orthologs have a large range in kcat (3.9 - 
1317 s-1), KM (20 – 105 μM) and kcat/KM (3.7 x 104 - 2.2 x 107 s-1M-1). The wild-type enzyme 
from A. aegypti has the highest catalytic efficiency (kcat/KM) towards the ester substrate. 
Figure 4.9. Kinetic data of the 10 orthologs for the ester substrate 4-NPB. Red represents WT 
of the ortholog for a Diptera species and blue represents the Gly137Asp variant for the species 
(A) KM (B) kcat (C) kcat/KM.
The Asp residue at position 137 decreases the enzymatic activity (kcat and kcat/KM) against 
the ester substrate in all cases. This result has been previously reported in LcαE7 and 
MdαE7 (72, 223, 264–266). The decrease in catalytic efficiency is a major example for the 
mutant ali-esterase theory and suggests there is a potential cost of native function with the 
Gly137Asp mutation in all of the orthologs (2, 72, 223, 264, 265, 268). In most cases, the 
KM is increased for the Gly137Asp variant, however, the exception is with the ScαE7 
ortholog. There is a statistically significant decrease in KM with Asp at position 137 for the 
ScαE7 variant. This was an unexpected result, however, for the Gly137Asp variant of 
ScαE7, the kcat is significantly reduced, resulting in a lower catalytic efficiency compared 
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to WT enzyme. This result was found to be consistent with multiple batches of purified 
ScαE7 and the Gly137Asp variant. 
Table 4.7. Summary of the kinetic data for the orthologs (WT and Gly137Asp) against the ester 
substrate 4-NPB. 
Species Variant kcat (s-1)  KM (μM) kcat/KM (s-1/M-1) 
Aedes aegypti (AaA2) 
WT 1317 ± 150 60 ± 11 2.2 x 107 ± 4.8 x 106 
Ala118Asp 16 ± 1.1 35 ± 6.6 4.6 x 105 ± 9.2 x 104 
Anopheles gambiae 
(AgB2) 
WT 149 ± 17 20 ± 6.0 7.5 x 106 ± 2.4 x 106 
Gly118Asp 37 ± 2.7 68 ± 12 5.4 x 105 ± 1.0 x 105 
Bactrocera dorsalis 
(BdB1) 
WT 6.9 ± 0.4 51 ± 4.1 1.4 x 105 ± 1.3 x 104 
Gly145Asp 1.2 ± 0.1 40 ± 8.0 3.0 x 104 ± 6.5 x 103 
Ceratitis capitata 
(CcαE7) 
WT 3.9 ± 0.7 105 ± 22 3.7 x 104 ± 1.0 x 104 
Gly145Asp 0.2 ± 0.1 172 ± 21 1.1 x 103 ± 6.0 x 102 
Calliphora stygia 
(CsαE7) 
WT 67 ± 1.0 82 ± 4.3 8.2 x 105 ± 4.4 x 104 
Gly137Asp 4.1 ± 0.1 101 ± 
9.3 
4.1 x 104 ± 3.9 x 103 
Cochliomyia 
hominivorax (ChαE7) 
WT 199 ± 2.7 55 ± 2.8 3.6 x 106 ± 1.9 x 105 
Gly137Asp 2.3 ± 0.1 97 ± 17 2.4 x 104 ± 4.3 x 103 
Culex 
quinquefasciatus 
(CqB2) 
WT 78 ± 2.2 20 ± 2.7 3.9 x 106 ± 5.5 x 105 
Gly118Asp 13 ± 0.2 52 ± 2.8 2.5 x 105 ± 1.4 x 104 
Musca domestica 
(MdαE7) 
WT 17 ± 1.4 45 ± 7.2 3.8 x 105 ± 6.8 x 104 
Gly137Asp 0.4 ± 0.1 137 ± 18 2.9 x 103 ± 8.3 x 102 
Stomoxys calcitrans 
(ScαE7) 
WT 23 ± 0.5 67 ± 5.8 3.4 x 105 ± 3.0 x 104 
Gly137Asp 0.8 ± 0.1 33 ± 2.5 2.5 x 104 ± 2.0 x 103 
Lucilia cuprina 
(LcαE7) 
WT 60 ± 1.1 34 ± 2.6  1.8 x 106 ± 1.4 x 105 
Gly137Asp 27 ± 0.7 109 ± 
9.3 
2.5 x 105 ± 2.3 x 104 
79 
 
 
Figure 4.10. Michaelis-Menten kinetics graphs for the WT protein (red) and Gly137Asp 
variant (blue) of the 10 orthologs. 
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4.5.3. Kinetic Assays – Organophosphate Activity 
The pre-steady and steady state kinetics of OP hydrolysis were monitored to understand 
the potential for OP hydrolase activity in the orthologs (Figure 4.11) (Table 4.8). Overall, 
despite the closer similarity in sequence identity between the orthologs, there is a large 
variation in the OP hydrolase activity. 
k3 represents the rate constant for the formation of phosphorylated intermediate and in the 
orthologs, this rate is slow (<1). The introduction of the Gly137Asp mutation generally 
decreases k3 in the orthologs with exception of CsαE7. This indicates this variant has the 
potential for an increase in the formation of the intermediate. k3 could not be calculated for 
four orthologs (AgB2, BdB1, CcαE7, MdαE7) and therefore, the KM for these species was 
estimated from the concentration dependence of k5. 
k5 is the turnover rate or the rate of hydrolysis for the bound OP. This rate constant dictates 
the potential of the ortholog to be involved in the quantitative mechanism. For the majority 
of the orthologs, the introduction of the Gly137Asp mutation results in an increase of k5. 
This suggests the mutation can potentially increase the turnover of the phosphor-Ser 
intermediate. In some cases (MdαE7 and ScαE7), there is a decrease in the rate constant. 
The biggest change in k5 is associated with LcαE7, where the enzyme has a 28 fold increase 
in k5 with the introduction of the Gly137Asp mutation. This indicates a high amount of OP 
turnover for this variant. 
With the exception of CsαE7 and LcαE7, the Gly137Asp variants have a 1-2 fold increase 
or decrease in k5. This shows the residue Asp137 has little effect on the turnover of the 
phosphor-Ser intermediate in the majority of the orthologs. This indicates the qualitative 
mechanism of resistance may not be selected for in some species by the orthologs tested. 
However, OPs are a strong selection pressure for insect species, therefore, any associated 
increase in OP hydrolysis could be selected for. The BdB1 WT ortholog has high OP 
turnover and there is no statistical difference in rate with the Gly145Asp mutation. The rate 
of turnover for the WT protein is higher than any other WT ortholog and similar to LcαE7 
Gly137Asp. This indicates the expression of the protein could be sufficient for resistance 
and it is observed in the species (322). 
The introduction of the Gly137Asp mutation in most cases, increases the KM and shows the 
Asp residue interferes with OP binding. The largest increase in KM is associated with CqB2 
(76 fold increase), however, there is no statistically change in KM for the MdαE7, ScαE7, 
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ChαE7 and BdB1 orthologs with the introduced mutation. There is a potential for 
inaccuracies with measuring the KM as the differences in phosphorylation rate at different 
substrate concentrations are very small. This could explain the small change in KM for the 
four orthologs. 
Overall, the catalytic efficiency (k5/KM) shows a large variation with the introduction of 
Asp137. The protein LcαE7 is the only ortholog to have a statistically significant increase 
in catalytic efficiency. The Gly137Asp mutation is associated with a decrease or no change 
in catalytic efficiency in the orthologs, with the large increase of KM for the OP not equally 
compensated by k5. The OP kinetic results shows despite the close similarity between the 
proteins, the orthologs have a large variation in OP kinetics with and without the 
Gly137Asp mutation. This shows OP turnover and binding is easily affected by differences 
in the protein sequence and structure. 
 
Figure 4.11. OP kinetic data for the 10 orthologs. WT protein of the ortholog is shown in red 
and Gly137Asp variant of the ortholog is in blue (A) k3 (B) k5 (C) KM (D) kcat/KM. 
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Table 4.8. Summary of the kinetic data for the 20 Diptera proteins (WT and Gly137Asp) against 
the OP, DEUP. 
Species Variant k3 (s
-1)  k5 (s
-1) 
×10-4 
KM 
(μM) 
k5/KM (s
-1. 
M-1) 
Aedes aegypti (AaA2) 
WT 0.02±0.001 1.0±0.1 <1.5 >70 
Ala118Asp 0.02±0.001 2.6±0.7 46±7  6±2 
Anopheles gambiae 
(AgB2)* 
WT - 0.8±0.3 <1.5 >50 
Gly118Asp - 3.5±1.4 8.6±2 40±20 
Bactrocera dorsalis 
(BdB1)*  
WT - 16±7 <1.5 >1000 
Gly145Asp - 15±6 <1.5 >1000 
Ceratitis capitata 
(CcαE7)* 
WT - 4.8±4 <1.5 >320 
Gly145Asp - 1.3±0.4 7.4±2 18±7 
Cochliomyia hominivorax 
(ChαE7) 
WT 0.21±0.02 3.7±0.5 27±10 13±5 
Gly137Asp 0.13±0.01 5.9±0.6 34±10 17±5 
Culex quinquefasciatus 
(CqB2) 
WT 1.4±0.8 0.6±0.1 <1.5 >40 
Gly118Asp 0.008 
±0.001 
0.9±0.1 110±40 1 ±0.3 
Calliphora stygia (CsαE7) 
WT 0.43±0.02 2.6±1.2 <1.5 >170 
Gly137Asp 0.97±0.1 31±2 48±10 65±20 
Lucilia cuprina (LcαE7) 
WT 2.0±0.3 0.5±0.1 <1.5 >33 
Gly137Asp 1.4±0.1 14±0.3 3.1±1.2 450±180 
Musca domestica 
(MdαE7)* 
WT - 7±0.4 <1.5 >470 
Gly137Asp - 5±0.3 <1.5 >330 
Stomoxys calcitrans 
(ScαE7) 
WT 0.07±0.01 4.0±0.4 24±7 17±5 
Gly137Asp 0.04±0.01 1.6±0.2 34±12  5±2 
 
*No pre-steady-state burst (*) was observed for Anopheles gambiae (AgB2), Bactrocera dorsalis (BdB1), Ceratitis 
capitata (CcαE7) or Musca domestica (MdαE7), the KM for these species was estimated from the concentration 
dependence of k5. Values are mean ± standard error for three replicates.  
4.5.4. Structure alignment and analysis 
To investigate if evolutionary contingency plays a role in the evolution of qualitative 
resistance in Diptera, the differences in sequence and structure was examined in further 
detail. Investigation of the sequence and structural differences between the proteins could 
suggest potential mutations that influence levels of activity. 
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First, the active site sequence changes were analysed including the second and third shell 
residues that are known to affect substrate binding (Table 4.9). A large body of work has 
focused on OP hydrolase activity in the enzyme LcαE7. The substrate-binding pocket of 
LcαE7 is asymmetrical and is made up of the p1 subsite (Trp251, Met308, Phe309, Phe355, 
Tyr420, Phe421) and the p2 subsite (Tyr148, Phe354, Tyr457) (Figure 4.12, Panel A) (55). 
Second and third shell residues have been identified to have a significant effect on OP 
binding and the rate of OP turnover (315, 316).  
Figure 4.12. (A) Active site residues of WT LcαE7 including the catalytic triad (green), 
oxyanion hole (cyan), p1 subsite (pink), p2 subsite (wheat) and the 2nd and 3rd shell residues 
(blue) (B) The structure of WT LcαE7 (PDB ID: 4FNG) (grey) aligned against the structure of 
LcαE7 Gly137Asp (blue) (PDB ID: 5C8V) (C) The structure of WT LcαE7 aligned against the 
structure of WT LcαE7 bound with diethyl hydrogen phosphate to the active site serine (PDB 
ID: 4FNM) (D) Cartoon structure of LcαE7 aligned against the solved structure of CqB2 and 
the 8 modelled orthologs. 
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Table 4.9. Analysis of the variability in residues making up the active site of the 10 proteins. 
Esterase Lc Cs Ch Md Sc Cq Aa Ag Bd Cc 
Catalytic 
Triad 
S218 
E351 
H471 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
S 
E 
H 
Oxyanion 
Hole 
G136 
G137 
A219 
G 
G 
A 
G 
G 
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*Non-conservatives changes in residues from L. cuprina are highlighted in red. Conservatives changes in residues from
L. cuprina are highlighted in blue.
The second shell residues Met308 and Phe309 in the LcαE7 structure are dynamic in nature 
and are important for the correct orientation of Asp137 for hydrolysis of the phosphor-Ser 
intermediate (315). Asp137 is highly mobile and requires a conformational change from 
the apoenzyme state to a productive state (315). Met308 and Phe309 undergo a 
conformation change for the correct orientation of Asp137 to be adopted, to allow for 
turnover of the intermediate (Figure 4.12, Panel C). As Asp137 frequently adopts non-
productive conformations, it suggests small changes in residues and structure could have 
significant effects on the conformational organization of Asp137. At positions Met308 and 
Phe309, there are three orthologs with changes at these positions, CqB2 (Phe, Thr), AgB2 
(Leu, Ser) and CcαE7 (Ser, Thr). It is unknown how the changes effect the OP kinetics, but 
as the 308 and 309 positions are important for the correct orientation of Asp137 in LcαE7 
for OP turnover, it could explain the differences in OP hydrolase activity for the orthologs. 
Other residues identified to affect OP kinetics in the LcαE7 structure include Tyr457, 
Met147, Tyr148 and Phe100 (316). In the open state, these residues are in a dynamic 
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network that is lost when the phosphorylated intermediate state is formed. Replacement of 
Tyr457 or Met147 to Ala affects the dissociation constant of the OP-LcαE7 Michaelis 
complex, which increases the KD (316).  
For analysis of the sequence differences in more detail, modelling of the proteins was 
performed using the I-TASSER server (325). The I-TASSER server has a reputation of 
being the most accurate modelling server based on the Critical Assessment of Protein 
Structure Prediction (CASP) (326). Currently, there are crystal structures of two orthologs, 
CqB2 (unpublished) and LcαE7 (PDB ID: 4FNG). The proteins share 38% sequence 
identity to each other (55). Despite the low sequence similarity between the proteins, they 
share a close similarity in structure when aligned (RMSD: 1.102). This suggests modelling 
of other Diptera orthologs will have some level of accuracy. The alignment of the 10 
orthologs have significantly overlap (RMSD range from 0.275-1.012), however, 
differences are observed in the active site makeup (Figures 4.12 Panel D, 4.13). 
Comparing the binding affinity for the OP between the WT orthologs, the KM is below 1.5 
µM for 8 of the orthologs with the exception of ScαE7 (24 µM) and ChαE7 (27 µM). The 
active sites of the proteins are similar to LcαE7. However, for ScαE7, Phe is found at 
position 457 instead of Tyr (Figure 4.13, Panel I). This site is important for the binding of 
the OP and the change to Phe457 is likely to be responsible for the poor binding that is also 
observed for the Gly137Asp variant (34 µM). In the modelled structure of ScαE7, Phe457 
is positioned away from the active site and not in a position to interact with the bound OP. 
Tyr is found at the second shell position of 147 instead of Met for both proteins and could 
have another effect on binding. This residue in LcαE7 is involved in a dynamic network 
with Tyr457 for OP binding. Replacement to Tyr is likely to effect the network and 
resulting OP binding.  
The Asp137 residue increases the KM, as the bulky size of the Asp residue in the oxyanion 
hole results in a steric clash with the bound OP intermediate (316). The Gly137Asp variants 
of the orthologs show large variations in KM, generally with an increase in KM compared to 
the WT enzymes. This is found to be significant in the CqB2 Gly118Asp ortholog where 
the KM is 110 µM compared to the KM of <1.5 µM for the WT enzyme. For the binding of 
the OP in LcαE7, Phe309 buries into the structure for the productive conformation of 
Asp137. However, in the structure of CqB2, Met308 and Phe309 are replaced by Phe308 
and Thr309. The Phe308 residue in CqB2 occupies the space between Met308 and Phe309 
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in LcαE7 (Figure 4.13, Panel F). Phe308 in the structure of CqB2 has limited movement 
and would be in a steric clash with Asp137. This would result in a little change of OP 
turnover and very poor affinity for the OP. 
For the other orthologs, there are multiple reasons for the large increase in KM compared to 
LcαE7 with the introduction of Asp137. Pro is found at position 310 in LcαE7, however, is 
found as Ala in the orthologs CsαE7, ChαE7, and ScαE7. This third shell residue is adjacent 
to the dynamic second shell residues Met308 and Phe309. From the structure, it could be 
predicted that this could increase the movement of Met308 and Phe309 and hinder OP 
binding (Figure 4.13, Panels E, G, I). For the AaA2 protein, the residue Arg at position 
140 obstructs Asp137 in the modelled structure (Figure 4.13, Panel A). This will steric 
clash with Asp137 and will likely cause a high KM and poor turnover of the OP. The Glu 
residue at position 310 also interferes with the ability of Phe309 to bury itself for the 
productive conformation of Asp137. 
The MdαE7 protein has little change in KM with the introduction of the Asp137 and from 
the modelled structure it is difficult to provide explanations (Figure 4.13, Panel H). The 
residue Phe140 could play a role, as well as the second shell Trp and Phe residues at 
positions 147 and 148 instead of Met and Trp. The position of Phe140 in the structure 
appears to shift the residue Ile139.  The shift causes the Ile139 to a steric clash with Asp137 
and it could explain the decrease in k5. Arg461 in the modelled structure of MdαE7 is 
orientated towards Asp137 and could be another explanation for the low OP turnover. 
CcαE7 has a number of active site changes compared to LcαE7 including the second shell 
positions 308 (Ser) and 309 (Thr). Though changes in these residues do not effect KM in a 
large amount for the Gly145Asp variant, it appears to interfere with the ability to turnover 
OPs. This suggests Asp145 cannot reach an optimal conformation for hydrolysis in CcαE7. 
The residue Val312 in the modelled structure also steric clashes with Asp145. AgB2 has 
significant changes in the second and third shell residues including Asn at position 139 
(Figure 4.13, Panel B). This residue may interfere with Asp137 and could explain the 
small change in k5 associated with the variant enzyme. 
The ortholog CsαE7 shares the highest amino acid identity to LcαE7 (89%), as well as the 
fewest changes in the active site. Surprisingly, the Gly137Asp variant of CsαE7 has a 
higher rate of OP turnover (k5) (31 vs. 14 s-1), but a significantly higher KM (48 vs. 3 µM). 
This results in lower catalytic efficiency (65 vs. 450 s-1. M-1). In the structure it is difficult 
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to rationalize the differences in OP kinetics between the enzymes. However, the third shell 
residue Ala310 instead of Pro310 could affect the dynamic nature of residues Met308 and 
Phe309, which are important for positioning of Asp137 for OP hydrolysis. 
In regards to the rate constant k5 (OP turnover), there is a large variation across the WT 
orthologs. However, it is unknown what factors dictate and affect k5 in the WT proteins. 
With the introduction of Asp137, there are some orthologs with little to no increase of k5. 
The poor OP turnover for the Gly137Asp variant of ScαE7 could be from the presence of a 
cysteine residue at position 140 in the active site. This residue could hinder the correct 
positioning of Asp137 for hydrolysis. For ChαE7, Val at position 139 causes a steric clash 
with Asp137 and could explain a low k5 for the Gly137Asp variant of this enzyme. BdB1 
is unique for the orthologs where the enzyme has a high k5 and low KM in the WT enzyme 
and the Gly145Asp variant. It is difficult to explain why, however, two changes in the 
active site include Trp at second shell positions 147 and 460. These residues could be 
responsible for high affinity and turnover for the OP. 
 
Figure 4.13. Active sites of the modelled orthologs (green) aligned with the structure of LcαE7 
(grey).  The active site serine is shown in red (A) AaA2 (B) AgB2 (C) BdB1 (D) CcαE7 (E) 
ChαE7 (F) CqB2 (G) CsαE7 (H) MdαE7 (I) ScαE7. 
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4.6. Discussion 
In this work, the effect of the point mutation at position 137 to Asp has been investigated 
in 10 dipteran CBEs. This work was performed to understand if the ability of the Asp137 
residue to hydrolyse OPs is unique or a general characteristic common to close orthologs 
of LcαE7. The results confirm that OP hydrolase activity is increased in some dipteran 
orthologs with the mutation, albeit at the significant cost of OP affinity (KM), which results 
in a poor catalytic efficacy. In some cases, there is no change in OP turnover with the 
introduced mutation. This supports the idea that the Gly137Asp mutation is limited in terms 
of being a viable route for resistance and there are limited options for evolving CBE-based 
metabolic resistance to OPs (268). Previous studies into the aspartate mutation in 
nonspecific CBEs from various insect species have supported the idea that the Gly137Asp 
mutation is a limited route for resistance (278, 279). In some cases, there is no increase in 
OP hydrolysis with the introduction of the mutation. When OP hydrolysis is increased, 
there is a total loss of native CBE function suggesting the mutation has a significant 
negative effect on fitness (278, 279).  
Three of the proteins (LcαE7, ChαE7, MdαE7) tested for OP activity are involved with 
insecticide resistance by the Asp137 mutation in wild blowfly species while three of the 
proteins tested (BdB1, AaA2, CqB2) are involved with resistance by upregulation without 
the Asp137 mutation present (2, 223, 262, 267, 322, 323). It is unknown if the other four 
proteins tested (CsαE7, ScαE7, CcαE7, AgB2) are involved in resistance. For the two 
mosquito proteins, CqB2 and AaA2, the introduced Asp137 mutation results in a significant 
increase in KM and minor increases to k5 compared to the three blowfly proteins (LcαE7, 
ChαE7, MdαE7) where k5 is increased significantly and changes to KM are minor. Slight 
changes in the structure are likely to explain why the Asp137 cannot adopt the 
conformation for sufficient OP hydrolysis activity in the mosquito species. For the Asp137 
residue to be favourable for resistance, it must not affect KM in a large amount for the 
protein to be able to scavenge the OP efficiently. The residue must also result in sufficient 
OP hydrolysis activity otherwise resistance is achieved by other means (upregulation). This 
is likely to be the reasoning why the mosquito species achieve resistance by upregulation 
as they lack both features for qualitative resistance in the selected proteins. The three 
blowfly species that have resistance by the Asp137 mutation have a sufficient k5 rate for 
OP hydrolysis activity to provide insecticide resistance to the strong selection pressure of 
OPs and a relatively low KM with the mutation to effectively scavenge the OP.  
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The BdB1 protein is involved in OP resistance by upregulation, the protein itself has a high 
turnover and low KM, and therefore, the benefits the Asp137 mutation offers may not be 
necessary for the species to achieve resistance. The four other proteins tested (CsαE7, 
ScαE7, CcαE7, AgB2) may not be involved in resistance by the Asp137 mutation with 
similar reasoning to the two mosquito proteins.  The minor increase in OP hydrolytic 
activity is matched with a significant increase in KM and therefore not favourable for 
selection with the Asp137 mutation. The low KM for the WT proteins and the reasonable 
turnover rate could suggest the proteins may be involved in resistance through upregulation 
and be able to scavenge the OP effectively. CcαE7 and AgB2 also require two nucleotide 
changes from Gly to Asp and therefore, it would be very unlikely for the Asp mutation to 
appear. The kinetic data from the 10 proteins suggests that the qualitative resistance 
mechanism through the Asp137 mutation may be a less common resistance mechanism in 
dipteran than previously thought. 
 
Homology models of the orthologs show amino acid differences in the active site and 
second shell residues affect the position of Asp137. This prevents the residue sampling 
optimal geometries for hydrolysis of the phosphor-Ser intermediate. The active site and 
second shell residues between the orthologs have varied over time, before the selection 
pressure of OPs. This suggests random neutral drift has produced few esterases that can 
evolve resistance with a sufficient OP turnover, without losing native function and a large 
increase in KM for the OP. This also suggests historical contingency plays a role in the 
protein structure, affecting the mechanism of insecticide resistance observed. This is 
supported by a laboratory mutagenesis experiment in the fruit fly species D. melanogaster. 
It was observed that resistance to OPs does not occur through the protein, DmαE7 (72). 
This protein shares 74% sequence identity to LcαE7 and it was suggested the enzyme’s low 
affinity for OPs (lower than AChE) does not allow for resistance (72).  
There are a number of additional reasons why the mutation Gly137Asp is not present in the 
orthologs in nature and the quantitative resistance mechanism is common in insect species. 
In two of the proteins (AaA2, BdB1), two nucleotide substitutions are required to convert 
Gly to Asp, which suggests a low chance for resistance by the quantitative mechanism to 
evolve. In other species, P450s or GSTs could be responsible for insecticide resistance, 
along with target site insensitivity. Another reason could be the loss of wild-type function 
and therefore, another resistance mechanism may be selected for (278, 279). The 
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quantitative mechanism is also able to sequester a wider range of insecticides than the 
qualitative mechanism of resistance and therefore, offering greater protection for insect 
species (32, 278, 279). Other factors contributing to the widespread of the quantitative 
mechanism of resistance in insects is from the limitations in the eukaryote genetic systems 
in introducing multiple mutations and recruiting genetic variation in a short amount of time 
(233). This limitation results in difficulties in modifying an enzyme’s active site for a new 
function, few options for resistance, and convergent evolution (233).  
It has been argued that the living world would be very different if evolution was replayed, 
however, it has also been argued there are limited evolutionary routes life can take (282, 
309). This will result in convergent evolution and contingency only affecting the minor 
details. This is found in insecticide resistance where selection finds similar adaptations and 
suggests evolution is repeatable (193, 195, 221). However, contingency affects the 
mechanism of resistance (quantitative or qualitative), which results in the small 
happenstances of history leading to different evolutionary paths of resistance (299). Given 
this, it makes predicting resistance difficult and furthermore, complications in predicting 
the resistance mechanism based on the choice of insecticide (274, 327). 
Overall, a detailed kinetic comparison of the wild-type and Gly137Asp variants of αE7 
orthologs from 10 dipteran species has suggested contingency has played a role in the 
evolution of resistance to OPs. Comparison of the sequences and structures of the L. 
cuprina αE7 (LcαE7) and several αE7 orthologs reveals that amino acid substitutions in the 
vicinity of residue 137 prevent the newly introduced Asp from sampling conformations 
necessary for the catalytic cycle effectively. However, the amino acid substitutions that 
restrict Asp137 do not substantially impact on the native CBE activity of the enzyme. 
Genetic drift before the introduction of insecticides predisposed blowflies to a mutational 
path that was not accessible to other insect species. This suggests that evolutionary 
innovation, even in the presence of strong selection pressure, is limited by the initial states 
or past events. 
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Chapter 5. Inhibitors of 
Acetylcholinesterase 
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5.2. Introduction 
5.2.1. Acetylcholinesterase 
Acetylcholinesterase (AChE) is a member of the carboxyl/cholinesterase gene family that 
is the target for OP insecticides which reduce pest invertebrate populations (17, 197). AChE 
catalyses the hydrolysis of the excitatory neurotransmitter, acetylcholine (Ach) (17, 197). 
In invertebrates, Ach is the prevalent excitatory neurotransmitter in the central nervous 
system (CNS), however, in the CNS of vertebrates, glutamate mediates most of the 
excitatory neurotransmission (328, 329). Instead of playing a strong role in the CNS, Ach 
is primarily found in the neuromuscular junctions and nerve-electro plaque junctions in 
vertebrates (328, 329). The hydrolysis of Ach by AChE is important to regulate 
neurotransmission and occurs in cholinergic brain synapses (Figure 5.1)  (4, 330). The 
rapid degradation of Ach at the synaptic junction results in decreases in and termination of 
the signal transmission in nerve synapses (330). Hydrolysis occurs at an extremely fast 
catalytic rate (25000 molecules of Ach per second), approaching the diffusion controlled 
limit (202, 331). 
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Figure 5.1. Transmission of the nerve impulse with the release of Ach from the presynaptic 
nerve terminal to the Ach receptors on the postsynaptic nerve terminal. After signalling, Ach is 
released from receptors and broken down by AChE to be recycled in a continuous process 
(330). Figured adapted from Lilienfeld (332). 
The X-ray crystal structure of AChE was solved in 1991 and was important to understand 
the fast catalytic rate of the enzyme (53). It was thought due to the high rate of Ach turnover, 
the binding site of AChE would be found on the surface of the protein. However, the 
catalytic triad and binding site of AChE are found at the bottom of a deep narrow binding 
gorge (53). The enzyme contains five main sites, which includes the catalytic triad (Ser, 
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His, Glu) and the oxyanion hole (Figure 5.2) (333–336). The third site is the catalytic 
anionic site that is comprised of aromatic residues. The aromatic residues bind the positive 
quaternary choline moiety of Ach via cation-π interactions (333–336). The acyl binding 
site is also found in the binding site, this region determines selectivity for AChE (333–336). 
The last site of AChE is the peripheral anionic site (PAS), this site is found at the entrance 
of the active site gorge and allosterically modifies catalysis (333–336). The binding of 
inhibitors to this region reduces Ach’s ability to enter the active site, leading to substrate 
inhibition (333, 337–339).  
 
Figure 5.2. The active site make up of AChE including the five regions: the catalytic triad, the 
oxyanion hole, the peripheral anionic site, the acyl pocket and the anionic site (53, 333–336). 
Figure adapted from Bajda et al (340). 
5.2.2. Alzheimer’s disease 
AChE is a drug target for treating the progressive neurodegenerative disorder Alzheimer’s 
disease (AD). This is due to the key role the substrate Ach plays in memory, cognition and 
connectivity between neurons (341). AD affects over 20 million individuals worldwide and 
is set to increase, becoming a major public health issue (342, 343). Impairment of 
cholinergic function, decreased cholinergic neurons, β-amyloid plaque formation and the 
decreased level of Ach is strongly associated with AD (Figure 5.3) (344, 345). 
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Figure 5.3. Symptoms and the physical observations in patients affected by AD (342). 
There are two hypotheses for the pathology of AD, either from the decrease in Ach 
production, or by the increase of toxic β-amyloids aggregating in the brain (343, 346–348). 
It has been suggested that inhibitors of AChE can slow the progression of AD (343, 349). 
Inhibiting AChE results in an increase in both level and duration of the Ach in the synapse. 
This compensates for the reduction in cholinergic function, particularly at the synaptic 
terminals (343, 347–349). AChE also has a role in accelerating β-amyloid aggregation and 
deposition onto fibrils. This is associated with the PAS of the enzyme (350). Therefore, 
inhibition of the PAS and the AChE active site are desired to target both Ach hydrolysis 
and plaque formation (348, 349). 
5.2.3. AChE Inhibitors to treat AD symptoms 
Due to the association of AChE in AD, it has been a major therapeutic target for treating 
AD (344, 351). Though there is no cure for AD, reversible inhibitors of AChE treat the 
symptoms of AD (Figure 5.3) (352, 353). The discovery of AChE inhibitors to treat AD 
symptoms has resulted in some promising leads (354). Physostigimine was the first 
reversible inhibitor of AChE used for the treatment of AD but only had a small beneficial 
effect in AD patients with many side effects (355). For similar reasons, metrifonate, a non-
active prodrug was discontinued from use before approval for significant muscle weakness 
side effects (354, 356). The compound is transformed to dichlorvos in vivo non-
enzymatically and is an irreversible cholinesterase inhibitor (354, 356). Huperzine A is a 
promising new option in treating AD symptoms (354, 355). Huperzine A is an alkaloid that 
is a reversible and highly selective inhibitor of AChE (357). This compound is more potent 
than the three approved drugs and has the least amount of inhibition to BChE (355, 357, 
358). It is currently used in China for treatment of memory disorders and AD symptoms 
(357, 358). Huperzine A is currently under trials in Europe and remains the next promising 
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inhibitor to treat symptoms of AD (355, 357, 358). Along with huperzine A, phenserine is 
a possible new drug candidate for targeting AChE (355). The compound is a pseudo-
irreversible cholinesterase inhibitor with a strong preference for AChE (355, 359) Phase II 
trials of the compound had mixed results but there may still be promise for this compound 
to treat AD symptoms (359). Currently, three AChE inhibitors have been approved by the 
Food and Drug Administration in the U.S.A and the European Medicines Agency in Europe 
for use to treat AD symptoms to improve life quality (344, 360). The compounds are 
rivastigmine, donepezil, and galanthamine (Figure 5.4) (344, 360). All three compounds 
inhibit both AChE and BChE with a difference in potency and selectivity, however, all 
three demonstrate similar efficacy for treatment of AChE (361).  
Galanthamine is a reversible AChE inhibitor that is further discussed in the next section 
(362, 363). The compound interacts with AChE, nicotinic Ach receptors and weakly 
inhibits BChE (362, 363). Donepezil is another reversible AChE inhibitor with a high 
specificity for AChE and the CNS, with limited activity in the peripheral tissue (363, 364). 
Donepezil was the second approved anti-Alzheimer’s drug and interacts with the active site 
and the PAS of AChE (363, 364). The compound also affects serotonin concentrations, 
which can influence the mood of AD patients (365). Rivastigmine is the third approved 
AChE inhibitor drug to treat AD symptoms and is a pseudo-irreversible inhibitor (363, 
366). The drug binds covalently to AChE and BChE forming a carbamylated complex (363, 
366). After the covalent link is formed, the complex is slowly hydrolysed over several 
hours. Similar to donepezil, rivastigmine has CNS selectivity and is rapidly excreted 
without binding to plasma proteins with limited interaction in the peripheral tissue (367, 
368). 
Tacrine is a rapidly-reversible inhibitor of AChE that was previously used to treat AD, 
however, was discontinued due to the fatal long-term side effects including hepatotoxicity 
(369, 370). The compound is non-selective and inhibits both cholinesterases (AChE and 
BChE) with a strong preference for BChE (371). Tacrine also has several other interactions 
including overstimulation of the peripheral cholinergic system, inhibition of L-type 
calcium channels, monoamine oxidase inhibition, potassium channel blockade and 
inhibition of the muscarinic and nicotinic receptors (372, 373). Improving the selectivity 
for AChE is important for fewer side effects and it has been proposed that high amounts of 
BChE inhibition are responsible for the unwanted side effects (363, 374). 
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Recently it has been shown AChE isoforms react differently to AChE inhibitors and raises 
questions on isoform selectivity for future drug development (375). G4 is a tetrameric 
isoform of AChE that is found in the mammalian brain and cholinergic synapses, it is also 
the relevant target for treating AD symptoms (375–377). On the contrast, the monomeric 
G1 isoform of AChE is found primarily in the cytoplasm and is unlikely to affect synaptic 
physiology in large amounts (375–377). Selective inhibition of the G4 isoform is suggested 
to prolong the action of Ach, necessary to treat AD symptoms (375). The currently 
approved drugs show a large variety in inhibition of the isoforms. Rivastigmine inhibits G1
preferentially while donepezil varies selectivity between the G4 and G1 isoforms of AChE 
depending on the region but inhibits the G4 isoform of AChE with high potency in the 
cortex (375, 378). Tacrine and galanthamine have no preference and bind the G4 and G1 
isoforms equally well. Future testing and development of effective inhibitors would inhibit 
brain AChE (G4) without any effect on the peripheral tissue AChE (G1) (375, 378). The G4 
isoform of AChE emerges as a potential molecular target for development of AChE 
inhibitors to treat AD symptoms and another consideration in drug development (375, 379, 
380). 
Figure 5.4. The four drugs that have been used for the treatment of AD, galanthamine, 
rivastigmine, donepezil and tacrine (currently not in use) (344). 
5.3. Preface 
In this chapter, two types of inhibitors that target AChE will be investigated. In the first 
section, derivatives based on the drug galanthamine have been designed and tested for 
inhibition against AChE. Section two describes a new potential set of drugs to treat AD 
identified as the marinoquinolines that are similar to tacrine in structure. 
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Section 1. The synthesis of certain derivatives and analogues of (−)- 
and (+)-Galanthamine and an assessment of their capacities to 
inhibit acetylcholine esterase 
5.4. Introduction 
5.4.1 Galanthamine 
(-)-Galanthamine (GAL) is an alkaloid obtained from the bulbs and flowers of Galanthus 
caucasicus and related Amaryllidaceae family species (381). It was first used as a drug for 
the treatment of myasthenia gravis, motor disorders of the CNS and residual poliomyelitis 
paralysis syndromes (381, 382). GAL has been widely successful in treatments, as the 
compound is able to cross the blood-brain barrier (381). GAL in the 1980s was investigated 
for the treatment of mild to moderate forms of AD. Following the initial trials, the 
compound was approved for use in Europe, U.S.A and Asia by the 2000s as GAL exhibits 
a significant improvement in cognitive function for those affected by AD (347, 383, 384). 
GAL is a selective and reversible AChE inhibitor (IC50 = 800 nM) that interacts with the 
anionic site and the aromatic gorge of AChE (385–387). GAL also allosterically affects 
nicotinic cholinergic receptors therefore, displaying a dual mechanism in treatment (388). 
This is beneficial for AD treatment as it can affect other neurotransmitter systems and can 
improve cognitive dysfunction, major depression and bipolar disorder (389).  
Due to the clinical effects of GAL, total synthesis of the compound has been of great 
interest for pharmaceutical companies (390, 391). Large scale production by a synthetic 
route is economically beneficial and more efficient for worldwide distribution than 
extraction from the botanical source (390, 391). For these reasons, several total synthetic 
routes of GAL have been developed (392–394). 
5.4.2. Interactions of GAL 
A X-ray crystal structure of GAL bound to AChE has identified four key sites for chemical 
modification based on structure-activity studies: (a) the hydroxyl site, (b) the cyclohexene 
ring, (c) the tertiary amine site and (d) the methoxy site (Figure 5.5) (385, 395, 396).  
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Figure 5.5. The four key sites of GAL that are known to interact with AChE. (a) the hydroxyl 
site, (b) the cyclohexene ring, (c) the tertiary amine site, and (d) the methoxy site (385, 395, 
396). 
In the structure, there are two classic hydrogen bonds. The first hydrogen bond is a strong 
interaction between the hydroxyl oxygen of the inhibitor and Glu199 (Figure 5.6) (385, 
395, 396). The hydroxyl moiety also interacts with two additional water molecules that are 
conserved in structures of AChE. The second hydrogen bond is between Ser200 and the O-
methyl group of the inhibitor. The O-methyl group of GAL is also involved in occupying 
the acyl-binding pocket by non-bonding s-p interactions with residues Phe288 and Phe290. 
A non-classical hydrogen bond interaction has been identified between the N-methyl group 
of GAL, Asp72 and with a conserved water molecule. The residue Asp72 commonly traps 
cationic ligands in the active site gorge and contributes to the tight binding of GAL to AChE 
(385, 395, 396). The final identified interaction between GAL and AChE involves the 
indole ring of Trp84 that stacks against the double bond of the cyclohexene ring with 
favourable π-π interactions (385, 395, 396). 
 
Figure 5.6. The X-ray crystal structure of GAL bound to AChE, showing the key interactions 
between GAL and AChE (385, 395, 396). 
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5.4.3. Galanthamine Derivatives 
Pharmaceutical companies and research groups have focussed on the synthesis of GAL 
derivatives to improve the inhibition against AChE (341, 397, 398). Previous work has 
shown a large variation in IC50 depending on the site modified (Figure 5.7) (Table 5.1) 
(385). Certain modified sites of GAL (hydroxyl site) have a major effect on AChE 
inhibition that can either cause an increase or decrease in inhibition (Table 5.1) (385). The 
large variation in IC50 between the derivatives suggests certain interacting sites of GAL are 
more sensitive to change compared to other sites.  
Figure 5.7. Selection of GAL derivatives that have been synthesised and tested against AChE 
(385) 
Table 5.1. Calculated IC50 for the GAL derivatives and the sites of GAL with the affect on 
inhibition upon modification (385). 
Compounds IC50 (µM) Site of Modification Generally associated with: 
Galanthamine 0.35 - - 
1 (Narwedine) 30 Hydroxyl group Decreased inhibition (higher IC50) 
2 30 Hydroxyl group Decreased inhibition 
3 0.03 Methoxy group Increased inhibition (lower IC50) 
4 3.15 Methoxy group Decreased Inhibition 
5 0.03 Tertiary amine Site Increased inhibition  
6 0.14 Tertiary amine Site Increased inhibition  
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5.5. Research Article 
5.5.1. Preface 
Currently, there are three drugs (rivastigmine, donepezil, and GAL) used to treat symptoms 
of AD by inhibiting the enzyme, AChE. A major focus in synthetic chemistry is to improve 
the effectiveness of existing drugs by changing functional groups. Well-established 
synthetic routes and an increasing market for GAL has resulted in numerous GAL 
derivatives being synthesised to increase the inhibition towards AChE. The following 
research article describes the synthesis and testing of new GAL derivatives. The inhibition 
towards AChE was measured by enzymatic assays. Molecular docking simulations were 
also performed to understand and further support the inhibition results. 
5.5.2. Published Research Article: The Synthesis of Certain Derivatives and 
Analogues of (−)- and (+)-Galanthamine and an Assessment of their Capacities to 
Inhibit Acetylcholine Esterase 
The Synthesis of Certain Derivatives and Analogues of (−)- and
(+)-Galanthamine and an Assessment of their Capacities to Inhibit
Acetylcholine Esterase
Joshua N. Buckler, Ehab S. Taher, Nicolas J. Fraser, Anthony C. Willis, Paul D. Carr, Colin J. Jackson,
and Martin G. Banwell*
Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital
Territory 2601, Australia
*S Supporting Information
ABSTRACT: Syntheses of certain di- and mono-oxygenated derivatives (e.g., 2 and 3, respectively) and analogues (e.g., 4, a D-
ring monoseco-analogue of 2) of both the (−)- and (+)-enantiomeric forms of the alkaloid galanthamine [(−)-1] are reported.
All have been assessed for their capacities to inhibit acetylcholine esterase but, in contrast to the predictions from docking
studies, none bind strongly to this enzyme.
■ INTRODUCTION
The alkaloid (−)-galanthamine [(−)-1] (Figure 1) has been
isolated from a range of plant sources and is currently used in
the clinic for the symptomatic treatment of mild to moderate
forms of Alzheimer’s disease.1 It exerts its beneﬁcial eﬀects by
crossing the blood-brain barrier and then, in part at least,
inhibiting acetylcholine esterase (AChE). It also acts as an
allosteric modulator of the nicotinic acetylcholine receptor.1,2
The non-natural enantiomer of compound 1, namely ent-1 or
(+)-galanthamine, has also been shown to accumulate in brain
tissue but does so through nonspeciﬁc binding.3
Currently, (−)-galanthamine is produced industrially by
extraction from various plants sources, most notably the red
spider lily (Lycoris radia), the wild daﬀodil (Narcissus
pseudonarcissus), the summer snowﬂake (Leucojum aestivum),
and the Caucasian snowdrop (Galanthus woronowii).1 However,
both the increasing demands for the natural product and the
erosion of habitat of at least some of the producing plants has
prompted investigations into other methods for obtaining it or
for identifying analogues with improved eﬃcacy. As part of such
eﬀorts, galanthamine has been the subject of a signiﬁcant
number of total synthesis studies with the ﬁrst of these being
reported by Barton and Kirby4 and involving mimicking of the
proposed biogenesis. Substantial reﬁnements of this process
have been reported in the interim,5 and one of these has
formed the basis of a pilot-plant scale synthesis of the alkaloid5a
although it is not clear if this contributes signiﬁcantly to the
commercial production of the alkaloid. Magnus and co-workers
have described6 a related and highly eﬀective approach.
Intramolecular Heck reactions have provided another means
for assembling the tetracyclic framework of galanthamine,7
including those accomplished in an enantioselective manner,
while various chirons (corresponding to the A-ring) have been
employed for the assembly in either enantiomeric form of the
alkaloid.8,9a New routes to (−)-galanthamine continue to be
reported,1e including approaches from our group.9
The identiﬁcation and biological evaluation of analogues of
galanthamine has been another focus of signiﬁcant activity10
that is now greatly assisted by data derived from high-resolution
X-ray analysis of the alkaloid bound to the active site of
acetylcholine esterase.11 Biomimetic diversity-oriented syn-
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Figure 1. Structure of the alkaloid (−)-galanthamine.
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thesis, sophisticated QSAR analyses, multicomponent-coupling
chemistries, as well as more conventional studies have all
revealed active compounds.12 The screening of natural products
for relevant activities remains an ongoing area of investigation
and has also resulted in the isolation of new inhibitors of the
title enzyme.13
As part of an ongoing program to establish concise routes to
the tetracyclic framework of galanthamine,1e,9 we now report
chemoenzymatic syntheses of two oxygenated derivatives, 2
and 3, as well as analogues 4−9 of the natural or (−)-form of
the alkaloid (Figure 2).14
Syntheses of the enantiomers of the ﬁrst ﬁve of these
derivatives/analogues, namely compounds ent-2 to ent-6, are
also described. As detailed below, and contrary to the
predictions arising from molecular docking studies, none of
these is an eﬀective inhibitor of acetylcholine esterase.
Our motivation for undertaking the studies described herein
was that the introduction of additional functionalities within the
galanthamine framework could increase water solubility and/or
provide the means for conjugating the drug with various groups
including peptide fragments10f or other entities (e.g. mem-
antine)10d and thus allow for the development of a multi-
targeted therapeutic approach.10d In principle, then, the
attachment of such moieties could provide new inhibitors (or
even just prodrug forms10e of galanthamine) that are superior
to existing therapies. As revealed below, the nature of our
synthetic strategy is such that additionally oxygenated forms of
the galanthamine A-ring were likely to be the most readily
accessible. Accordingly, and because this region of alkaloid has
not been “explored” previously, such derivatives became a
major focus of the work detailed below.
■ RESULTS AND DISCUSSION
Chemical Synthesis Studies. The reaction sequence used
to assemble ABC-ring substructures of (−)-galanthamine is
shown in Scheme 1 and employs the readily available L-tartaric
acid (10) as starting material. Thus, as speciﬁed in a recent
publication,15 compound 10 can be converted over 11 steps,
involving reduction, Grignard addition, and ring-closing
metatheses as key transformations, into the 1,2-diacetal
annulated bromocyclohexene 11. Coupling of compound 11
with the readily available16 aryl boronic acid ester 12 proceeded
under conventional conditions to give the anticipated arylated
cyclohexene 13 (68%). Following protocols established during
the course of our syntheses of the ribisins,17 this last compound
was engaged in an intramolecular Mitsunobu reaction using
triphenylphosphine in conjunction with di-iso-propyl azodicar-
boxylate (DIAD) wherein the phenolic hydroxyl group served
as the internal nucleophile and so aﬀording the acid-sensitive
isobenzofuran 14 (33%). As demonstrated through work in the
enantiomeric series (see below), if appropriate account is taken
of this acid-sensitivity, then the Mitsunobu reaction can be a
high yielding one. Despite concerns about the potential for
competing isomerization of compound 14 to its more
conjugated (fully aromatic) counterpart, upon subjecting it to
conditions previously employed for eﬀecting the Eschenmos-
er−Claisen rearrangement of allylic alcohols,18 amide 15 was
produced in 84% yield. The structure of this compound
followed not only from the derived NMR, IR, and mass spectral
Figure 2. Galanthamine derivatives/analogues 2−9 targeted for synthesis.
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data but also from a single-crystal X-ray analysis of its
enantiomer (see below). Compound 15 embodies both the
targeted ABC-ring substructure of (−)-galanthamine and the
associated quaternary carbon. In anticipation of installing the
ﬁnal D-ring of the title alkaloid, the amide residue within
compound 15 was reduced using LiBHEt3 and 1° alcohol 16
thereby obtained in 92% yield. Oxidation of compound 16
under conditions deﬁned by Bobbitt and Bailey19 then gave
acid 17 (76%), which represents the key precursor to the
targeted galanthamine derivatives/analogues 2−6.
The straightforward manipulations of acid 17 leading to the
targeted (−)-galanthamine derivatives/analogues 2, 3, 5, and 6
are shown in Scheme 2. Thus, coupling of compound 17 and
methylamine, using 1,1′-carbonyldiimidazole (CDI) for activa-
tion of the acid, aﬀorded amide 5 (79%), and on exposure of
the latter to modiﬁed Pictet−Spengler conditions7c,20 involving
paraformaldehyde in the presence of triﬂuoroacetic acid (TFA),
tetracyclic lactam 2 (47%) was formed as a result of
concomitant cleavage of the Ley acetal moiety. Upon treatment
with sodium bis(2-methoxyethoxy)aluminum dihydride, com-
pound 2 was reduced to azepine 3 (44%), and hydrolysis of the
1,2-diacetal residue within compound 5 using aqueous
triﬂuoroacetic acid (TFA) aﬀorded diol 6 (66%). Compound
6 can be considered as a hybrid of the title alkaloid and the
neurologically active natural product ribisin D.17,21
The synthesis of compound 4, a monoseco derivative of 5R-
hydroxy-(−)-galanthamine (3), simply involved (Scheme 3)
acid-catalyzed hydrolysis of precursor 15 under conventional
conditions. This reaction proceeded in 88% yield.
All of the spectral data obtained on targeted compounds 2−6
were in complete accordance with the assigned structures but
ﬁnal conﬁrmation of that of the ﬁrst (i.e., 2) followed from a
single-crystal X-ray analysis of its enantiomer (see below).
In an eﬀort to establish a more meaningful SAR proﬁle for
the above-mentioned analogues, the enantiomerically related
derivatives/analogues ent-2 to ent-6 (Figure 3) were sought.
Scheme 1. Synthesis of Key Acid 17 Embodying the ABC-Ring Substructure and Associated Quaternary Carbon of
(−)-Galanthamine
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Although the routes deﬁned above could simply be adapted for
this purpose by starting with D- rather than L-taratric acid, we
were able to establish a shorter pathway by starting with an
enzymatically derived chiron that is readily available in the
required enantiomeric form (but less so in the opposite one
required to prepare the derivatives/analogues just described).
The synthesis of the enantiomeric series of compounds
started, as shown in Scheme 4, with the enzymatically derived
and enantiomerically pure cis-1,2-dihydrocatechol 1822 that was
converted into the corresponding and well-known23 acetonide
19 under standard conditions. Immediate treatment of the last
compound with m-chloroperbenzoic acid (m-CPBA) then
aﬀorded, in a completely regio- and stereo-selective fashion,
epoxide 2023 (93% from 18). Reaction of compound 20 with a
large excess of p-methoxybenzylalcohol (p-MBnOH) in the
presence of boron triﬂuoride etherate (BF3·Et2O) resulted in
selective nucleophilic opening of the epoxide ring at the allylic
Scheme 2. Conversion of Acid 17 into the (−)-Galanthamine Derivatives/Analogues 2, 3, 5, and 6
Scheme 3. Hydrolysis of Biacetal 15 Leading to Compound 4
Figure 3. Enantiomeric series of derivatives/analogues.
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carbon,24 but the protected bromoconduritol thus formed was
not isolated. Rather, it was simply allowed to react with
methanol in the presence of pyridinium tosylate (PPTS) and
thereby aﬀording triol 21 (71%). Treatment of a methanolic
solution of this last compound with 2,2,3,3-tetramethoxybutane
(2,2,3,3-TMB) in the presence of p-toluenesulfonic acid
monohydrate (p-TsOH·H2O) then resulted in the selective
formation of the “Ley”-acetal25 ent-11 (85%) and so establish-
ing an “enantiomeric overlap” with the synthetic sequence
leading to the original sets of analogues.
During the conversion, 21 → ent-11 acetal formation is
presumed to take place prior to cleavage of the PMB-ether unit
because the reverse order of events would lead to an
intermediate conduritol embodying two adjacent trans-diol
moieties and the formation of two isomeric Ley-type acetals
would therefore be expected. Indeed, when the tetra-ol derived
from hydrolysis of compound 21 was subjected to reaction with
2,2,3,3-TMB in the presence of p-TsOH·H2O then an ∼1:1
mixture of the two possible bis-acetals is formed.
Scheme 4. Synthesis of Bromoconduritol ent-11 from the Enzymatically-Derived and Homochiral cis-1,2-Dihydrocatechol
Scheme 5. Synthesis of Key Acid ent-17 from Bromoconduritol ent-11
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As shown in Scheme 5, and as was the case in the
enantiomeric series, compound ent-11 could be engaged in a
Suzuki−Miyaura cross-coupling reaction26 with arylboronic
acid ester 12, thus aﬀording the anticipated product ent-13
(71%) that participated in an intramolecular Mitsunobu
reaction to give compound ent-14 (96%). Allylic alcohol ent-
14 underwent an Eschenmoser−Claisen rearrangement reac-
tion on thermolysis with the dimethyl acetal of N,N-
dimethylacetamide in reﬂuxing toluene and thereby aﬀording
N,N-dimethylamide ent-15 (86%). The structure of this last
Scheme 6. Synthesis of Aryl Boronate Ester 27
Scheme 7. Synthesis of Analogue 7
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compound was conﬁrmed by a single-crystal X-ray analysis,
details of which are provided in the Experimental Section and
the Supporting Information (SI). Reduction of compound ent-
15 with lithium triethylborohydride and oxidation of the
resulting 1° alcohol ent-16 (quant.) using the Bobbitt−Bailey
protocol19 then gave acid ent-17 (80%).
Following precisely the same reaction sequences as detailed
above in Schemes 2 and 3, compound ent-17 was converted
into target derivatives ent-2 to ent-6 (Figure 3) with the
structure of the ﬁrst of these being conﬁrmed by single-crystal
X-ray analysis. The monoseco analogue of compound ent-2,
namely amide ent-4, was readily obtained in 77% yield by
simply treating bis-acetal ent-15 with aqueous triﬂuoroacetic
acid (compare to Scheme 3).
As part of an eﬀort to develop galanthamine derivatives
containing additional functionality in the aromatic C-ring,
especially ones capable of conjugation with motifs that might
bind to the so-called peripheral and anionic binding site of
acetylcholine esterase,27 we sought to exploit the synthetic
chemistry detailed above for this purpose. As such, the relevant
arylboronate acid ester (representing a synthon for the C-ring)
was required and the route used to obtain this is shown in
Scheme 6. Thus, vanillin (22) was converted, under established
conditions, into its bromo-derivative 2328 (90%), and the
aldehydic residue within the latter then protected as the
corresponding ethylene acetal using standard conditions and
thus aﬀording compound 24 in 55% yield. The readily derived
MOM-ether 25 (70%) of the last compound was subjected to a
metalation/borylation protocol, and the intermediate boronic
acid 26 obtained on hydrolytic work up was reacted with
sodium iodide/trimethylsilyl chloride (to cleave the MOM
ether) and then pinacol and thus aﬀording the hitherto
unreported ester 27 (45% from 25). The structure of this last
compound was conﬁrmed by single-crystal X-ray analysis (see
Experimental Section and SI for details).
In the opening stages of attempts to exploit ester 27 in the
production of galanthamine analogues related to those
described above, epoxide 19 (Scheme 7) was subjected to
hydrolytic cleavage, thus aﬀording previously reported29 trans-
diol 28 (68%). The allylic hydroxyl group of diol 28 was
selectively protected through its reaction with tri-iso-propylsilyl
triﬂuoromethanesulfonate (TIPS-OTf) in the presence of 2,6-
lutidine and thus producing allylic ether 29 (88%).30 The
location of the TIPS group within this product was established
using COSY experiments. Upon treating compound 29 with
methyl iodide in the presence of sodium hydride, bis-ether 30
(49%) rather than the anticipated regioisomer was obtained.
Because the illustrated locations of the ether residues within
compound 30 (that thwart the application of the anticipated
Eschenmoser−Claisen rearrangement) were not appreciated
until an X-ray analysis was carried out on a derivative, this was
carried forward by ﬁrst treating it with TBAF and thus aﬀording
homoallylic alcohol 31 (98%). Compound 31 was engaged in a
Suzuki−Miyaura cross-coupling reaction with ester 27 to give
Scheme 8. Synthesis of Analogue 8
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the arylated and crystalline cyclohexene 32 (45%), the
illustrated structure of which was established by single-crystal
X-ray analysis. Acid-catalyzed hydrolysis of the acetonide
residue within the last compound then gave triol 33 (81%).
Even though the position of the methoxy group within
compound 33 precluded the application of the type of EC
rearrangement used earlier, it was subjected to an intra-
molecular Mitsunobu reaction so as to produce a system,
namely compound 7 (85%), that embodies the ABC-ring
ensemble associated with (−)-galanthamine.
The synthesis of analogue 8 is shown in Scheme 8 and
involved, as the initial step, the regio- and diastereo-selective cis-
dihydroxylation of diene 19. Selective silylation of the allylic
hydroxyl group within the resulting and previously repor-
ted17b,31 diol 34 (62%) was readily achieved using TIPS-OTf in
the presence of 2,6-lutidine, and the product ether 35 (88%)
was subjected to O-methylation using methyl iodide/base.
Treatment of product bis-ether 36 (92%) with TBAF
resulted in cleavage of the O-TIPS bond and formation of
alcohol 37 (88%) that could be cross-coupled with boronate
ester 27 under Suzuki−Miyaura conditions and thus aﬀording
the anticipated product 38 (55%). Contrary to expectations,
however, the allylic alcohol residue within compound 38 failed
to engage in an Eschenmoser−Claisen rearrangement upon
treatment with N,N-dimethylacetamide dimethyl acetal. Rather,
the replacement of the associated allylic hydroxyl group with an
N,N-dimethylacetamide residue took place to give, in a
stereoselective manner and after accompanying O-methylation
of the phenolic hydroxyl group, amide 39 (40%). This was
contaminated by small amounts (7%) of its chromato-
graphically inseparable C5 epimer. “Thwarted E-C rearrange-
ments” of this type have been reported previously32 and in this
instance the process may be driven by electron-rich arene
residues facilitating ionization of the intermediate mixed acetal
with the ensuing and extensively stabilized cation then
undergoing nucleophilic capture by 1-methoxy-N,N-dimethy-
lethen-1-amine that is itself generated through thermal cracking
of the starting dimethyl acetal. The basic structure of product
39 follows from the observation that the diastereotopic
methylene hydrogens of the acetamide side-chain both show
vicinal couplings to the adjacent allylic hydrogen. The
illustrated conﬁguration of the C5 acetamide residue is assigned
on the basis that this would be introduced preferentially during
the course of the nucleophilic capture process mentioned above
from that face of the intermediate cation opposite to the
sterically demanding and nearby acetonide residue. Hydrolysis
of this acetonide residue within compound 33 under standard
conditions then gave analogue 8 in 69% yield.
The synthesis of ﬁnal galanthamine analogue 9 followed a
very similar route to that used in preparing congener 8. The
reaction sequence involved is shown in Scheme 9. Thus,
reaction of epoxide 19 with acetic acid in the presence of a
mineral acid gave the previously reported trans-diol mono-
acetate 409a (81%), the free hydroxyl of which was protected as
Scheme 9. Synthesis of Analogue 9
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the corresponding MOM ether using standard protocols and
thus aﬀording compound 419a in 90% yield.
Cleavage of the acetate unit with the last compound could be
eﬀected under conventional conditions, and the resulting allylic
alcohol 429a (95%) then cross-coupled with boronate ester 27
in the usual manner to give product 43 (49%). As was the case
with congener 32 (Scheme 8), upon subjecting compound 43
to conditions often used to eﬀect the EC rearrangement, this
substrate also engaged in both an allylic substitution reaction
and O-methylation of the phenolic hydroxyl of the precursor.
As a consequence, a chromatographically inseparable and 3:1
mixture of amide 44 and its β-epimer (35% combined yield)
was formed. The salient spectral features of compound 44
resembled those of congener 33. Hydrolysis of the mixture of
acetonide 44 and its C5-epimer under conventional conditions
then gave, after chromatographic puriﬁcation, diol 9 (69%)
that, like the other galanthamine derivatives/analogues, was
subjected to molecular docking studies and evaluation as a
potential inhibitor of acetylcholine esterase. Details are
presented in the following section.
Biological Evaluation and Molecular Docking Studies.
The above-mentioned derivatives/analogues of (−)- and
(+)-galanthamine were each evaluated for their ability to
inhibit AChE using a modiﬁed method involving addition of
DMSO so as to ensure dissolution of these otherwise rather
insoluble compounds.33 The inhibitory eﬀect of DMSO itself
on the AChE was taken into account by subtracting a control
measurement for obtaining the IC50 values of the tested
materials. A summary of the inhibition data thus obtained is
shown in Table 1. These assays reveal that only one of the
compounds, namely derivative 3, showed a measurable IC50
value (of 420 μM) compared to the positive control
(−)-galanthamine [(−)-1] which had an IC50 value of 0.9
μM. Clearly, then, and regardless of the absolute stereo-
chemistries of the systems involved, none of the above-
mentioned derivatives/analogues are strong inhibitors of AChE.
Analysis of these inhibition data was undertaken through
molecular docking simulations and using the structure of
(−)-galanthamine bound to human AChE.34 Crystallographic
studies have revealed that (−)-galanthamine binds into the
active site of AChE with the tetrahydroazepine or D-ring
assuming a boat-like conformation and the associated N-methyl
group in a pseudoequatorial orientation spanning the acyl- and
choline-binding sites.35 Docking simulations, using AUTO-
DOCK, matched the solved structure (see Figure 4A) with the
key interactions between AChE and (−)-galanthamine being
evident, thus suggesting that docking simulations of this type
can provide the correct orientation of binding for the
compounds. Surprisingly, with the exception of compounds 5
and ent-5, 8 and 9, for which no bound structures could be
obtained (in the case of the ﬁrst two of these compounds, this
may be a consequence of their signiﬁcantly greater size), the
derivatives all had signiﬁcant docking binding energies, albeit
weaker than (−)-galanthamine (see right-hand column, Table
1). This highlights some of the known limitations in the
prediction of binding aﬃnity by docking programs.36−38 The
docking studies do, however, reveal the likely structural basis
for the reduced aﬃnity of these analogues. For example, the
conﬁguration of compound 3 matches the orientation of
(−)-galanthamine, except that the additional (C5) hydroxyl
moiety is positioned toward tryptophan 84 and thus produces a
distortion in the shape of the A-ring. This most likely results in
destabilization of the π−π stacking interaction between the
indole ring of Trp84 and this ring (A)39 with this loss of
interaction impairing the compound’s capacity to inhibit AChE.
The (+)-enantiomer, ent-3, of compound 3 also has a
hydroxyl positioned toward Trp84, again disrupting the
stabilizing cyclohexene−indole interactions, although on this
occasion it is the same hydroxyl moiety that is present in
galanthamine, potentially explaining, in part at least, why
(+)-galanthamine derivatives are not potent inhibitors of
AChE.
■ CONCLUSIONS
The synthetic chemistry studies detailed above have established
that the ABC-ring system of galanthamine is readily obtained
through the Suzuki−Miyaura cross-coupling of o-hydroxyar-
ylboronates with conduritols incorporating a brominated
double-bond and then engaging the products of such processes
in an intramolecular Mitsunobu reaction. Furthermore, most of
the polyhydroxylated tetrahydrodibenzofurans arising from
such a reaction sequence engage in a thermally promoted
Eschenmoser−Claisen-type rearrangement reaction upon treat-
ment with N,N-dimethylacetamide dimethyl acetal in reﬂuxing
toluene. The angularly substituted tetrahydrodibenzofurans
thus formed, which embody the quaternary carbon center
associated with the title alkaloid and represent monoseco
analogues of the same, can then be elaborated, using Pictet−
Spengler chemistry, to give oxygenated derivatives of galanth-
amine, certain variants of which have recently been isolated
Table 1. Outcomes of Evaluating Galanthamine Derivatives
and Analogues as Inhibitors of AChE and Their Calculated
Docking Binding Energies (BEs)
entry compd IC50 (μM) docking BE (kcal)
1 2 >500 −8.9
2 ent-2 >500 −9.6
3 3 420 ± 57 −8.4
4 ent-3 >500 −9.5
5 4 >500 −6.0
6 ent-4 >500 −9.1
7 5 >500
8 ent-5 >500
9 6 >500 −6.3
10 ent-6 >500 −9.2
11 7 >500 −7.8
12 8 >500
13 9 >500
14 1 (+ve control) 0.9 ± 0.2 −10.2
Figure 4. Overlap of (−)-galanthamine (1) (blue) and the docked
derivatives 3 (A, purple) and ent-3 (B, peach) in the active site of
AChE.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b01062
J. Org. Chem. 2017, 82, 7869−7886
7877
111
from Chinese medicinal plants.40 Interestingly, these new
natural products were also poor inhibitors of AChE.
The biological evaluation of the galanthamine derivatives and
analogues obtained by the pathways described above reveals the
ﬁnely tuned nature of the interactions of the parent alkaloid
with the target enzyme AChE. In particular, structurally
“modest” changes to the galanthamine framework, as embodied
in the oxygenated derivatives 2, ent-2, 3, and ent-3, can
completely disrupt binding such that the compounds are
rendered inactive. These studies have also revealed that the
computational prediction of the likely binding aﬃnity of
galanthamine analogues to AChE is fraught.
■ EXPERIMENTAL SECTION
General Protocols. Unless otherwise speciﬁed, proton (1H) and
carbon (13C) NMR spectra were recorded at room temperature in
base-ﬁltered CDCl3 on a spectrometer operating at 400 MHz for
proton and 100 MHz for carbon nuclei. The signal due to residual
CHCl3 appearing at δH 7.26 and the central resonance of the CDCl3
“triplet” appearing at δC 77.0 were used to reference
1H and 13C NMR
spectra, respectively. 1H NMR data are recorded as follows: chemical
shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral]
where multiplicity is deﬁned as s = singlet; d = doublet; t = triplet; q =
quartet; m = multiplet or combinations of the above. Infrared spectra
(νmax) were recorded on an FTIR spectrometer. Samples were
analyzed as thin ﬁlms or ﬁnely divided solids. Low-resolution ESI mass
spectra were recorded on a single quadrupole mass spectrometer
interfaced with a liquid chromatograph, whereas high-resolution
measurements were conducted on a time-of-ﬂight instrument. Low-
and high-resolution EI mass spectra were recorded on a magnetic-
sector machine. Melting points were measured on an automated
melting point system and are uncorrected. Analytical thin layer
chromatography (TLC) was performed on aluminum-backed 0.2 mm
thick silica gel 60 F254 plates. Eluted plates were visualized using a 254
nm UV lamp and/or by treatment with a suitable dip followed by
heating. These dips included phosphomolybdic acid:ceric sulfate:sul-
furic acid (concd):water (37.5 g: 7.5 g: 37.5 g: 720 mL), potassium
permanganate:potassium carbonate:5% w/v aq. sodium hydroxide
solution:water (3 g: 20 g: 5 mL: 300 mL)), p-anisaldehyde or
vanillin:sulfuric acid (concd):ethanol (15 g: 2.5 mL: 250 mL). Flash
chromatographic separations were carried out following protocols
deﬁned by Still et al.41 with silica gel 60 (40−63 μm) as the stationary
phase and using the AR- or HPLC-grade solvents indicated. The
melting points of solids puriﬁed by such means were recorded directly
(i.e., after they had crystallized from the concentrated chromatographic
fractions). Starting materials, reagents, drying agents, and other
inorganic salts were generally commercially available and used as
supplied. THF, methanol, and CH2Cl2 were dried using a solvent
puriﬁcation system that is based upon a technology originally
described by Grubbs et al.42
Speciﬁc Chemical Transformations (2R,3R,4aS,5S,8R,8aS)-6-(2-
Hydroxy-3-methoxy-phenyl)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-di -ol (13) and
Enantiomer ent-13. A magnetically stirred solution of bis-acetal
1115 (805 mg, 2.37 mmol), ester 12 (720 mg, 2.88 mmol), and
triethylamine (3 mL) in THF/water (20 mL of a 9:1 v/v mixture) was
subjected to sonication under an atmosphere of nitrogen for 0.5 h.
PdCl2dppf·CH2Cl2 (140 mg, 0.191 mmol) was then added, and the
ensuing mixture was heated under reﬂux for 2 h before being cooled
and quenched with phosphate buﬀer (5 mL of a 1 M aqueous solution
at pH 7). The mixture thus obtained was cooled to 0 °C, treated with
methanol/30% aq hydrogen peroxide (10 mL of a 1:1 v/v mixture),
and then allowed to warm to room temperature over 1 h. The
resulting mixture was diluted with water (50 mL) and extracted with
ethyl acetate (5 × 20 mL). The combined organic phases were washed
with brine (2 × 20 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The ensuing thick orange oil
was triturated with diethyl ether (5 × 2 mL), and the resulting yellow
solid was subjected to ﬂash column chromatography (silica, 4:15:1 v/v
ethyl acetate/hexane/methanol →12:7:1 v/v ethyl acetate/hexane/
methanol gradient elution). Concentration of the appropriate fractions
(Rf = 0.3 in 10:9:1 v/v/v ethyl acetate/hexane/methanol) aﬀorded
phenol 13 (618 mg, 68%) as a white powder: mp 202−210 °C; [α]20D
−93.8 (c 0.1, methanol); 1H NMR (400 MHz, CD3OD) δ 6.89 (dd, J
= 7.5 and 1.8 Hz, 1H), 6.83−6.73 (complex m, 2H), 5.76 (d, J = 2.5
Hz, 1H), 4.60 (d, J = 3.7 Hz, 1H), 4.23 (dd, J = 8.0 and 2.5 Hz, 1H),
4.09 (dd, J = 11.0 and 8.0 Hz, 1H), 3.85 (s, 3H), 3.69 (dd, J = 11.0 and
3.7 Hz, 1H), 3.34 (s, 3H), 3.28 (s, 3H), 1.34 (s, 3H), 1.33 (s, 3H)
(signals due to hydroxyl protons not observed); 13C NMR (100 MHz,
CD3OD) δ 149.0, 145.0, 138.9, 132.9, 128.6, 123.6, 120.3, 112.2,
100.7, 100.3, 71.4, 70.7, 69.7, 69.0, 56.6, 48.3, 48.2, 18.1(5), 18.1(0);
IR νmax 3456, 3283, 2941, 1589, 1468, 1218, 1129, 1119, 914, 594
cm−1; MS (ESI, +ve) m/z 788 ([(2 M + Na)+, 80%], 405 [(M + Na)+,
100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H26NaO8
405.1525, found 405.1526.
Compound ent-13 was prepared in an analogous fashion from ent-
11 (2.04 g, 5.34 mmol) to give 1.60 g (71%) of product; [α]20D +86.4
(c 0.1, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 13.
(2R,3R,4aS,5R,11aR,11bS)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,4a,5,11a,11b-hexahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-5-ol (14) and Enantiomer ent-14. A magnetically stirred
solution of phenol 13 (605 mg, 1.58 mmol) and PPh3 (456 mg, 1.74
mmol) in THF (70 mL) maintained at −5 °C was treated dropwise
over 0.5 h with di-iso-propyl azodicarboxylate (364 μL, 1.74 mmol).
The resulting solution was stirred at −5 °C for 4 h and then allowed to
warm to room temperature over 1 h before being concentrated under
reduced pressure. The orange oil thus obtained was subjected to two
successive ﬂash chromatographic separations (silica, hexane→ 1:1 v/v
ethyl acetate/hexane gradient elution), and concentration of
appropriate fractions (Rf = 0.7, 2:1 v/v ethyl acetate/hexane) aﬀorded
allylic alcohol 14 (193 mg, 33%) as a white foam; [α]20D −157 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.99 (dd, J = 7.5 and 1.2 Hz,
1H), 6.89 (apparent t, J = 7.5 Hz, 1H), 6.82 (dd, J = 8.1 and 1.2 Hz,
1H), 5.81 (m, 1H), 5.14 (dt, J = 9.0 and 3.6 Hz, 1H), 4.67−4.61
(complex m, 1H), 4.04 (dd, J = 10.5 and 9.0 Hz, 1H), 3.93 (dd, J =
10.5 and 7.7 Hz, 1H), 3.88 (s, 3H), 3.34 (s, 6H), 2.34 (d, J = 4.8 Hz,
1H), 1.36(3) (s, 3H), 1.35(9) (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 151.6, 145.4, 139.1, 125.7, 122.1, 116.2, 113.6, 113.5, 99.2, 98.9, 84.0,
74.1, 71.3, 70.1, 56.0, 48.4, 48.0, 17.7, 17.6; IR νmax 3486, 2959, 2897,
1614, 1597, 1494, 1445, 1133, 1114, 1098, 1035, 1015, 786 cm−1; MS
(ESI, +ve) m/z 752 [(2 M + Na)+, 25%], 387 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H24NaO7 387.1420,
found 387.1423.
Compound ent-14 was prepared in an analogous fashion from ent-
13 (345 mg, 0.90 mmol) to give 314 mg (96%) of product; [α]20D
+102 (c 1.0, CHCl3). All the other spectral data acquired on this
material were identical with those reported above for compound 14.
N,N-Dimethyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-
2,3-dimethyl-2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (15) and Enantiomer ent-15. A
magnetically stirred solution of allylic alcohol 14 (180 mg, 0.494
mmol) in toluene (20 mL) maintained at 22 °C was treated with N,N-
dimethylacetamide dimethyl acetal (900 μL, 4.9 mmol), and the
resulting solution was heated under reﬂux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was triturated with diethyl ether. The resulting
waxy solid was subjected to ﬂash chromatography (silica, 20:79:1 v/v
ethyl acetate/hexane/methanol → 60:39:1 v/v ethyl acetate/hexane/
methanol gradient elution), and concentration of appropriate fractions
(Rf = 0.2 in 2:1 v/v ethyl acetate/hexane) aﬀorded amide 15 (178 mg
84%) as a white foam; [α]20D −89.9 (c 1.0, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.83 (m, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.72 (d, J =
7.6 Hz, 1H), 6.02 (dd, J = 10.0 and 2.7 Hz, 1H), 5.74 (dd, J = 10.0 and
2.0 Hz, 1H), 5.04 (d, J = 9.6 Hz, 1H), 4.55 (dt, J = 9.6 and 2.0 Hz,
1H), 3.85 (s, 3H), 3.76 (t, J = 9.6 Hz, 1H), 3.30 (s, 3H), 3.16 (s, 3H),
2.89 (s, 3H), 2.78 (s, 3H), 2.71 (d, J = 15.8 Hz, 1H), 2.61 (d, J = 15.8
Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
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169.0, 145.6(4), 145.5(6), 134.2, 128.9, 126.9, 121.5, 115.3, 112.0,
99.8, 87.1, 70.5, 65.9, 56.1, 51.0, 48.1, 47.4, 42.5, 37.3, 35.3, 17.7(4),
17.7(0) (one signal obscured or overlapping); IR νmax 2954, 2889,
1651, 1491, 1459, 1380, 1276, 1115, 1061, 1000, 954, 739 cm−1; MS
(ESI, +ve) m/z 456 [(M + Na)+, 100%], 201 (35); HRMS (ESI, +ve)
m/z (M + Na)+ calcd for C23H31NNaO7 456.1998, found 456.2000.
Compound ent-15 was prepared in an analogous fashion from ent-
14 (234 mg, 0.64 mmol) to give 238 mg (86%) of product as a white
foam. A small sample was crystallized (diethyl ether/methanol/
hexane) to give a white, crystalline solid; mp 160−165 °C (dec);
[α]20D +87.1 (c 1.0, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
15.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)ethan-1-ol (16) and Enantiomer ent-16. A magnetically
stirred solution of amide 15 (146 mg, 0.337 mmol) in THF (17 mL)
maintained at 0 °C was treated dropwise with lithium triethylborohy-
dride (1.7 mL of a 1 M solution in THF, 1.7 mmol). The resulting
mixture was warmed to room temperature over 2 h, recooled to 0 °C,
quenched with methanol (2 mL), and then treated with silica (200 mg
of ﬂash chromatographic-grade material) before being subjected to
ﬂash chromatography (silica, 1:4 v/v ethyl acetate/hexane → 1:1 v/v
ethyl acetate/hexane gradient elution). Concentration of relevant
fractions (Rf = 0.6, 2:1 v/v ethyl acetate/hexane) aﬀorded compound
16 (122 mg, 92%) as a white foam; [α]20D −131.9 (c 1.8, CHCl3); 1H
NMR (400 MHz, CDCl3) δ 6.84 (apparent t, J = 7.8 Hz, 1H), 6.74
(m, 1H), 6.69 (dd, J = 7.5 and 1.2 Hz, 1H), 5.91 (broad d, J = 10.0 Hz,
1H), 5.70 (broad d, J = 10.0 Hz, 1H), 4.89 (d, J = 9.6 Hz, 1H), 4.31
(ddd, J = 9.6, 2.7, and 1.5 Hz, 1H), 3.84 (s, 3H), 3.72 (t, J = 9.6 Hz,
1H), 3.67−3.57 (complex m, 2H), 3.28 (s, 3H), 3.17 (s, 3H), 1.96 (dt,
J = 13.7 and 6.7 Hz, 1H), 1.85 (dt, J = 13.7 and 6.4 Hz, 1H), 1.40
(triplet, J = 5.2 Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100
MHz, CDCl3) δ 145.7, 145.4, 133.6, 130.1, 126.4, 121.8, 114.9, 112.0,
99.9, 99.7, 86.9, 70.8, 65.4, 59.3, 56.1, 51.7, 48.0, 47.5, 43.5, 17.7, 17.6;
IR νmax 3508, 2948, 2837, 1619, 1588, 1491, 1459, 1281, 1130, 1116,
1036, 753, 736 cm−1; MS (ESI, +ve) m/z 415 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C21H28NaO7 415.1733,
found 415.1733.
Compound ent-16 was prepared in an analogous fashion from ent-
15 (177 mg, 0.408 mmol) to give 160 mg (quantitative) of product;
[α]20D +108 (c 0.9, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
16.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)acetic Acid (17) and Enantiomer ent-17. A magnetically
stirred solution of alcohol 16 (122 mg, 0.310 mmol) in acetonitrile/
water (9:1 v/v, 2.3 mL) maintained at room temperature was treated
in one portion with 4-(acetylamino)-2,2,6,6-tetramethyl-1-oxo-piper-
idinium tetraﬂuoroborate (280 mg, 0.93 mmol). The resulting dark-
brown solution was stirred at 22 °C for 48 h (by which time it was a
pale-yellow color) and then poured into water (3 mL) and extracted
with diethyl ether (5 × 4 mL). The combined organic extracts were
washed with HCl (2 × 1 mL of a 1 M aqueous solution) and brine (2
× 5 mL) before being dried (Na2SO4), ﬁltered, and concentrated
under reduced pressure. The residue thus obtained was subjected to
ﬂash chromatography (silica, CH2Cl2 → 1:19 v/v methanol/CH2Cl2
gradient elution) and concentration of appropriate fractions (Rf = 0.2
in 1:19 v/v methanol/CH2Cl2) aﬀorded acid 17 (96 mg, 76%) as a
clear, colorless gum; [α]20D −88.5 (c 0.6, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.85 (m, 1H), 6.76 (d, J = 7.4 Hz, 1H), 6.74 (d, J =
7.4 Hz, 1H), 5.96 (dd, J = 10.0 and 2.6 Hz, 1H), 5.77 (d, J = 10.0 Hz,
1H), 5.17 (d, J = 9.7 Hz, 1H), 4.40 (d, J = 9.7 Hz, 1H), 3.85 (s, 3H),
3.75 (t, J = 9.7 Hz, 1H), 3.29 (s, 3H), 3.17 (s, 3H), 2.76 (d, J = 15.6
Hz, 1H), 2.63 (d, J = 15.6 Hz, 1H), 1.36 (s, 3H), 1.28 (s, 3H) (signal
due to carboxylic acid group proton not observed); 13C NMR (100
MHz, CDCl3) δ 174.8, 145.6, 132.9, 128.1, 127.9, 121.9, 115.0, 112.3,
99.9, 99.8, 86.0, 70.5, 65.5, 56.1, 50.9, 48.0, 47.5, 44.0, 17.7 (signals
due to two carbons obscured or overlapping); IR νmax 2950, 1710,
1712, 1619, 1491, 1459, 1284, 1128, 1116, 1034, 960, 732 cm−1; MS
(ESI, +ve) m/z 429 [(M + Na)+, 100%]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C21H26NaO8 429.1525, found 429.1524.
Compound ent-17 was prepared in an analogous fashion from ent-
16 (150 mg, 0.382 mmol) to give 115 mg (80%) of product; [α]20D
+95.7 (c 1.2, CHCl3). All of the other spectral data acquired on this
material were identical with those reported above for compound 17.
N-Methyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-2,3-
dimethyl-2,3,-11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (5) and Enantiomer ent-5. A
magnetically stirred solution of acid 17 (93 mg, 0.23 mmol) in THF
(12 mL) maintained at room temperature was treated with 1,1′-
carbonyldiimidazole (49 mg, 0.30 mmol). The resulting solution was
heated under reﬂux for 1 h before being cooled to room temperature
and then placed in an ice bath at 0 °C. Methylamine (700 μL of a 2 M
solution in THF, 1.4 mmol) was then added dropwise, and the ensuing
solution was maintained at 0 °C for 3 h before being warmed to 22 °C
and stirred at this temperature for another 8 h. After this time, the
reaction mixture was diluted with ethyl acetate (40 mL) and washed
with NH4Cl (3 × 15 mL of a saturated aqueous solution). The
combined aqueous phases were extracted with ethyl acetate (3 × 10
mL), and the combined organic phases were washed with brine (2 ×
10 mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/methanol →
8:11:1 v/v ethyl acetate/hexane/methanol gradient elution) and
concentration of appropriate fractions (Rf = 0.3 in 10:9:1 v/v ethyl
acetate/hexane/methanol) gave amide 5 (76 mg, 79%) as a clear,
colorless oil; [α]20D −102.1 (c 1.2, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 6.81 (m, 1H), 6.72 (dd, J = 8.0 and 1.2 Hz, 1H), 6.68 (dd, J
= 7.5 and 1.2 Hz, 1H), 6.09 (dd, J = 10.0 and 2.6 Hz, 1H), 5.72 (dd, J
= 10.0 and 1.5 Hz, 1H), 5.36 (broad q, J = 4.8 Hz, 1H), 4.97 (d, J = 9.7
Hz, 1H), 4.37 (ddd, J = 9.7, 2.6, and 1.5 Hz, 1H), 3.81 (s, 3H), 3.71 (t,
J = 9.7 Hz, 1H), 3.27 (s, 3H), 3.13 (s, 3H), 2.71 (d, J = 4.8 Hz, 3H),
2.51 (d, J = 14.0 Hz, 1H), 2.42 (d, J = 14.0 Hz, 1H), 1.32 (s, 3H), 1.26
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.5, 145.5, 133.4, 128.7,
126.9, 121.6, 115.2, 112.1, 99.8, 99.7, 86.9, 70.3, 65.5, 56.0, 51.2, 48.0,
47.4, 46.8, 26.2, 17.7, 17.6 (signal due to one carbon obscured or
overlapping); IR νmax 3317, 2952, 2921, 1646, 1548, 1491, 1457, 1377,
1197, 1114, 1034, 999, 955, 735 cm−1; MS (ESI, +ve) m/z 442 [(M +
Na)+, 100%]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C22H29NNaO7 442.1842, found 442.1842.
Compound ent-5 was prepared in an analogous fashion from ent-17
(115 mg, 0.28 mmol) to give 91 mg (79%) of product; [α]20D +89.1 (c
1.3, CHCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 5.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a(5aH)-yl)-N-methylacetamide (6) and
Enantiomer ent-6. A round-bottomed ﬂask charged with a magnetic
stirrer bar and amide 5 (16.7 mg, 0.04 mmol) was treated sequentially
with water (250 μL) and triﬂuoroacetic acid (250 μL) and the ensuing
mixture stirred at 22 °C for 0.5 h; then, the volatiles were removed
under reduced pressure. The residue thus obtained was subject to ﬂash
chromatography (silica, 5:4:1 v/v ethyl acetate/hexane/methanol) and
concentration of appropriate fractions (Rf = 0.3 in 8:1:1 v/v ethyl
acetate/hexane/methanol) aﬀorded diol 6 (8.1 mg, 66%) as a white
foam; [α]20D −11 (c 0.4, methanol); 1H NMR [400 MHz, (CD3)2CO]
δ 7.04 (broad s, 1H), 6.84−6.74 (complex m, 3H), 6.00 (dd, J = 10.1
and 2.3 Hz, 1H), 5.67 (dd, J = 10.1 and 1.5 Hz, 1H), 5.25 (d, J = 8.7
Hz, 1H), 4.75 (broad s, 1H), 4.22 (partially obscured and broad s,
1H), 4.18 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.40 (t, J = 8.7 Hz, 1H),
2.63 (d, J = 4.6 Hz, 3H), 2.48 (d, J = 13.9 Hz, 1H), 2.41 (d, J = 13.9
Hz, 1H); 13C NMR [100 MHz, (CD3)2CO] δ 170.7, 146.9, 146.2,
135.5, 131.6, 128.5, 122.1, 116.1, 113.3, 90.4, 75.8, 69.9, 56.4, 51.6,
46.8, 25.9; IR νmax 3315, 2943, 1642, 1491, 1272, 1199, 1179, 1132,
1064, 945, 723 cm−1; MS (ESI, +ve) m/z 634 [(2 M + Na)+, 40], 328
[(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C16H19NNaO5 328.1161, found 328.1158.
Compound ent-6 was prepared in an analogous fashion from ent-5
(16.7 mg, 0.04 mmol) to give 11.8 mg (97%) of product; [α]20D +16.7
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b01062
J. Org. Chem. 2017, 82, 7869−7886
7879
113
(c 1.0, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 6.
(4aR,5R,6S,8aS)-5,6-Dihydroxy-3-methoxy-11-methyl-4a,5,11,12-
tetrahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-10(9H)-one (2)
and Enantiomer ent-2. A magnetically stirred solution of amide 5
(56 mg, 0.133 mmol) in acetonitrile (14 mL) was treated sequentially
with paraformaldehyde (20 mg, 0.67 mmol) and triﬂuoroacetic acid
(63 μL, 0.82 mmol). The resulting solution was stirred at room
temperature for 8 h and then quenched with phosphate buﬀer (15 mL
of a 1 M aqueous solution at pH 7) and extracted with CH2Cl2 (3 ×
10 mL). The combined organic extracts were washed with brine (1 × 5
mL) and dried (Na2SO4) before being ﬁltered and then concentrated
under reduced pressure. The residue thus obtained was subjected to
ﬂash chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/
methanol → 8:1:1 v/v ethyl acetate/hexane/methanol gradient
elution) and concentration of the appropriate fractions (Rf = 0.4 in
8:1:1 v/v ethyl acetate/hexane/methanol) aﬀorded lactam 2 (19.7 mg,
47%) as a white, amorphous solid; [α]20D −139 (c 0.4, methanol). 1H
NMR (400 MHz, CDCl3) δ 6.71 (apparent s, 2H), 5.97 (dd, J = 10.2
and 4.7 Hz, 1H), 5.58 (d, J = 10.2 Hz, 1H), 4.78−4.73 (complex m,
1H), 4.67−4.63 (complex m, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.32 (d, J
= 16.0 Hz, 1H), 4.12 (m, 1H), 3.85 (s, 3H), 3.18 (d, J = 14.2 Hz, 1H),
3.07 (d, J = 14.2 Hz, 1H), 3.04 (s, 3H) (signals due to hydroxyl group
protons not observed); 13C NMR (100 MHz, CDCl3) δ 171.8, 145.9,
144.8, 131.9, 128.7, 125.7, 125.1, 120.4, 111.9, 88.4, 68.5, 67.0, 56.1,
52.1, 43.2, 42.3, 35.9; IR νmax 3357, 2924, 1623, 1508, 1438, 1280,
1101, 1070, 1031, 971, 880, 793 cm−1; MS (ESI, +ve) m/z 657 [(2 M
+ Na)+, 40%], 340 [(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C17H19NNaO5 340.1161, found 340.1159.
Compound ent-2 was prepared in an analogous fashion from ent-5
(20 mg, 0.048 mmol) to give 9.5 mg (63%) of product as a white,
amorphous solid. A small sample was recrystallized (diethyl ether) to
give a white, crystalline solid; mp 135−140 °C; [α]20D +127 (c 0.4,
methanol). All of the other spectral data acquired on this material were
identical with those reported above for compound 2.
(4aR,5R,6S,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahy-
dro-6H-benzo[2,3]-benzofuro[4,3-cd]azepine-5,6-diol (3) and
Enantiomer ent-3. A magnetically stirred solution of lactam 2 (9.5
mg, 0.03 mmol) in THF (5 mL) maintained at room temperature was
treated with NaAlH2(OCH2CH2OCH3) 2 (60 μL of a 60% w/v
solution in toluene, 0.184 mmol) and the ensuing mixture heated
under reﬂux for 24 h after which time it was cooled to 0 °C (ice-bath),
quenched with potassium sodium tartrate (2 mL of a saturated
aqueous solution), diluted with water (10 mL) and then extracted with
CHCl3 (3 × 5 mL). The combined organic extracts were washed with
brine (1 × 2 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:19 v/v NH3 saturated
methanol/CHCl3→ 1:9 v/v NH3 saturated methanol/CHCl3 gradient
elution) and concentration of appropriate fractions (Rf = 0.2 in 1:9 v/v
NH3 saturated methanol/CHCl3) aﬀorded amine 3 (4.0 mg, 44%) as a
white, amorphous solid; [α]20D −86.6 (c 0.3, CDCl3); 1H NMR (400
MHz, CDCl3) δ 6.66 (d, J = 8.2 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H),
6.23 (d, J = 10.2 Hz, 1H), 5.93 (dd, J = 10.2 and 3.8 Hz, 1H), 4.57 (d,
J = 4.6 Hz, 1H), 4.30 (m, 1H), 4.19−4.09 (complex m, 2H), 3.84 (s,
3H), 3.63 (m, 1H), 3.27 (m, 1H), 2.98 (broad d, J = 14.8 Hz, 1H),
2.34 (s, 3H), 2.18 (m, 1H), 1.81 (dd, J = 13.4 and 2.2 Hz, 1H) (signals
due to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ 145.4, 144.0, 132.3, 129.1, 128.1, 126.6, 122.4, 111.1, 90.9,
72.4, 67.6, 60.1, 55.9, 54.2, 49.8, 42.0, 36.0; IR νmax 3345, 2921, 1626,
1596, 1507, 1439, 1282, 1041, 948, 793, 726 cm−1; MS (ESI, +ve) m/z
629 [(2 M + Na)+, 30%], 326 [(M + Na)+, 100], 304 [(M + H)+, 7];
HRMS (ESI, +ve) m/z (M + H)+ calcd for C17H22NO4 304.1549,
found 304.1544.
Compound ent-3 was prepared in an analogous fashion from ent-2
(9.5 mg, 0.030 mmol) to give 4.0 mg (44%) of product, [α]20D +60.5
(c 0.4, CDCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 3.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a-(5aH)-yl)-N,N-dimethylacetamide (4)
and Enantiomer ent-4. Amide 15 (15 mg, 0.035 mmol) was treated
triﬂuoroacetic acid/water (200 μL of a 1:1 v/v mixture), and the
resulting mixture was stirred at 22 °C for 0.5 h; then, the volatiles were
removed under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:19 v/v methanol/
CH2Cl2), and concentration of the relevant fractions (Rf = 0.1)
aﬀorded diol 4 (9.8 mg, 88%) as a clear, colorless oil; [α]20D +5.7 (c
0.9, CH3OH);
1H NMR (400 MHz, CDCl3) δ 6.86 (m, 1H), 6.78−
6.73 (complex m, 2H), 5.98 (d, J = 9.9 Hz, 1H), 5.83 (d, J = 9.9 Hz,
1H), 5.01 (d, J = 7.5 Hz, 1H), 4.45 (broad s, 1H), 3.85 (s, 3H), 3.71
(m, 1H), 2.88 (s, 3H), 2.81 (s, 3H), 2.79 (m, 1H), 2.58 (d, J = 15.8
Hz, 1H) (signals due to hydroxyl protons not observed); 13C NMR
(100 MHz, CDCl3) δ 169.7, 145.5, 145.3, 134.1, 129.4, 128.5, 122.0,
115.4, 111.9, 90.5, 74.4, 69.2, 56.1, 50.1, 42.7, 37.5, 35.6; IR νmax 3389,
2927, 1616, 1489, 1457, 1402, 1271, 1093, 1058, 941, 749, 731 cm−1;
MS (ESI, +ve) m/z 661 [(2 M + Na)+, 40%], 342 [(M + Na)+, 100];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C17H21NNaO5 342.1317,
found 342.1311.
Compound ent-4 was prepared in an analogous fashion from ent-15
(23.7 mg, 0.055 mmol) to give 13.4 mg (77%) of product; [α]20D −8.2
(c 1.3, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 4.
(1S,2S,3S,6S)-4-Bromo-6-((4-methoxybenzyl)oxy)cyclohex-4-ene-
1,2,3-triol (21). Step i. BF3·OEt2 (100 μL of a 10% v/v solution in
CH2Cl2) was added dropwise over 0.25 h to a magnetically stirred
solution of epoxide 2023 (2.00 g, 8.09 mmol) and p-methoxybenzyl
alcohol (23.8 g, 175 mmol) in dry CH2Cl2 (80 mL) maintained at −20
°C. The resulting solution was allowed to warm to −10 °C over 2 h
after which time a second aliquot of BF3·OEt2 (150 μL of a 10% v/v
solution in CH2Cl2) was added dropwise over 0.25 h. The reaction
mixture thus formed was warmed to 22 °C over 12 h then quenched
with phosphate buﬀer (3 mL of a 1 M aqueous solution at pH 7), and
the solvent was then removed under reduced pressure. The residue
thus obtained, which was comprised of a mixture of the desired PMB-
ether and p-methoxybenzyl alcohol, was submitted directly to step ii as
detailed immediately below.
Step ii. A magnetically stirred solution of the material obtained from
step i in methanol (160 mL) was treated with pyridinium p-
toluenesulfonate (2.03 g, 8.09 mmol) and the mixture so-formed was
heated at 50 °C for 48 h; then, it was cooled to 22 °C and treated with
NaHCO3 (500 mg), and the solvent was removed under reduced
pressure. The residue thus obtained was treated with ethyl acetate
(200 mL) and then water (100 mL), and the separated aqueous layer
was extracted with ethyl acetate (4 × 50 mL). The combined organic
phases were washed with brine (1 × 30 mL) and then dried (Na2SO4),
ﬁltered, and concentrated under reduced pressure. The resulting
yellow oil was subjected to ﬂash column chromatography (silica,
CH2Cl2 → 1:19 v/v methanol/CH2Cl2 gradient elution), and
concentration of appropriate fractions (Rf = 0.2 in 1:19 v/v
methanol/CH2Cl2) aﬀorded triol 21 (1.98 g, 71% from 20) as a
white foam; [α]20D +132.1 (c 1.1, CHCl3);
1H NMR [400 MHz,
(CD3)2CO] δ 7.32 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.14
(d, J = 2.4 Hz, 1H), 4.67 (s, 2H), 4.58 (d, J = 5.1 Hz, 1H), 4.27−4.20
(complex m, 2H), 4.03 (broad s, 1H), 3.86 (dd, J = 7.4 and 2.0 Hz,
1H), 3.82 (broad d, J = 9.7 Hz, 1H), 3.78 (s, 3H), 3.54 (m, 1H); 13C
NMR [100 MHz, (CD3)2CO] δ 160.2, 132.8, 131.8, 130.2, 124.8,
114.4, 80.8, 74.1, 72.3(2), 72.2(5), 71.8, 55.5; IR (KBr) νmax 3437,
2918, 2848, 1732, 1449, 1368, 1241, 1072, 1026 cm−1; MS (ESI, +ve)
m/z 369 and 367 [(M + Na)+, 100 and 98%]; HRMS (ESI, +ve) m/z
(M + Na)+ calcd for C14H17
79BrNaO5 367.0155, found 367.0157.
(2S,3S,4aR,5S,8S,8aR)-6-Bromo-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-diol (ent-11). A
magnetically stirred solution of triol 21 (2.57 g, 7.44 mmol), 2,2,3,3-
tetramethoxybutane (1.91 g, 10.7 mmol), and trimethyl orthoformate
(3.40 mL, 31.1 mmol) in dry methanol (50 mL) was treated with p-
TsOH·H2O (73 mg, 5 mol %). The resulting mixture was heated
under reﬂux for 24 h, cooled to 22 °C, and treated with NaHCO3
(2.00 g), and the solvent was removed under reduced pressure. The
residue thus obtained was treated with ethyl acetate (100 mL) and
then NaHCO3 (30 mL of a saturated aqueous solution). The separated
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organic phase was washed with NaHCO3 (1 × 30 mL of a saturated
aqueous solution) and water (1 × 30 mL), and then the combined
aqueous layers were extracted with ethyl acetate (3 × 30 mL). The
combined organic phases were washed with brine (2 × 20 mL) and
then dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The resulting thick, orange oil was subjected to ﬂash column
chromatography (silica, 1:20 v/v methanol/CH2Cl2 elution), and
concentration of appropriate fractions (Rf = 0.3) aﬀorded bis-acetal
ent-11 (2.14 g, 85%) as a white foam; [α]20D +72.6 (c 1.1, CHCl3)
{lit.15 (for 11); [α]20D −76.5 (c 1.0, CHCl3)}; 1H NMR (400 MHz,
CD3OD) δ 6.05 (d, J = 2.5 Hz, 1H), 4.22 (d, J = 4.1 Hz, 1H), 4.06
(dd, J = 7.9 and 2.5 Hz, 1H), 3.87 (dd, J = 11.1 and 7.9 Hz, 1H), 3.63
(dd, J = 11.1 and 4.1 Hz, 1H), 3.30 (s, 3H), 3.25 (s, 3H), 1.32 (s, 3H),
1.29 (s, 3H) (signals due to hydroxyl group protons not observed);
13C NMR (100 MHz, CD3OD) δ 135.2, 124.0, 100.8, 100.2, 73.1,
71.8, 69.8, 69.2, 48.3, 48.2, 18.1, 18.0; IR (KBr) νmax 3160, 2940, 1636,
1454, 1375, 1136, 1077, 1031, 980, 915 cm−1; MS (ESI, +ve) m/z 363
and 361 [(M + Na)+, 95 and 100%]; HRMS (ESI, +ve) (M+Na)+
calcd for C12H19
79BrNaO6 361.0263, found 361.0263.
3-Bromo-4-hydroxy-5-methoxybenzaldehyde (23). A magneti-
cally stirred solution of vanillin (22) (4.00 g, 26.3 mmol) in acetic
acid (10 mL) was treated with molecular bromine (1.34 mL, 0.03
mol), and the ensuing mixture was stirred at 22 °C for 3 h during
which time a precipitate appeared. The reaction mixture was quenched
with water (30 mL), and the precipitate was ﬁltered oﬀ, washed with
water (1 × 50 mL) and then methanol (1 × 20 mL) before being dried
under vacuum to aﬀord compound 2328 (5.40 g, 90%) as a white,
crystalline solid; mp 164 °C (lit.28 mp 160−162 °C); 1H NMR
(CDCl3, 400 MHz) δ 9.79 (s, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.36 (d, J
= 1.7 Hz, 1H), 6.52 (s, 1H), 3.99 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 189.6, 148.9, 147.7, 130.1, 130.0, 108.2, 108.0, 56.6; IR νmax
3305, 2980, 1674, 1590, 1463, 1290, 1157, 1047, 680 cm−1; MS (ESI,
+ ev) m/z 255 and 253 [(M+Na)+, 100 and 99%]; HRMS (ESI, +ve)
(M+Na)+ calcd for C8H7
79BrNaO3 252.9476, found 252.9479.
2-Bromo-4-(1,3-dioxolan-2-yl)-6-methoxyphenol (24). Com-
pound 23 (5.00 g, 21.8 mmol), toluene (120 mL), p-TsOH·H2O
(39 mg, 0.21 mmol) and ethylene glycol (3.60 mL, 65.2 mmol) were
placed in a round-bottom ﬂask ﬁtted with a Dean−Stark trap and
condenser. The ensuing mixture was heated under reﬂux for 5 h before
being cooled, quenched with NaHCO3 (100 mL of a saturated
solution), and extracted with ethyl acetate (1 × 100 mL). The organic
phase was dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure, and the light-yellow oil thus obtained was subjected ﬂash
chromatography (silica, 5:1 v/v hexane/ethyl acetate elution).
Concentration of the relevant fractions (Rf = 0.4 in 1:9 v/v ethyl
acetate/hexane) gave compound 24 (3.30 g, 55%) as a light-yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 1.5 Hz, 1H), 6.94 (d, J =
1.5 Hz, 1H), 5.97 (s, 1H), 5.71 (s, 1H), 4.14−4.11 (complex m, 2H),
4.04−3.98 (complex m, 2H), 3.92 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 147.2, 143.8, 130.7, 123.2, 108.0, 107.9, 102.9, 65.2, 56.4; IR
νmax 3358, 2963, 2887, 1684, 1603, 1589, 1503, 1466, 1426, 1280,
1181, 1090, 1044 cm−1; MS (ESI, +ve) m/z 299 and 297 [(M+Na)+,
92 and 100%] 277 and 275 [(M+H)+, 45 and 40]; HRMS (ESI, +ve)
(M+H)+ calcd for C10H12
79BrO4 274.9919, found 274.9921.
2-(3-Bromo-5-methoxy-4-(methoxymethoxy)phenyl)-1,3-dioxo-
lane (25). A magnetically stirred mixture of phenol 24 (3.23 g, 11.79
mmol) in dry THF (30 mL) maintained at 0 °C was treated with NaH
(564 mg of a 60% suspension in oil, 14.2 mmol). After 0.5 h, the
reaction mixture was treated with chloromethyl methyl ether (980 μL,
12.9 mmol) and then stirred at 22 °C for 18 h before being quenched
with water (100 mL; CAUTION! possibility of hydrogen gas
evolution). The separated aqueous layer was extracted with diethyl
ether (3 × 30 mL), and the combined organic phases were washed
with brine (1 × 30 mL) and then dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:4 v/v ethyl acetate/hexane
elution) and gave, after concentration of the relevant fractions (Rf =
0.5 in 1:3 v/v ethyl acetate/hexane), bromide 25 (2.65 g, 70%) as a
clear, colorless oil; 1H NMR (CDCl3, 400 MHz) δ 7.28 (d, J = 1.9 Hz,
1H), 6.98 (d, J = 1.9 Hz, 1H), 5.74 (s, 1H), 5.17 (s, 2H), 4.13−4.01
(complex m, 4H), 3.86 (s, 3H), 3.64 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 153.3, 143.9, 135.1, 123.1, 117.6, 109.6, 102.6, 98.6, 65.3,
58.0, 56.1; IR νmax 2941, 2891, 2839, 1696, 1570, 1484, 1463, 1416,
1384, 1274, 1157, 1081, 1043, 942, 854 cm−1; MS (EI, 70 eV) m/z
320 and 318 (M+•, 99 and 100%), 289 and 287 (55 and 53), 239 (85),
166 (25); HRMS (EI, 70 eV) M+• calcd for C12H15
79BrO5 318.0103,
found 318.0104.
4-Hydroxy-3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)benzaldehyde (27). Step i. A magnetically stirred mixture of
bromide 25 (1.30 g, 4.15 mmol) in dry THF (15 mL) maintained at
−78 °C was treated with n-BuLi (3.1 mL of a 1.6 M solution in THF,
5.0 mmol). After 1 h, the reaction mixture was treated with tri-iso-
propyl borate (1.9 mL, 8.3 mmol) and then stirred at 22 °C for 15 h
before being quenched with HCl (10 mL of a 10% w/v aqueous
solution). The separated aqueous layer was extracted with ethyl acetate
(3 × 50 mL), and the combined organic phases were washed with
brine (1 × 50 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained, and
which is presumed to contain boronic acid 26, was subjected directly
to step ii of the reaction sequence.
Step ii. A magnetically stirred mixture of the product obtained from
step i in dry acetonitrile (40 mL) maintained at 0 °C was treated with
sodium iodide (0.62 g, 14.5 mmol) and chlorotrimethylsilane (530 μL,
14.5 mmol). The resulting solution was warmed to 22 °C over 4 h and
then treated with Na2S2O3 (20 mL of a saturated aqueous solution).
The separated aqueous layer was extracted with ethyl acetate (3 × 20
mL), and the combined organic phases were washed with brine (1 ×
20 mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was immediately
subjected to step iii of the reaction sequence.
Step iii. A magnetically stirred suspension of the product obtained
from step ii in benzene (30 mL) was treated with pinacol (990 mg,
8.40 mmol), and the solution thus obtained was heated under reﬂux
for 2 h in an apparatus ﬁtted with a Dean−Stark trap and a condenser.
The cooled reaction mixture was treated with water (20 mL), and the
separated aqueous layer was extracted with ethyl acetate (3 × 20 mL).
The combined organic phases were then washed with brine (1 × 50
mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 2:3 v/v diethyl ether/hexane elution) to
aﬀord, after concentration of the relevant fractions (Rf = 0.4), boronic
ester 27 (520 mg, 45% from 25) as a white, crystalline solid; mp 73
°C; 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 8.33 (s, 1H), 7.72 (d,
J = 1.9 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 3.93 (s, 3H), 1.38 (s, 12H);
13C NMR (CDCl3, 100 MHz) δ 190.9, 158.6, 148.3, 133.8, 129.6,
111.7, 85.1, 56.0, 24.8; IR νmax 3407, 2992, 2931, 2830, 2797, 2714,
1683, 1620, 1587, 1467, 1388, 1372, 1298, 1256, 1140, 1056, 980, 846,
674 cm−1; MS (EI, 70 eV) m/z 278 (M+•, 38%), 221 (100), 178 (51),
177 (30); HRMS (EI, 70 eV) M+• calcd for C14H19BO5 278.1326,
found 278.1326.
(3aS,4S,5S,7aS)-7-Bromo-2,2-dimethyl-5-((triiso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (29). Tri-iso-propylsilyl
triﬂuoromethanesulfonate (1.95 mL, 7.3 mmol) was added dropwise
to a magnetically stirred solution of compound 2829 (1.40 g, 5.3
mmol) and 2,6-lutidine (2.5 mL, 21.5 mmol) in CH2Cl2 (30 mL)
maintained at −78 °C under a nitrogen atmosphere. The ensuing
mixture was allowed to warm to 22 °C over 3 h and then treated with
NH4Cl (60 mL of a saturated aqueous solution). The separated
aqueous phase was extracted with CH2Cl2 (1 × 20 mL), and the
combined organic phases were dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The resulting light yellow oil
was subjected to ﬂash chromatography (silica, 3:100 v/v ethyl acetate/
hexane elution) and gave, after concentration of the appropriate
fractions (Rf = 0.3 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
an ∼6:1 mixture of compound 29 and its regioisomeric silyl ether
(1.95 g, 88% combined yield) as a light-yellow oil; 1H NMR (400
MHz, CDCl3) δ 6.42 (s, 1H), 4.66 (d, J = 6.6 Hz, 1H), 4.17 (m, 1H),
4.11 (m, 1H), 3.55 (t, J = 8.7 Hz, 1H), 2.45 (s, 1H), 1.54 (s, 3H), 1.40
(s, 3H), 1.15−1.04 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ 144.5, 110.2, 92.2, 79.3, 77.0, 74.5, 73.6, 28.0, 25.7, 18.0(1), 17.9(9),
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12.4; IR νmax 3469, 2943, 2893, 2866, 1635, 1463, 1382, 1248, 1070,
1019, 997, 882, 866, 828 cm−1; MS (ESI, +ve) m/z 445 and 443 [(M
+Na)+, 100 and 97%]; HRMS (ESI, +ve) (M + Na)+ calcd for
C18H33
79BrNaO4Si 443.1229, found 443.1232.
(((3aR,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-4-yl)oxy)tri-iso-propylsilane (30).
Sodium hydride (342 mg of a 60% dispersion in mineral oil, 8.6
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 29 and its regioisomer (1.20 g, 2.9 mmol) and
iodomethane (391 μL, 6.3 mmol) in dry THF (20 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (70 mL)
(CAUTION! possibility of hydrogen evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 30 mL), and
the combined organic phases were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/ hexane), an ∼5:1
mixture of compound 30 and its regioisomer (612 mg, 49% combined
yield) as a yellowish oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.16 (m, 1H), 4.63 (m, 1H), 4.47 (m, 1H), 4.36 (m, 1H),
3.86 (m, 1H), 3.41 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.12−0.95
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 129.4, 122.3, 110.0, 77.3, 77.2(3), 77.2(2), 69.9, 57.3,
27.5, 26.2, 18.0(2), 17.9(5), 12.5; IR νmax 2939, 2892, 2866, 1645,
1463, 1381, 1234, 1163, 1078, 1039, 1011, 941, 882, 815, 680 cm−1;
MS (ESI, +ve) m/z 459 and 457 [(M+Na)+, 98 and 96%], 355 (100),
347 and 345 (67 and 65); HRMS (ESI, +ve) (M+Na)+ calcd for
C19H35
79BrNaO4Si 457.1386, found 457.1389.
(3aS,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-tet-
rahydrobenzo-[d][1,3]dioxol-4-ol (31). A magnetically stirred sol-
ution of an ∼5:1 mixture of compound 30 and its regioisomer (600
mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a nitrogen
atmosphere was treated with tetra-n-butylammonium ﬂuoride (2 mL
of 1.0 M solution in THF, 2.0 mmol). After 2 h, the reaction mixture
was concentrated under reduced pressure, and the residue so-formed
was subjected to ﬂash chromatography (silica, 1:2 v/v ethyl acetate/
hexane elution) to provide, after concentration of the appropriate
fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
compound 31 (377 mg, 98%) as a light-yellow oil; [α]20D −15.7 (c 2.4,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.28 (s, 1H), 4.68 (d, J = 6.5
Hz, 1H), 4.15 (m, 1H), 3.66 (m, 2H), 3.48 (s, 3H), 2.64 (broad s,
1H), 1.55 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
132.2, 118.8, 111.0, 80.3, 77.5, 77.2, 72.5, 57.5, 28.1, 25.9; IR νmax
3453, 2987, 2934, 2826, 1646, 1457, 1381, 1217, 1164, 1074, 869
cm−1; MS (EI, 70 eV) m/z 280 and 278 (M+•, both 3%), 265 and 263
(both 35%), 101 (100); HRMS (EI, 70 eV) M+• calcd for
C10H15
79BrO4 278.0154, found 278.0148.
4-Hydroxy-3-((3aR,6S,7R,7aS)-7-hydroxy-6-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (32). A magnetically stirred solution of compound 31 (150
mg, 0.54 mmol), ester 27 (180 mg, 0.65 mmol), PdCl2dppf·CH2Cl2
(31.5 mg, 0.04 mmol), and triethylamine (3 mL) in THF/water (18
mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and then
heated under reﬂux for 2 h before being cooled, poured into water (50
mL), and extracted with ethyl acetate (3 × 30 mL). The combined
organic phases were washed with brine (1 × 40 mL) and then dried
(Na2SO4), ﬁltered, and concentrated under reduced pressure. The
ensuing light-yellow oil was subjected to ﬂash chromatography (silica,
1:4 v/v ethyl acetate/hexane elution), and concentration of the
relevant fractions (Rf = 0.5 in 1:3 v/v ethyl acetate/hexane) aﬀorded
phenol 32 (85 mg, 45%) as a white, crystalline solid; mp 129 °C,
[α]20D +16.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.83 (s,
1H), 7.45 (d, J = 1.8 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.09 (s, 1H),
6.19 (d, J = 1.3 Hz, 1H), 5.17 (d, J = 6.4 Hz, 1H), 4.27 (dd, J = 8.9 and
6.4 Hz, 1H), 3.98 (s, 3H), 3.86 (m, 1H), 3.79 (m, 1H), 3.54 (s, 3H),
2.71 (broad s, 1H), 1.53 (s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 190.9, 149.2, 147.7, 132.3, 131.7, 129.2, 128.2, 125.1, 110.7,
108.4, 79.9, 77.7, 73.9, 72.9, 57.5, 56.4, 28.2, 26.0; IR νmax 3400, 2986,
2935, 2830, 1681, 1588, 1488, 1455, 1432, 1373, 1301, 1254, 1217,
1148, 1067, 990, 863, 732 cm−1; MS (EI, 70 eV) m/z 350 (M+•, 5%),
292 (53), 260 (55), 232 (100), 231 (72), 218 (53), 203 (39), 189
(33); HRMS (EI, 70 eV) M+• calcd for C18H22O7 350.1366, found
350.1369.
(2′R,3′R,4′S,5′S)-2′ ,3′ ,4′ ,6-Tetrahydroxy-5,5′-dimethoxy-
2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-3-carbaldehyde (33). Com-
pound 32 (60 mg, 0.17 mmol) was treated with acetic acid/water
(10 mL of a 2:1 v/v mixture), and the resulting mixture was stirred at
22 °C for 18 h and then cooled and concentrated under reduced
pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 1:8:1 v/v/v methanol/ethyl acetate/hexane
elution) gave, after concentration of the appropriate fractions (Rf =
0.4), compound 33 (43 mg, 81%) as a white powder; mp 191 °C;
[α]20D +7.5 (c 0.1, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ 9.83
(s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 1.9 Hz, 1H), 6.03 (d, J =
2.5 Hz, 1H), 4.63 (d, J = 3.8 Hz, 1H), 3.97 (m, 1H), 3.92 (s, 3H), 3.84
(dd, J = 7.6 and 2.5 Hz, 1H), 3.62 (dd, J = 10.3 and 3.8 Hz, 1H), 3.49
(s, 3H), 2.83 (broad, s, 3H) (signal due to a hydroxyl group proton
not observed); 13C NMR [100 MHz, (CD3)2CO] δ 191.3, 151.3,
149.5, 137.4, 132.1, 129.9, 128.6, 128.4, 110.1, 82.9, 72.7, 71.8, 70.2,
57.6, 56.6; IR νmax 3346, 2926, 2839, 2821, 1678, 1586, 1454, 1429,
1383, 1298, 1257, 1145, 1106, 1070, 943, 858, 696 cm−1; MS (ESI,
+ve) m/z 643 [(2M + Na)+, 35%], 333 [(M + Na)+, 100]; HRMS
(ESI, +ve) (M+Na)+ calcd for C15H18NaO7 333.0950, found 333.0952.
(5aS,6S,7S,8S)-6,7-Dihydroxy-4,8-dimethoxy-5a,6,7,8-
tetrahydrodibenzo[b,d]-furan-2-carbaldehyde (7). A magnetically
stirred solution of phenol 33 (40 mg, 0.13 mmol) in THF (12 mL)
was treated with Ph3P (40 mg, 0.15 mmol), cooled to 0 °C, and
treated dropwise with a solution of di-iso-propyl azodicarboxylate (25
μL, 0.13 mmol) in THF (1 mL). The reaction mixture thus obtained
was stirred at 0 °C for 2 h and then concentrated under reduced
pressure, and the ensuing light-yellow oil was subjected to ﬂash
chromatography (silica, 3:97 v/v methanol/CH2Cl2 elution). Con-
centration of the relevant fractions (Rf = 0.4 in 0.5:9.5 v/v methanol/
CH2Cl2) aﬀorded benzofuran 7 (32 mg, 85%) as a clear, light-yellow
oil; [α]20D +92.0 (c 0.2, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ
9.87 (s, 1H), 7.69 (d, J = 1.5 Hz, 1H), 7.44 (d, J = 1.5 Hz, 1H), 6.19 (t,
J = 3.6 Hz, 1H), 5.09 (m, 1H), 4.94 (s, 1H), 4.48 (broad s, 1H), 4.09
(m, 1H), 3.95 (s, 3H), 3.81−3.77 (complex m, 2H), 3.49 (s, 3H); 13C
NMR [100 MHz, (CD3)2CO] δ 191.1, 157.6, 146.9, 138.0, 133.1,
127.7, 118.2, 117.6, 114.0, 89.1, 83.8, 77.3, 75.6, 57.5, 56.6; IR νmax
3339, 2926, 2892, 2853, 2823, 1686, 1604, 1590, 1437, 1337, 1313,
1185, 1119, 1092, 1069, 997, 920, 721, 694 cm−1; MS (ESI, +ve) m/z
607 [(2M + Na)+, 40%], 315 [(M + Na)+, 100], 293 (23), 195 (30);
HRMS (ESI, +ve) (M + Na)+ calcd for C15H16NaO6 315.0845, found
315.0847.
(3aS,4S,5R,7aS)-7-Bromo-2,2-dimethyl-5-((tri-iso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (35). Tri-iso-propylsilyl
triﬂuoromethanesulfonate (620 μL, 2.3 mmol) was added dropwise to
a magnetically stirred solution of compound 3431 (500 mg, 1.9 mmol)
and 2,6-lutidine (880 μL, 7.6 mmol) in CH2Cl2 (15 mL) maintained at
−78 °C under a nitrogen atmosphere. The ensuing mixture was
allowed to warm to 22 °C over 3 h and then treated with NH4Cl (30
mL of a saturated aqueous solution). The separated aqueous phase was
extracted with CH2Cl2 (1 × 10 mL), and the combined organic phases
were dried (MgSO4), ﬁltered, and concentrated under reduced
pressure. The resulting light-yellow oil was subjected to ﬂash
chromatography (silica, 3:100 v/v ethyl acetate/hexane elution) and
gave, after concentration of the appropriate fractions (Rf = 0.3 in
0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼6:1 mixture of
ether 35 and its regioisomer (700 mg, 88% combined yield) as a light-
yellow oil. 1H NMR (400 MHz, CDCl3) δ (major regioisomer) 6.00
(m, 1H), 4.62 (dd, J = 5.2 and 1.5 Hz, 1H), 4.49 (m, 2H), 4.24 (m,
1H), 2.67 (d, J = 1.5 Hz, 1H), 1.40 (s, 3H), 1.39 (s, 3H), 1.12−0.99
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 130.8, 123.5, 110.0, 75.9, 75.7, 69.3, 68.3, 27.5, 26.2,
17.9(4), 17.9(3), 12.2; IR νmax 3560, 2943, 2893, 2867, 1645, 1463,
1382, 1370, 1340, 1236, 1080, 1055, 882, 863, 682 cm−1; MS (EI, 70
eV) m/z 423 and 421 [(M+ H)+, 10 and 9%], 407 and 405 [(M −
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CH3•)+, 7 and 6], 321 and 319 (100 and 97); HRMS (EI, 70 eV) (M
− CH3•)+ calcd for C17H3079BrO4Si 405.1097, found 405.1096.
(((3aS,4S,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]diox-ol-5-yl)oxy)tri-iso-propylsilane (36).
Sodium hydride (172 mg of a 60% dispersion in mineral oil, 4.3
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 35 and its regioisomer (600 mg, 1.4 mmol) and
iodomethane (267 μL, 4.3 mmol) in dry THF (15 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (30 mL)
(CAUTION! possibility of hydrogen gas evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 15 mL), and the
combined organic phases were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼5:1
mixture of compound 36 and its regioisomer (570 mg, 92% combined
yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.15 (d, J = 3.0 Hz, 1H), 4.62 (m, 1H), 4.56 (m, 1H),
4.44 (t, J = 5.4 Hz, 1H), 3.70 (m, 1H), 3.54 (s, 3H), 1.41 (s, 3H), 1.38
(s, 3H), 1.10−0.98 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ (major regioisomer) 133.1, 122.2, 109.9, 80.3, 76.9, 75.1, 68.2, 59.7,
27.5, 26.0, 17.9(8), 17.9(6), 12.2; IR νmax 2941, 2887, 2865, 1649,
1460, 1383, 1335, 1241, 1197, 1138, 1121, 1079, 1040, 956, 880, 858,
680 cm−1; MS (ESI, +ve) m/z 459 and 457 [(M + Na)+, 83 and 81%],
437 and 435 (88 and 86), 205 and 203 (97 and 100); HRMS (ESI,
+ve) (M + Na)+ calcd for C19H35
79BrNaO4Si 457.1386, found
457.1375.
(3aS,4R,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-5-ol (37). A magnetically stirred
solution of an ∼5:1 mixture of compound 36 and its regioisomer
(600 mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a
nitrogen atmosphere was treated with tetra-n-butylammonium ﬂuoride
(2 mL of 1.0 M solution in THF, 4.1 mmol). After 2 h, the reaction
mixture was concentrated under reduced pressure, and the residue so-
formed was subjected to ﬂash chromatography (silica, 1:2 v/v ethyl
acetate/hexane elution). Concentration of the relevant fractions (Rf =
0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane) gave compound
37 (338 mg, 88%) as a white powder; mp 61 °C; [α]20D +15.3 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3, 400 MHz) δ 6.15 (d, J = 3.0
Hz, 1H), 4.59 (m, 1H), 4.53 (t, J = 5.1 Hz, 1H), 4.33 (complex m,
1H), 3.76 (t, J = 4.4 Hz, 1H), 3.54 (s, 3H), 2.55 (broad s, 1H), 1.42 (s,
3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 132.0, 123.2,
110.3, 78.7, 76.2, 73.9, 66.3, 59.2, 27.6, 26.2; IR νmax 3453, 2987, 2935,
2900, 2831, 1646, 1457, 1381, 1372, 1231, 1109, 1077, 1041, 964, 868
cm−1; MS (EI, 70 eV) (EI, 70 eV) 280 and 278 (M+•, both 1%), 265
and 263 (74 and 76), 177 and 175 (13 and 15), 124 (28), 115 (100);
HRMS M+• calcd for C10H15
79BrO4 278.0154, found 278.0153.
4-Hydroxy-3-((3aR,6R,7R,7aR)-6-hydroxy-7-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (38). A magnetically stirred solution of compound 37 (116
mg, 0.42 mmol), boronate ester 27 (139 mg, 0.50 mmol), PdCl2dppf·
CH2Cl2 (25 mg, 0.03 mmol), and triethylamine (2 mL) in THF/water
(15 mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and
then heated under reﬂux for 3 h before being cooled, poured into
water (40 mL), and extracted with ethyl acetate (3 × 20 mL). The
combined organic phases were washed with brine (1 × 30 mL) and
then dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The ensuing light-yellow oil was subjected to ﬂash
chromatography (silica, 1:4 v/v ethyl acetate/hexane elution), and
concentration of the relevant fractions (Rf = 0.5 in 1:3 v/v ethyl
acetate/hexane) gave phenol 38 (80 mg, 55%) as a light-yellow oil;
[α]20D +7.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.82 (s,
1H), 7.39 (d, J = 1.5 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H), 6.10 (d, J = 3.3
Hz, 1H), 5.15 (d, J = 5.8 Hz, 1H), 4.64 (t, J = 5.5 Hz, 1H), 4.52 (m,
1H), 3.96 (s, 3H), 3.79 (t, J = 4.6 Hz, 1H), 3.59 (s, 3H), 2.65 (broad
d, J = 8.3 Hz, 1H), 1.46 (s, 3H), 1.40 (s, 3H) (signal due to hydroxyl
group proton not observed); 13C NMR (100 MHz, CDCl3) δ 190.8,
149.4, 147.9, 134.8, 132.0, 129.2, 128.3, 125.9, 109.8, 108.4, 79.7, 73.6,
73.3, 65.0, 59.1, 56.3, 27.6, 25.9; IR νmax 3368, 2985, 2936, 1681, 1588,
1456, 1432, 1297, 1149, 1120, 1071, 913, 873 cm−1; MS (EI, 70 eV)
m/z 350 (M+•, 4%), 274 (41), 115 (100); HRMS (EI, 70 eV) M+•
calcd for C18H22O7 350.1366, found 350.1370.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-me-
thoxy-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-yl)-
N,N-dimethylacetamide (39). A magnetically stirred solution of
compound 38 (60 mg, 0.17 mmol) in toluene (10 mL) was treated
with N,N-dimethylacetamide dimethyl acetal (126 μL, 0.87 mmol),
and the ensuing mixture was heated under reﬂux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was subjected to ﬂash chromatography (silica,
4:1 v/v ethyl acetate/hexane elution). Concentration of the
appropriate fractions (Rf = 0.3 in 5:1 v/v ethyl acetate/hexane) then
gave an ∼5:1 mixture of amide 39 and its β-epimer (30 mg, 40%
combined yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3)
δ (major epimer) 9.87 (s, 1H), 7.39−7.36 (complex m, 2H), 6.01 (d, J
= 4.6 Hz, 1H), 5.20 (d, J = 6.7 Hz, 1H), 4.41 (t, J = 6.7 Hz, 1H), 3.91
(s, 3H), 3.86 (s, 3H), 3.65−3.59 (complex m, 1H), 3.48 (s, 3H), 3.34
(m, 1H), 3.01 (s, 3H), 2.94 (s, 3H), 2.73 (dd, J = 15.9 and 5.1 Hz,
1H), 2.27 (dd, J = 15.9 and 9.4 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H);
13C NMR (100 MHz, CDCl3) δ (major epimer) 191.2, 171.3, 153.3,
152.1, 134.6, 133.9, 133.1, 132.3, 127.5, 109.6, 109.0, 79.7, 74.4, 73.6,
60.8, 58.1, 56.0, 37.3, 35.5, 33.7, 33.4, 27.9, 25.7; IR νmax 2982, 2932,
2857, 2831, 1691, 1646, 1578, 1458, 1421, 1384, 1240, 1142, 1034,
1002, 913, 863, 733 cm−1; MS (ESI, +ve) m/z 456 [(M + Na)+, 78%],
434 (100), 376 (21); HRMS (ESI, +ve) (M + Na)+ calcd for
C23H31NNaO7 456.1998, found 456.1996.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′,4-trimethoxy-
3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dimethylacetamide (8).
An ∼5:1 mixture of compound 39 and its β-epimer (16 mg, 0.04
mmol) was treated with acetic acid/water (10 mL of a 2:1 v/v
mixture), and the resulting solution was heated at 50 °C for 22 h and
then cooled to 22 °C and concentrated under reduced pressure.
Subjection of the residue thus obtained to ﬂash chromatography
(silica, 1:8:1 v/v methanol/ethyl acetate/hexane elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:9 v/v
methanol/ethyl acetate), an ∼6:1 mixture of compound 8 and its β-
epimer (10 mg, 69% combined yield) as a light-yellow oil; 1H NMR
(400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.39 (complex m,
2H), 5.99 (m, 1H), 4.71 (m, 1H), 4.01 (dd, J = 9.2 and 4.0 Hz, 1H),
3.92 (s, 3H), 3.87 (s, 3H), 3.80 (m, 1H), 3.50 (m, 1H), 3.46 (s, 3H),
3.02 (s, 3H), 2.95 (s, 3H), 2.85 (broad s, 1H), 2.74 (dd, J = 15.9 and
5.0 Hz, 1H), 2.20 (dd, J = 15.9 and 9.0 Hz, 1H) (signal due to a
hydroxyl group proton not observed); 13C NMR (CDCl3, 100 MHz) δ
(major epimer) 191.1, 171.4, 153.2, 151.7, 135.1, 134.9, 133.3, 132.4,
127.5, 109.8, 77.7, 69.0, 68.5, 61.0, 57.9, 56.0, 37.3, 35.6, 34.3, 32.4; IR
νmax 3395, 2957, 2935, 2828, 1688, 1627, 1463, 1420, 1387, 1260,
1128, 1105, 1089, 797 cm−1; MS (ESI, +ve) m/z 787 [(2M + H)+,
30%], 416 [(M + Na)+, 100], 394 (92), 376 (20); HRMS (ESI, +ve)
(M + Na)+ calcd for C20H27NNaO7 416.1685, found 416.1685.
4-Hydroxy-3-((3aR,6S,7R,7aR)-6-hydroxy-7-(methoxymethoxy)-
2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-me-
thoxybenzaldehyde (43). A magnetically stirred solution of
compound 429a (100 mg, 0.33 mmol), boronate ester 27 (108 mg,
0.39 mmol), PdCl2dppf·CH2Cl2 (19 mg, 0.02 mmol), and triethyl-
amine (3 mL) in THF/water (18 mL of a 9:1 v/v mixture) was purged
with nitrogen for 0.5 h and then heated under reﬂux for 2 h before
being cooled, poured into water (50 mL), and extracted with ethyl
acetate (3 × 30 mL). The combined organic phases were washed with
brine (1 × 40 mL) and then dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil
was subjected to ﬂash chromatography (silica, 1:1 v/v ethyl acetate/
hexane elution), and concentration of the relevant fractions (Rf = 0.3
in 1:3 v/v ethyl acetate/hexane) then gave phenol 43 (60 mg, 49%) as
a light-yellow oil; [α]20D +18.4 (c 0.9, CHCl3);
1H NMR (400 MHz,
CDCl3) δ 9.82 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.6 Hz,
1H), 7.07 (s, 1H), 6.16 (d, J = 2.2 Hz, 1H), 5.21 (d, J = 6.2 Hz, 1H),
4.90 (d, J = 6.8 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 4.36 (dd, J = 8.4 and
6.2 Hz, 1H), 4.27 (broad d, J = 8.1 Hz, 1H), 4.08 (d, J = 3.3 Hz, 1H),
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3.97 (s, 3H), 3.67 (m, 1H), 3.50 (s, 3H), 1.51 (s, 3H), 1.40 (s, 3H);
13C NMR (100 MHz, CDCl3) δ 190.8, 149.2, 147.6, 133.6, 131.8,
129.2, 128.5, 125.0, 110.5, 108.1, 98.0, 83.2, 76.5, 74.0, 69.4, 56.4, 55.9,
28.2, 26.0; IR νmax 3370, 2985, 2948, 2936, 1683, 1588, 1488, 1456,
1432, 1372, 1300, 1250, 1217, 1149, 1105, 1058, 1037, 996, 866, 732
cm−1; MS (EI, +ve) m/z 380 (M+•, 2%), 362 (12), 260 (59), 259 (54),
231 (100), 218 (48); HRMS (EI, +ve) M+• calcd for C19H24O8
380.1471, found 380.1478.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-(me-
thoxymethoxy)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]-
dioxol-5-yl)-N,N-dimethylacetamide (44). A magnetically stirred
solution of compound 43 (33 mg, 0.09 mmol) in toluene (10 mL)
was treated with N,N-dimethylacetamide dimethyl acetal (64 μL, 0.44
mmol), and the ensuing mixture was heated under reﬂux for 18 h. The
cooled reaction mixture was concentrated under reduced pressure, and
subjection of the ensuing residue to ﬂash chromatography (silica,
9.5:0.5 v/v ethyl acetate/hexane elution) gave, after concentration of
the appropriate fractions (Rf = 0.4 in ethyl acetate), an ∼3:1 mixture of
amide 44 and its β-epimer (14 mg, 35% combined yield) as a clear,
colorless oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s,
1H), 7.38 (m, 2H), 5.98 (d, J = 4.3 Hz, 1H), 5.22 (d, J = 6.0 Hz, 1H),
4.77 (m, 2H), 4.46 (t, J = 6.5 Hz, 1H), 4.04 (dd, J = 6.9 and 4.5 Hz,
1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.43 (s, 3H), 3.30 (m, 1H), 3.01 (s,
3H), 2.94 (s, 3H), 2.75 (dd, J = 15.8 and 5.1 Hz, 1H), 2.33 (dd, J =
15.8 and 9.5 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H); 13C NMR (mixture
of epimers) (100 MHz, CDCl3) δ 191.3, 171.2, 153.3, 152.0, 134.6,
134.0, 133.0, 132.3, 129.3, 127.7, 113.8, 109.6, 109.2, 100.0, 96.5, 76.2,
75.0, 74.1, 73.8, 60.8, 56.0, 55.7, 37.2, 35.5, 34.2, 33.8, 28.0, 27.9, 26.0;
IR νmax 2982, 2933, 2843, 1692, 1647, 1579, 1455, 1384, 1243, 1145,
1070, 1037, 918, 863 cm−1; MS (ESI, +ve) m/z 486 [(M + Na)+,
100%], 464 (3), 60 (10); HRMS (ESI, +ve) (M + Na)+ calcd for
C24H33NNaO8 486.2104, found 486.2105.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′-dimethoxy-4-(me-
thoxymethoxy)-3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dime-
thylacetamide (9). Compound 44 (8 mg, 0.02 mmol) was treated
with acetic acid/water (10 mL of a 2:1 v/v mixture), and the resulting
solution was heated at 50 °C for 22 h and then cooled and
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, 1:8:1 v/v methanol/ethyl
acetate/hexane elution) gave, after concentration of the appropriate
fractions (Rf = 0.4 in 1:9 v/v methanol/ethyl acetate), an ∼6.5:1
mixture of compound 9 and its β-epimer (5 mg, 69%) as a light-yellow
oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.38
(m, 2H), 5.97 (d, J = 4.4 Hz, 1H), 4.76−4.71 (complex m, 3H), 4.14
(dd, J = 9.1 and 5.7 Hz, 1H), 4.01 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H),
3.45 (s, 3H), 3.34 (broad s, 1H), 3.02 (s, 3H), 2.94 (s, 3H), 2.84 (dd, J
= 15.9 and 5.2 Hz, 1H), 2.25 (dd, J = 15.9 and 8.9 Hz, 1H) (signal due
to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ (major epimer) 191.2, 171.4, 153.2, 151.7, 135.2, 135.0,
133.3, 132.5, 127.4, 109.8, 97.5, 76.9, 69.2, 68.9, 61.0, 56.0(1), 55.9(6),
37.3, 35.8, 35.6, 33.2; IR νmax 3384, 2919, 2848, 1688, 1630, 1579,
1463, 1419, 1387, 1329, 1292, 1245, 1147, 1130, 1037, 917, 862 cm−1;
MS (ESI, +ve) m/z 446 [(M + Na)+, 68%], 424 (100); HRMS (ESI,
+ve) (M + Na)+ calcd for C21H29NNaO8 446.1791, found 446.1780.
Crystallographic Studies. Crystallographic Data. Compound
ent-2. C17H19NO5, M = 317.34, T = 150 K, orthorhombic, space group
P212121, Z = 4, a = 6.58612(5) Å, b = 9.28140(8) Å, c = 23.3001(2) Å;
V = 1424.30(2) Å3, Dx = 1.480 g cm
−3, 2794 unique data (2θmax =
144.6°), R = 0.027 [for 2725 reﬂections with I > 2.0σ(I)]; Rw = 0.072
(all data), S = 1.01.
Compound ent-15. C23H31NO7, M = 433.50, T = 150 K,
monoclinic, space group P21, Z = 2, a = 10.14845(9) Å, b =
10.61199(7) Å, c = 10.80864(10) Å; β = 106.8796(9)°; V =
1113.89(2) Å3, Dx = 1.292 g cm
−3, 3907 unique data (2θmax = 144.8°),
R = 0.026 [for 3843 reﬂections with I > 2.0σ(I)]; Rw = 0.067 (all
data), S = 1.03.
Compound 27. C14H19BO5, M = 278.11, T = 150 K, orthorhombic,
space group Pbam, Z = 8, a = 23.0535(6) Å, b = 18.2756(6) Å, c =
6.8183(2) Å; V = 2872.66(15) Å3, Dx = 1.286 g cm
−3, 3098 unique
data (2θmax = 145.2°), R = 0.084 [for 2982 reﬂections with I >
2.0σ(I)]; Rw = 0.191 (all data), S = 1.06.
Compound 32. C18H22O7, M = 359.38, T = 150 K, monoclinic,
space group P21, Z = 4, a = 7.3153(1) Å, b = 31.4358(3) Å, c =
7.8245(1) Å; β = 94.8743(8)°; V = 1792.83(4) Å3, Dx = 1.331 g cm
−3,
7018 unique data (2θmax = 145°), R = 0.030 [for 6919 reﬂections with
I > 2.0σ(I)]; Rw = 0.080 (all data), S = 0.99.
Structure Determination. Diﬀraction images for compounds ent-2,
ent-15, 27, and 32 were all measured on a diﬀractometer (Mo Kα,
mirror monochromator, λ = 0.71073 Å or, for 32, Cu Kα mirror
monochromator, λ = 1.54184 Å) ﬁtted with an area detector, and the
data were extracted using the DENZO/Scalepack package.43 The
structure solutions for all four compounds were solved by direct
methods (SIR92)44 and then reﬁned using the CRYSTALS program
package.45 Atomic coordinates, bond lengths and angles, and
displacement parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC nos. 1517512, 1517513,
1517514 and 1517515). These data can be obtained free-of-charge
via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@
ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: + 44
1223 336033.
AChE Inhibition Testing. The galanthamine derivatives/ana-
logues described above were tested for inhibition against AChE as
described by Sangnoi et al.46 Thus, the compounds were dissolved in
DMSO and made up to concentrations ranging from 5 mM to 3.05
μM by serial dilution with DMSO. Then, 2.5 μL of a solution of each
compound was added to a solution of 5,5′-dithiobis(2-nitrobenzoic
acid) (125 μL of a 1.5 mM aqueous solution), tris(hydroxymethyl)-
aminomethane buﬀer (72.5 μL of a 15 mM solution at pH 8.0), and
acetylthiocholine iodide (25 μL of a 150 μM aqueous solution) in
water. Enzyme activity was followed after the addition of AChE (25 μL
of 0.03 μM solution of Electrophorus electricus, Type V−S, EC 3.1.1.7)
by measuring the absorption at 412 nm using a microplate
spectrophotometer. Assays were repeated in triplicate, and the
hydrolysis rate was calculated during the data from the absorptions
observed over the ﬁrst 2 min. Standard commercially available graphic
software was used to calculate the tabulated IC50 values.
Molecular Docking Studies. The three-dimensional coordinates
of each compound were generated with the PRODRG server (http://
davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg).47 Galanthamine and the
above-mentioned derivatives/analogues were docked into the structure
of human acetylcholine esterase (4EY6) using Autodock Vina v1.1.2
after removal of galanthamine from the active site gorge.48
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J.; Lan, P.; Ma, X.; Matousǒva,́ E.; Nugent, J. Strategies and Tactics in
Organic Synthesis 2015, 11, 29. (f) Rinner, U.; Dank, C.; Hudlicky, T.
In Targets in Heterocyclic Systems − Chemistry and Properties; Attanasi,
O. A., Merino, P., Spinelli, D., Eds., 2017; Vol 20, pp 286−318;.
(g) Fraser, M. D.; Davies, J. R. T.; Chang, X. J. Alzheimer's Dis. 2017,
55, 1321.
(2) For a useful point-of-entry into the literature on this topic, see:
Gallagher, R.; Chebib, M.; Balle, T.; McLeod, M. D. Aust. J. Chem.
2015, 68, 1834.
(3) Kimura, H.; Kawai, T.; Hamashima, Y.; Kawashima, H.; Miura,
K.; Nakaya, Y.; Hirasawa, M.; Arimitsu, K.; Kajimoto, T.; Ohmomo, Y.;
Ono, M.; Node, M.; Saji, H. Bioorg. Med. Chem. 2014, 22, 285.
(4) Barton, D. H. R.; Kirby, G. W. J. Chem. Soc. 1962, 806, 1.
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Section 2. Identification of new inhibitors - Marinoquinolines 
5.6. Introduction 
5.6.1. Marinoquinolines 
AChE is a drug development target for treating symptoms of AD, as a deficit in Ach is a 
neurochemical characteristic of patients affected by AD (341, 343, 347, 348). AChE 
inhibitors prevent the hydrolysis of Ach and compensate for the Ach deficiency in the 
synapse (341, 343, 347, 348). Currently, three drugs have been approved for the treatment 
of AD (344, 360). The identification of novel natural products is of great importance for 
new drugs to combat diseases worldwide (399). Therefore, for treating AD, it is crucial to 
search for new effective compounds that inhibit AChE (399). 
The marine gliding bacterium, Rapidithrix thailandica, has been studied for novel 
secondary metabolites. One compound isolated was marinoquinoline A (MQ-A), which 
contains a rare 3H-pyrrolo[2,3-c]quinolone system (Figure 5.8) (400). This molecule was 
shown to be a strong inhibitor of AChE (IC50 = 4.9 µM), however, it is unknown how the 
compound interacts with AChE (400–402). MQ-A has been proposed to interact with 
AChE by a π-π stacking interaction with Trp84 found in the active site. This is similar to 
the drug, tacrine that shows high structural similarity to MQ-A (333, 349). 
Five other derivatives of MQ-A have also been isolated from the bacterium, Ohtaekwangia 
kribbensis, and have been labelled marinoquinolines B–F (MQ-B-F) (Figure 5.8) (403). 
The compounds have a similar structural motif but with a different ‘R’ group (Figure 5.8). 
The five compounds have strong activity against the resistant malaria parasite, Plasmodium 
falciparum and also have cytotoxicity against cancer cell lines (403). The compounds, MQ-
B-F, have not been tested against AChE, therefore, it is important to investigate if the 
molecules are effective inhibitors of AChE similar to MQ-A (403). 
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Figure 5.8. The identified marinoquinolines from the species Rapidithrix thailandica and 
Ohtaekwangia kribbensis (400, 403). Red shows the variation in the ‘R’ group between the 
compounds. 
Three other compounds (MQ-F Isomer, MQ-H and lactame) have been synthesised by 
Martin Banwell’s research group at the Research School of Chemistry, The Australian 
National University, Australia. The compounds were designed to investigate the binding of 
the marinoquinolines (MQ) to AChE (Figure 5.9). Another compound of interest is 
Aplidiopsamine A (AAA). This compound is an antiplasmodial alkaloid that has been 
isolated from the temperate Australian ascidian (Aplidiopsis confluata). Similar to 
compounds MQ-B-F, AAA shows inhibition to resistant strains of P. falciparum, with 
minimal toxicity to human cells. However, the inhibition to AChE has not been 
characterized for AAA (404, 405).  
Figure 5.9. Synthesised MQs from Dr. Martin Banwell’s research group to study interaction of 
MQs with AChE (404). 
The aim of the project was to understand the interaction between the MQs and AChE. 
Currently, it is unknown if the identified MQ compounds (MQ-B-F) interact with AChE 
similar to MQ-A. Molecular docking simulations in combination with inhibition assays 
were performed to further elucidate the interaction of the compounds with AChE and for 
the potential development of compounds based on the results. 
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5.7. Materials and Methods 
 
5.7.1. Synthesis of MQ derivatives 
The total synthesis of the MQ compounds was done by members of Dr. Martin Banwell’s 
research group (Australian National University, Research School of Chemistry, Australia) 
5.7.2. AChE Inhibition Assay 
The compounds were tested for inhibition against AChE as described previously by 
Sangnoi et al. (400, 406). Compounds were dissolved in DMSO and made up to 
concentrations ranging from 5 mM to 3.05 µM by half dilutions. 2.5 µl of each compound 
was added to a solution consisting of 125 µl 5,5’-dithiobis-(2-nitrobenzoic acid) (1.5 mM), 
72.5 µl Tris buffer (15 mM, pH 8.0) and 25 µl acetylthiocholine iodide (150 µM). Enzyme 
activity was followed by the addition of 25 µl AChE at 0.03 µM (Electrophorus electricus, 
Type V-S, EC 3.1.1.7) measuring at 412 nm using the Epoch microplate spectrophotometer 
(BioTek). The assays were repeated in triplicates and the rate was calculated using the first 
two minutes. Prism v6.0 (GraphPad Software, USA.) was used to calculate the IC50. 
5.7.3. Molecular Docking Studies 
The three-dimensional coordinates of each compound were generated with the PRODRG 
server (http://davapc1.bioch.dundee.ac. uk/cgi-bin/prodrg) (407). The MQs and AAA were 
docked into the structure of human AChE (4BDT) using autodock Vina v1.1.2 with tacrine 
removed from the active site (408). 
5.8. Results and Discussion 
5.8.1. Inhibition studies of MQ 
After testing the 10 MQs compounds against AChE (Figures 5.8, 5.9), it was observed that 
six of the compounds inhibited the enzyme AChE with IC50’s between 4.7 µM and 42.7 
µM (Table 5.2). Three compounds (MQ-C, MQ-D and MQ-H) were not as effective 
inhibitors of AChE compared to MQ-A. There was no statistically significant difference in 
inhibition for MQ-B (4.7 µM) and MQ-E (5.8 µM) compared to MQ-A (5.5 µM). Four 
compounds (MQ-F, MQ-F isomer, lactame, AAA) did not show any inhibition towards 
AChE at the highest concentration tested. 
The results from the inhibition assays indicate the MQ structures containing an extended 
‘R’ group chain or a bulky ‘R’ group (MQ-C, MQ-D, MQ-F, MQ-F Isomer, AAA) are poor 
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inhibitors of AChE. This suggests there is little room in the structure of AChE for the ‘R’ 
group to occupy when the group is bulky or when the ‘R’ group carbon chain is extended 
(C0 to C1). MQ-E with a bulky ‘R’ group has similar inhibition to MQ-A, which contradicts 
the trend, however, the carbon chain making up the ‘R’ group is not increased in length 
(C0) as in MQ-C and MQ-D (C1 in length). The introduction of hydrophilic nature into the 
MQ structure (MQ-D) results in poor binding. This suggests the pocket in AChE where the 
‘R’ group interacts with is generally hydrophobic in nature. The MQ-F isomer compound 
has the ‘R’ group extending from a different site in the molecule and has no detectable 
inhibition towards AChE. This indicates the ‘R’ group extends into a region of the AChE 
structure that is limited in space, therefore, the inhibitor cannot bind similar to the other 
structures. Removal of the ‘R’ group (MQ-H) removes a large proportion of inhibition 
towards AChE (8-fold) and shows the ‘R’ group interaction is important for inhibition. 
Table 5.2. IC50 results from the 10 MQs tested against AChE along with the predicted docking 
binding energy from autodock Vina. 
Compound IC50 (µM) Docking Binding Energy 
(kcal/mol) with 4BDT 
MQ-A 5.5 ± 0.8 -8.8 
MQ-B 4.7 ± 1.2 -9.6 
MQ-C 8.1 ± 1.5 -10.5 
MQ-D 31.8 ± 3.1 -11.0 
MQ-E 5.8 ± 0.8 -12.1 
MQ-F IC50 > 31.25 (No inhibition 
observed at solubility limit) 
-11.9 
MQ-F 
Isomer 
IC50 > 125 (No inhibition 
observed at solubility limit) 
-10.9 
MQ-H 42.7 ± 3.4 -8.3 
lactame IC50 > 125 (No inhibition 
observed at solubility limit) 
-9.1 
AAA IC50 > 72.5 (No inhibition 
observed at solubility limit) 
-10.2 
 
5.8.2. Docking studies of MQ 
Molecular docking simulations were performed with autodock Vina to elucidate the 
binding site of the MQ derivatives in the structure of AChE and for future direction in 
designing stronger binding inhibitors. Docking simulations of MQ-A were previously done 
in 2014 by Stoddard et al (349). This reported the compound, MQ-A, interacted with AChE 
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by π-π stacking interactions with Trp84 in the choline binding site (349). This residue is 
important in AChE to interact with the positive charge character of the Ach substrate (333).  
Molecular docking simulations showed all 10 compounds binding into the active site of 
AChE. Nine compounds interact with Trp84 forming the π-π stacking interaction in all low-
energy states (Table 5.2). The three ring structure is stacked against the indole ring of 
Trp84 and sandwiched between Phe330, providing a strong interaction (Figure 5.10). The 
MQ derivative, lactame, does not appear to stack with Trp84 or Phe330 in the docking 
studies. 
 
Figure 5.10. MQ-B docked into the structure of human acetylcholinesterase (4BDT) showing 
the main interaction between Trp84 and Phe330. The three different orientations of the ‘R’ 
group are shown in panels A,B and C. 
Similar to tacrine, the nitrogen of the indole ring hydrogen bonds to the main chain carbonyl 
oxygen of His440 (333). Without water molecules in the docking simulations, it is unknown 
if a hydrogen bond is formed with the amino nitrogen of the MQs and the water molecule 
that is observed in the structure of tacrine bound to AChE.  
From the molecular docking simulations, the ‘R’ group can orient into two pockets while 
retaining the His440 hydrogen bond. One pocket (A) is lined with Gly80, Trp432, Ile439 
and Tyr442. The other potential binding pocket (B) is towards Tyr130, Ile444 and Ser200. 
A third pocket (C) that is commonly observed in the docking experiments as the lowest 
energy position is towards Asp72, Asn85 and Ser122. However, binding into this pocket, 
the hydrogen bond between His440 and MQ is lost (Figure 5.10). It is difficult to 
rationalize the correct orientation of the ‘R’ group from the docking simulations. 
Pocket C is unlikely to be the correct pocket for the ‘R’ group to interact with. In the tacrine 
structure, this side of the pocket is where a hydrogen bonding network is formed (Figure 
5.11) (333). The ‘R’ group in this direction would disrupt this, however, the compound 
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could nullify the loss of the hydrogen bonding interaction with new interactions involving 
the ‘R’ group. 
 
Figure 5.11. Tacrine co-crystallised into the structure of Pacific electric ray AChE (1ACJ) 
showing the main interaction between Trp84, His440 and tacrine (333). 
Pocket A and B are similar in residue makeup but the increase in the hydrophobic nature 
of pocket A would match the results with compounds MQ-C and MQ-D. The comparison 
between the compounds suggests an increase in hydrophobic character produces a tighter 
binding inhibitor. Future experiments with soaking the compounds into AChE would be 
required to elucidate the binding site of the MQs in full detail. 
The ‘R’ group orientating into pocket A could explain why MQ-F and AAA do not bind to 
AChE (at the concentrations measured). This is due to the narrow space of pocket A. The 
reduced flexibility with MQ-F and the bulkiness of AAA would prevent the correct 
orientation of the main ring for interaction with Trp84 and His440, which will result in poor 
binding.  
This is further supported by the difference between MQ-E and MQ-F. MQ-E binds at 
similar affinity to MQ-A, but MQ-F does not bind to AChE at the concentrations measured, 
despite similar structures of the compounds. This suggests the increase in length in the MQ-
F ‘R’ group compared to MQ-E (C0-C1) or the decrease in the hydrophobicity character 
does not allow for the ‘R’ group to favourably orientate into pocket A, resulting in no 
observed inhibition. 
It is difficult to rationalize why MQ-E binds at similar affinity to MQ-A given the large ‘R’ 
group. It is possible the compound has additional interactions with residues in pocket A, 
however, this is not observed in the docking simulations. Lactame has a carbonyl in the 
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main ring structure and in the docking experiments, the compound binds into a similar site 
as the MQs. The carbonyl in this compound distorts the ring resulting in the disruption of 
the key π-π stacking interactions. The MQ-F Isomer compound with the ‘R’ group at an 
alternative position does not bind to AChE at the concentrations measured. The large ‘R’ 
group orientates into an unfavourable position in the structure, which will result in poor 
binding. 
The values of the binding energies varied significantly and did not match the experimental 
data. Four compounds (MQ-F, MQ-F Isomer, lactame, AAA) that showed no inhibition in 
the assays, showed a significantly tighter binding energy than MQ-A in the molecular 
docking studies. This falsely indicates inhibition by the compounds and shows the false 
positives from the docking results (binding into pocket C). This highlights the importance 
of experimental data over molecular docking studies in designing derivatives. 
MQ-A and tacrine are similar in structure and binding affinity that could suggest MQ-A 
can be used as a drug against AD. However, as the structures are similar in aromatic nature, 
this could cause issues with side effects. The hepatotoxicity of tacrine resulted in the 
discontinued use of the drug, which could be a similar issue for MQ-A (369, 370). MQ-A 
would need to be extensively tested for selectivity with BChE and other enzymes to identify 
if MQ-A behaves similarly to tacrine in being a non-selective cholinesterase inhibitor and 
having similar affinity for both isoforms of AChE. The compound may not be suitable for 
treatment if the selectivity is similar to tacrine. 
The testing of the inhibitors designed to target human AChE for both projects involved 
AChE from Electrophorus electricus. The findings for the human-based inhibitors on E. 
electricus AChE can be applied to human AChE due to the similarity in structure. The 
RMSD of the two proteins is 0.63, highlighting the close similarity of the proteins, with no 
changes in the residues making up the active site and the PAS. It should be noted that as it 
was observed in chapter four, subtle differences in structure can have a major effect, 
therefore, the IC50 calculated for E. electricus AChE may not be the same for human AChE. 
There may be potential differences in inhibitor sensitivity between AChE’s from different 
species, however, differences between the AChE structures are negligible between species, 
suggesting to not affect IC50’s significantly (409).  
 
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Conclusions and Future 
Work 
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6.1. Conclusions 
 
In this thesis, four chapters of work are described that mainly focussed on dipteran 
carboxylesterases. Chapter 2 investigated the higher-order oligomeric species present in the 
thermostable protein LcαE7-4a after a directed evolution experiment towards greater 
thermostability. This work highlights the importance of oligomeric species during 
evolution for maintaining protein stability. The chapter provides a significant case study 
for the investigation of stability associated with oligomerisation and advances our 
understanding of the evolution of new oligomers through point mutations. It also reinforces 
the nature of structure/activity/stability trade-offs, which have been well illustrated 
throughout enzyme evolution and that oligomerisation impacts evolution, and in this case, 
was not selectively neutral. 
Chapter 3 describes the structure determination and kinetic assays of Esterase-6 from D. 
melanogaster, an enzyme important for reproductive success in Drosophila species. This 
section shows the importance of new insect carboxylesterase structures to understand 
protein function, as homology models of EST6 were not informative with regard to the 
enzyme’s active site. The structure is the first of an odorant degrading enzyme which is 
able to provide a probable function of esterase-6. This chapter also shows the enzyme is 
not directly involved in the degradation of long chain pheromones, which had been strongly 
believed. 
Chapter 4 is focussed on the characterization of several orthologs from Diptera to 
investigate the ability of the enzymes to evolve through the incorporation of a point 
mutation to catalyse the hydrolysis of organophosphates. This work shows a large variation 
in organophosphate binding and turnover, despite the similar sequence similarity and 
structure between the proteins. It suggests neutral drift plays an important role for the 
evolution of qualitative resistance in Diptera and emphasises that there are limited 
evolutionary routes from which qualitative resistance to organophosphates can evolve.  
Chapter 5 describes the testing of inhibitors in targeting AChE. This chapter demonstrates 
the importance of docking simulations in combination with rational design for the 
development of new drugs. This chapter also describes the pitfalls with molecular docking 
simulations giving false positive results.  
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Overall, this body of work has answered fundamental questions on insect CBEs and also 
expanded the knowledge on this superfamily.  EST6 gives a small insight into the structural 
diversity within insect CBEs, as this protein is completely unrelated to the functions of the 
other solved CBE proteins. This sheds light on the potential structural differences 
(alternative active site entries) between the 14 clades and the difficulties in predicting 
function and structure from homology models alone that have been used previously for 
insect CBEs.  
The versatility of insect CBEs to break down multiple substrates has been highlighted in 
chapters two, three and four, especially with the enzyme, EST6. EST6 is able to hydrolyse 
multiple functionally diverse esters from small short-chain esters (methyl propionate) to 
larger complex esters (E2-hexenyl acetate). This strongly relates to animal CBEs, where 
the human liver CBE is important to hydrolyse and biotransform multiple functionally 
diverse ester substrates.  
Chapter four highlights how malleable the active sites of CBEs are with small sequences 
changes affecting the catalytic machinery resulting in the ability to break down new 
substrates. A single point mutation (Gly137Asp) is able to convert the function of a CBE 
towards a functionally different substrate, completing changing the kinetics of the CBE 
from native function. This is observed throughout the multiple CBEs tested and in the CBE 
literature showcasing the ability of CBEs to adapt to new selection pressures. The CBE 
active site makeup and subtle structural differences between CBEs have also shown to be 
vital in this thesis (chapter four) for a new function to be favourable. The minor active site 
differences between closely related CBEs shown in chapter four add to the complications 
in predicting insecticide resistance and protein evolution. 
Subtle structural differences in CBEs are further highlighted in chapter two and five, where 
a few mutations can change the oligomerisation state of an insect CBE or for new inhibitors 
to be effective. This shows the plasticity and tolerance of CBEs to mutations with the ever 
going ability to adapt to new roles and diverse functions that are found throughout past 
work on insects proteins. 
The work has provided a significant contribution to fields of structural biology with the 
fourth insect CBE structure and answered key questions to the function of an important 
CBE involved in odorant degradation. Contributions have also been made to protein 
evolution with a greater understanding for the formation of oligomeric species and evidence 
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has been provided for the limitations for the evolution of new function involved with 
insecticide resistance. Additionally, this thesis also provides the framework to investigate 
new questions on the evolution of insecticide resistance and to further understand structural 
differences throughout the CBE family. 
 
6.2. Future Work 
 
6.2.1. Chapter 2.  
Future experiments to investigate the evolution of quaternary structure in insect CBEs 
should focus on increasing the level of the higher order oligomeric species. The ratio 
between the oligomeric species is approximately 60:30:10 between the monomer, dimer 
and tetramer species. Directed evolution experiments towards thermostability could be 
continued to further amplify the relative amounts of the higher order species. This could be 
useful in a number of ways, as the oligomeric species are more stable, the tetramer/dimer 
species could have increase longevity in vivo if LcαE7 is used as a bio-scavenger (55). This 
could also lead to future structural studies using crystallization to elucidate the interface of 
the tetramer and to confirm the dimer interface. Cross linking experiments could also be 
used to further support the results. 
The ratio of dimer to monomer could also be increased using the protein MdαE7. This 
protein has been identified in this work (Chapter 4) to elute from SEC as a dimer species. 
Mapping a homology model of this protein to the proposed dimer interface of LcαE7 
generated from the PISA server could locate surface mutations located in the interface to 
result in LcαE7 being essentially a dimer.  
6.2.2. Chapter 3.  
With the structure of EST6 being solved in this thesis, there are a number of additional 
pathways available to extend this project. There are numerous mutations that have been 
found in wild-type EST6 including the two identified allozymes ‘Fast’ and ‘Slow’ EST6 
(410). These allozymes have been suggested to have major differences in stability/activity 
and response to inhibitors (410). Mapping the mutations found in the EST6 population to 
the structure and recombinant testing of the mutations could result in a further 
understanding of the natural mutations and allozymes. As the recombinant characterization 
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of EST6 has not been performed in great detail due to the low expression, this could be an 
opportunity to characterize the allozymes with high purity enzyme. Preliminarily work 
suggests that the ‘fast’ and ‘slow’ mutations are located at positions remote from the active 
site. 
The structure of EST6 could be used to understand the other member of the β-cluster, EST7. 
This protein has been suggested to be a “dying” enzyme, with many non-catalytic alleles 
of this protein being observed in D. melanogaster species (152). By recombinant 
expression of the enzyme or generating homology models, further analysis could reveal 
possible reasons into why the enzyme is not under strong evolutionary selective pressure. 
The substrate range and stability could also give possible suggestions into the enzyme’s 
function. This technique could also be adapted to other members of the β-cluster in other 
species to understand the microevolution that has been observed. 
The contributions of the disulfide bonds in EST6 to protein folding have been shown to be 
essential for the recombinant soluble expression of EST6. The structure of EST6 shows a 
high degree of overlap with LcαE7, yet in EST6, a disulfide bond is formed between Cys65 
and Cys84 while at the analogous positions in LcαE7 (Ser95 and Cys111), there is no 
disulfide bond. At position 95 in LcαE7, a cysteine is replaced with a serine. To introduce 
additional stability to LcαE7, a disulfide bond could possibly be introduced into LcαE7 at 
this position. Likewise, the effect of the disulfide bonds on stability/activity of EST6 could 
be studied by mutation of one of these cysteine residues to serine. 
6.2.3. Chapter 4.  
To further understand the structural differences between the proteins, crystal structures 
could be solved of the orthologs. In combination with inhibitor soaking, this could further 
elucidate the differences between the proteins and could explain the observed changes with 
OP binding and activity between the orthologs. To also understand the differences in OP 
binding, different OP insecticides could be assayed against the orthologs. This could result 
in OP affinity differences between the orthologs that could give more insight into the 
proteins and understand if the orthologs can be involved in the qualitative resistance 
mechanism. 
There is a large variation in the oligomeric state between the orthologs, despite the close 
sequence identity. Initial work has estimated the oligomeric state of the orthologs, but this 
could be investigated by detailed characterisation of the oligomeric species including 
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stability and activity data to coincide with the work in Chapter 2. With one of the orthologs 
(CsαE7) there appears to be a large increase in OP turnover with the introduction of 
Gly137Asp mutation. Sequencing of C. stygia flies in the wild could investigate if the 
protein has the Gly137Asp mutation and could be another example of insecticide resistance.  
6.2.4. Chapter 5.  
No derivatives of tacrine have been observed with modifications at the ‘R’ group position 
of MQ. Generally, groups have focussed on extending from the amine group of tacrine to 
reach the PAS site of AChE for tighter binding and better inhibition (411, 412). Future 
work could focus on tacrine derivatives that extend out from the ‘R’ position of MQ-A. 
Similarly, tighter binding MQs could be designed with the extension from the nitrogen to 
reach the PAS of AChE. 
6.2.5. The Future of Carboxylesterase Research.  
Overall, there are still many questions this thesis has not answered, and there are more 
research areas involving CBEs to pursue. Currently, four of the fourteen insect CBE clades 
have been structurally identified. Since all four CBEs are structurally unique, it is vital to 
understand structural features that make up each member of a clade to find out the structural 
diversity in this superfamily. Furthermore, there are two clades with unknown function and 
should be studied in more detail. This is important to understand the functions of the 
unknown clades to know the variety of roles CBEs plays in insect species. Future genomic 
projects and sequencing information will also help to comprehend the fourteen clades and 
could further separate the CBEs to better characterize this superfamily. This could not only 
help to understand the evolution of CBEs, but can identify potential new targets for 
insecticides. 
Juvenile hormone esterase is separated in the clades between Lepidopteran and Diptera. 
Studying the functional and structural differences between the two juvenile hormone 
esterases are important to know the differences in reproduction and evolution between the 
two orders and why they are separated in phylogenetic studies. 
 
There is also no current understanding of what determines a range of substrates for a CBE. 
Further testing the substrate specificity for several CBEs could help to find out the full 
range of esters that can be turned over and structural features that determine a substrate 
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range for a CBE. This could play a role for biocatalysts projects involving 
transesterification or in developing CBEs for detoxifying certain compounds. 
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Appendices 
 
Appendix A. Supporting Information for the Research Article in Chapter 2. 
 
 
 
SI Fig. 1. The effect of viscosity on oligomerization. Size exclusion chromatograms of LcαE7-4a 
and LcαE7-4a WT in the presence of 10% glycerol show that for LcαE7-4a, the tetrameric and 
dimeric fractions (peak heights 15 mAU and 35 AU) comprise approximately 50% of the total 
protein (monomer peak height 51 mAU). In contrast, for LcαE7-4a WT, the higher-molecular-
weight species (tetramer and dimer peak heights 6 mAU and 15 mAU versus 50 for monomer) 
comprise less than 30% of the total protein. 
 
 
SI Fig. 2. (a) Re-equilibration of monomeric fraction (single 5 mL fraction from middle of 
monomeric peak) into dimeric and tetrameric peaks after 5 h at 4 °C. (b) Re-equilibration of 
tetrameric fraction (single 5 mL fraction from middle of tetrameric peak) into dimeric and 
monomeric species after 24 h at 4 °C. 
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SI Fig. 3. Activity decay over time at 46 °C for monomeric and tetrameric species of LcαE7-4a. 
Aliquots were taken over a series of time points when tetrameric and monomeric species were 
incubated at 46 °C. Specific activity was measured using 4-nitrophenyl butyrate, 200 mM NaCl 
and 20 mM HEPES (pH 7.5). 
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SI Fig. 4. Thermally induced unfolding of LcαE7 and the LcαE7-4a oligomeric species. Ellipticity 
as a function of temperature was monitored at 208 nm and curves were fit by non-linear 
regression with Eq. (1). For theLcαE7-4a monomer and dimer data, a three-state model was used 
to fit the data. Spectra of the protein before denaturation are shown next to the denaturation 
curves. (a) LcαE7. (b) LcαE7-4a monomer. (c)LcαE7-4a dimer. (d) LcαE7-4a tetramer. 
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SI Fig. 5. DSF analysis of pre-SEC samples of LcαE7 (2 mg/mL). (a) WT LcαE7 undergoes a 
single transition, with an apparent melting point of 40.6 ± 0.6 °C, whereas LcαE7-4a (b) is 
composed of one species with an apparent melting point of 44.8 ± 0.5 °C and a second species 
with an apparent melting point of 50.9 ± 0.9 °C. 
 
 
SI Fig. 6. DSF analysis of monomeric and tetrameric fractions of LcαE7-4a. (a) Tetrameric fraction 
of LcαE7-4a at 0.3 mg/mL shows a single apparent melting point at 52.8 °C, whereas monomeric 
fraction of LcαE7-4a (b) at 0.3 mg/mL shows a single transition at 47.9 °C. After concentration to 
3 mg/mL, some re-equilibration occurred and both tetrameric and monomeric samples (c and d) 
showed two transitions, one corresponding to monomer (~ 47 °C) and the other corresponding to 
tetramer (~ 53 °C). 
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SI Fig. 7. Thermostability effects of the A285S and F478L mutations. Both mutations were 
introduced in to LcαE7-4a. Thermostability was estimated by DSF. (a) Monomeric fraction 
of LcαE7-4a (A285S) at 0.3 mg/mL shows a single apparent melting point at 47.6 ± 1.3 °C, within 
error of LcαE7-4a (47.9 ± 0.2 °C). (b) Monomeric fraction of LcαE7-4a (F478L) at 0.3 mg/mL 
shows a two apparent melting points: a major species at 48.2 ± 0.9 °C, within error of LcαE7-4a 
(47.9 ± 0.2 °C), and a minor species at 51.2 ± 0.2 °C, which was not higher than the higher-order 
species in LcαE7-4a (52.5 ± 0.3 °C). Thus, A285S and F478L are both likely to be selectively 
neutral in terms of thermostability to LcαE7. 
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SI Fig. 8. Multiple sequence alignment of LcαE7 with αE7 genes from other fly species (Calliphora 
stygia,Cochliomyia hominivorax, Musca domestica, and Haematobia irritans) reveals significant 
variation at the positions that were mutated during the directed evolution experiment. Specifically, 
the I419F, A472T, and I505T sequence differences already exist across the five species compared. 
SI Table 1. Calculated Transition Temperature (TT50) for the LcαE7 proteins as measured by DSF. 
The 3 mg/mL sampled were concentrated prior to analysis.  
Appendix B. Supporting Information for the Research Article in Chapter 3. 
Protein Concentration TT50 (° C) 
LcαE7-4a Monomer 0.3 mg/mL 47.92 ± 0.2  
3mg/mL 46.0 ± 0.9, 52.5 ± 0.3 
LcαE7-4a Tetramer 0.3 mg/mL 52.8 ± 0.3 
3mg/mL 48.0 ± 0.4, 53.4 ± 0.7 
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Substrate Solvent conditions
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M.s-1
KM 
μM 
kcat/KM
M-1 s-1 × 103
4-Nitrophenyl acetate 5% ethanol 105 ± 2 269 ± 18 392 
5% acetonitrile 36 ± 1 19 ± 3 1828 
0.5% acetonitrile 49 ± 0 23 ± 1 2111 
5% dimethyl sulfoxide 45 ± 0 14 ± 1 3253 
2-Naphthyl acetate 5% ethanol 135 ± 2 121 ± 6 1118 
Supplementary Figure S1. EST6 kinetic data towards the model substrates 4-nitrophenyl acetate and 2-naphthyl acetate. (a) 
EST6 Michaelis-Menten plot for 4-nitrophenyl acetate under various solvent conditions. (b) EST6 Michaelis-Menten plot for 2-
naphthyl acetate. (c) EST6 kinetic parameters. 
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Amino acid position
Supplementary Figure S2. Sample of EST6 replacement changes observed over six rounds of directed evolution. Variable amino 
acid positions and the status of EST6 Wt are indicated along the top with amino acids numbered from the first residue of the mature 
EST6 protein as it would be processed in its native form within the fly.  Sequence variation in the six rounds of random mutagenesis 
and directed evolution are indicated below where a dot “.” indicates no change. Variant #6.1, which was used for the 
crystallography, is simply labelled EST6-1 in the main text. 
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Supplementary Figure S3. Comparison of the catalytic activities of wildtype and evolved EST6 against 11 substrates. Specific 
activities at 200 µM substrate of wildtype EST6 compared to the evolved EST6-1. 
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Supplementary Figure S4. Expression and purification of EST6-1. (a) Expression gel of whole cell (W) and soluble (S) EST6WT 
and EST6-1 in the BL21 expression strain and the Origami B expression strain with soluble EST6-1 marked with an arrow. M, 
molecular markers with sizes indicated in kDa. (b) Size exclusion chromatogram of EST6-1 displaying the predominant monomer 
species used for crystallization. 
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Supplementary Figure S5. Docking of representative substrates in EST6. A series of representative substrates/acyl intermediates 
were covalently docked into EST6: (a) pentyl butyrate, (b) pentyl pentanoate, (c) hexyl acetate, (d) octyl acetate, (e) octyl 
propionate, (f) geranyl acetate, (g) phenethyl acetate, (h) phenyl acetate.  
170
M Est6+ Est6°  Est6+ Est6° 
170—
130—
95—
72—
55—
43—
34—
26—
Supplementary Figure S6. Western blot and immunohistochemistry with anti-EST6 antibody showing its specificity for EST6. (a) 
Protein staining of head extracts from wildtype (Est6+) and Est6 null mutant (Est6°) flies separated by SDS –PAGE. M, molecular 
markers with sizes indicated in kDa. (b) Same samples showing the location of the bound anti-EST6 antibody. (a) Section from 
third antennal segment of Est6 null mutant showing autofluorescence of the cuticle. (b) DAPI staining of the nuclei. (c) EST6 
localization on the same section: no labelling with anti-EST6 antibody was detected. (d) Merge image of (a), (b) and (c).
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Supplementary Figure S7. EST6 and elav expression in the third antennal segment. (a) Membrane-tethered GFP expressed with 
the elav promoter (elavLexA/LexAOP-mCD8::GFP transgenic flies). (b) EST6 protein localization in the same section. (c) DAPI 
staining of the nuclei. (d) Merge image of (a), (b) and (c): Est-6 and elav are not expressed in the same cells. (e) Higher 
magnifications of (c): EST6 protein surrounds the elav+ dendrites.
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Supplementary Figure S8. EST6 and Lush expression in the third antennal segment, transversal sections. (a) Membrane-tethered 
RFP expressed with the lush promoter (lushGal4/UAS-mCD8::RFP transgenic flies). (b) EST6 protein localization in the same 
section. Arrow indicate sensillum. (c) Merge image of (a) and (b): EST6 and lush are not expressed in the same cells. (d) Higher 
magnifications of (c): EST6 protein is secreted in the sensillum lymph. 
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Supplementary Table S1. EST6 kinetic parameters. 
kcat/KMEst‡ Ki 
Substrate M-1.s-1 × 103 µM 
Straight chain esters 
Methyl decanoate 22 ± 5
Methyl myristate 15 ± 8
Propyl acetate 226 ± 30
Propyl propionate 897 ± 9
Propyl butyrate 90 ± 20
Propyl hexanoate 276 ± 25
Propyl decanoate 28 ± 10
Butyl formate 472 ± 38
Butyl acetate 425 ± 34
Butyl propionate 966 ± 39
Butyl butyrate 226 ± 24
Butyl pentanoate 210 ± 18
Butyl decanoate 109 ± 13
Pentyl formate 416 ± 38
Pentyl acetate 309 ± 49
Pentyl butyrate 185 ± 15
Pentyl pentanoate 150 ± 20
Pentyl hexanoate 271 ± 31
Hexyl formate 309 ± 27
Hexyl acetate 540 ± 21
Hexyl propionate 1055 ± 15 
Hexyl butyrate 332 ± 23 
Hexyl hexanoate 72 ± 36 
Heptyl acetate 579 ± 42 
Heptyl propionate 577 ± 124 
Heptyl butyrate 200 ± 15 
Octyl acetate 416 ± 23 
Octyl propionate 1343 ± 12 
Octyl butyrate 365 ± 28 
Nonyl acetate 698 ± 38 
Decyl acetate 740 ± 19 
Cyclic alcohol moieties 
Cyclohexyl acetate 102 ± 8 
Benzyl formate 156 ± 42 
Benzyl acetate 328 ± 22 430 ± 40 
Phenyl acetate 298 ± 13 190 ± 0 
Phenethyl acetate 142 ± 9 880 ± 40 
4-Nitrophenyl acetate* 224 • 
2-Naphthyl acetate* 399 • 
Branched and unsaturated alcohol moieties
Isobutyl acetate 369 ± 48 
Isopentyl acetate 315 ± 38 
2-Methylbutyl acetate 213 ± 18 
cis-3-Hexenyl acetate 295 ± 32 
E2-hexenyl acetate 689 ± 32 
Geranyl formate 375 ± 42 
Geranyl acetate 378 ± 83 
Neryl acetate 421 ± 105 
Modified acid moieties
Butyl 2-methylbutyrate† 26 ± 8 
Hexyl 2-methylbutyrate 220 ± 29 
† kcat/KMEst was taken from group assay results.  
‡ kcat/KMEst was below 1.5 x 104 for the following substrates: methyl propionate, methyl butyrate, methyl pentanoate, methyl 
hexanoate, methyl heptanoate, methyl octanoate, methyl laurate, methyl palmitate, ethyl propionate, ethyl butyrate, ethyl 
pentanoate, ethyl hexanoate, ethyl heptanoate, ethyl octanoate, ethyl decanoate, linalyl acetate, cis-vaccenyl acetate, ethyl lactate, 
methyl 3-hydroxyhexanoate, ethyl (R)-3-hydroxybutyrate, ethyl (S)-3-hydroxybutyrate, ethyl 3-hydroxybutyrate, ethyl 3-
hydroxyhexanoate, ethyl 2-methylbutyrate, ethyl isovalerate, butyl isovalerate, ethyl trans-2-butenoate, hexyl trans-2-butenoate, 
ethyl tiglate, methyl benzoate, ethyl benzoate, methyl salicylate, ethyl cinnamate, methyl jasmonate, isopentyl tiglate, dimethyl 
carbonate, dimethyl glutarate, diethyl succinate and diethyl phthalate. All except cis-vaccenyl acetate were assayed in group 
assays only. 
* Model substrates for which direct UV/vis spectrophotometric assays exist.
• Value back calculated from full Michaelis-Menten kinetic data (Supplementary Fig. S1).
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Supplementary Table S2. Compounds from Fig. 1 for which there is evidence of bioactivity in Drosophila. 
Substrate 
Nature of Evidence 
References 
In vitro activity 
against known OR 
Behavioural 
differences 
Straight chain esters 
Methyl myristate   1
Propyl acetate   2
Propyl propionate  2
Propyl butyrate  3
Propyl hexanoate  2
Butyl acetate   2
Butyl butyrate  3
Butyl pentanoate  2
Pentyl acetate   2
Pentyl pentanoate  3
Hexyl acetate   2
Hexyl butyrate   2
Hexyl hexanoate   2
Cyclic alcohol moieties 
Benzyl acetate  2
Phenethyl acetate   2
Branched and unsaturated alcohol moieties 
Heptyl acetate  2
Octyl acetate  2
Nonyl acetate  2
Decyl acetate  2
Isobutyl acetate  2
Isopentyl acetate   2
2-Methylbutyl acetate  2
cis-3-Hexenyl acetate  2
E2-Hexenyl acetate   2
cis-Vaccenyl acetate   2
Geranyl formate  2
Geranyl acetate  2
Neryl acetate  2
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Supplementary Table S3. Proteins closest in structure to EST6 using the Q-score calculated by the SALAMI server 
accessed on May 20164. 
Protein Name PDB Code Seq ID (%) Q Score 
Manducta sexta JHE 2fj0A 22 0.9435 
Lucilia cuprina αE7 4fnmA 26 0.9321 
Drosophila melanogaster AChE 1qo9A 25 0.9001 
Torpedo californica AChE 3m3dA 27 0.9000 
Homo sapiens AChE 4m0eA 26 0.8985 
Homo sapiens BChE  2j4cA 25 0.8967 
Bos taurus Lipase 1aqlB 28 0.8961 
Mus musculus AChE 2c0pA 26 0.8912 
Ophiostoma piceae Esterase 4be4A 22 0.8861 
Homo sapiens Lipase 1jmyA 29 0.8843 
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Supplementary Table S4. DOCKovalent5 binding scores for the representative range of potential substrates docked into 
the active site of EST6. 
Ester Structure Score*
Pentyl butyrate -24.8
Pentyl pentanoate -6.04
Hexyl acetate -29.1
Octyl acetate -22.0
Octyl propionate -22.4
Geranyl acetate -18.3
Phenyl acetate 0.63 
Phenethyl acetate -26.5
cis-Vaccenyl acetate NA† 
* Total score is calculated according to the physics-based scoring function implemented in DOCK3.7. The scoring function
evaluates the ligand-protein electrostatic and van der Waals interactions and corrects for desolvation5.
† No suitable binding poses (without steric clashes) obtained.
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Supplementary Table S5. Data collection and refinement statistics for EST6-1. The diffraction data were indexed, 
integrated and scaled using Aimless and XDS6,7. Molecular replacement was used to obtain phases using the structure of 
LcαE7 with MOLREP8. Model building was carried out via iterative cycles of automated model building with BUCCANEER9  
and manual rebuilding with COOT10. Refinement was undertaken using REFMAC V 5.7.0032 accessed through the CCP4 
suite of programs11,12 and phenix.refine13. 
EST6-1 
Data collection 
Space group P212121
Cell dimensions 
    a, b, c (Å) 67.7, 80.6, 107 
    α, β, γ () 90, 90, 90 
Resolution (Å) 40.32-2.15 
(2.22-2.15) 
Rsym or Rmerge 0.114 (0.331) 
CC1/2 0.996 
CC* 0.995 
I / σ /I 18.1 (4.51) 
Completeness (%) 96.6 (73.4) 
Redundancy 11.7 (10.4) 
Refinement 
Resolution (Å) 40.32-2.15 
(2.52-2.15) 
No. reflections 31400 
Rwork / Rfree 0.1554/0.2104 
(0.1698/0.2325) 
No. atoms 
    Protein 520 
    Ligand/ion 1 
    Water 353 
B-factors
Protein 19.44 
Ligand/ion 25.13 
Water 22.11 
R.m.s. deviations
Bond lengths (Å) 0.008 
Bond angles () 0.95 
PDB ID 5THM 
*Values in parentheses are for highest-resolution shell.
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Supplementary Text 
Supplementary Results 
In order to corroborate  the results of the immunohistochemical experiment showing different localization of EST6 and 
LUSH within the antennae we performed a set of male-male courtship experiments on Est6 knock-down flies bearing 
RNAi constructs driven by Est6 or lush Gal4 lines to demonstrate that Est6 is not co-expressed with lush. Previous work 
has shown that Est6° null mutant flies exhibit lower levels of male-male courtship14. As expected, we observed a 
significant reduction in the male-male courtship index (CI) when the UAS-RNAi transgene was driven by Est6Gal4 (12.20 
± 3.27% for Est6Gal4/UAS-RNAi Est6), whereas the CI when the UAS-RNAi transgene was driven by lushGal4 (29.29 ± 
4.48 for lushGal4/UAS-RNAi Est6) was not significantly different from the various parental genotypes (27.24 ± 4.88 for 
lushGal4, 25.60 ± 4.75 for Est6Gal4 and 23.00 ± 4.76 for UAS-RNAi Est6). This result strongly suggests that EST6 and 
LUSH are not produced by the same cells of the sensilla since even an overlap of cells expressing both proteins would 
be expected to result in an intermediate phenotype.  
Supplementary Methods 
Flies. Additional lines used are UAS-RNAi Est6 flies from the NIG Stock Center (Japan) and transgenic Est6 Gal4 flies 
described in Chertemps et al.14. Both stocks were maintained as described in the main text. 
Courtship assays. Male-male courtship assays were performed as described in Chertemps et al.14. Briefly, all 
experiments were done under dim red lights at 25 ˚C (50% to 60% relative humidity). A single male (5 to 7 days old) 
was placed in a test chamber (30 mm diameter, 5 mm height) for 10 minutes before introducing a decapitated CS ‘target’ 
male. Courtship behaviour was observed over 10 minutes and a courtship index (CI) was calculated as the fraction of 
time spent in courtship activity over the observation period. The CIs of the parental control strains lushGal4, Est6Gal4 and 
UAS-RNAi Est6 were compared to the CIs of the lushGal4/UAS-RNAi Est6 and Est6Gal4/UAS-RNAi Est6 strains, in which 
Est6 inhibition is driven by either the lush or Est6 promoters. At least 22 flies of each genotype were tested. 
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